Vaccine

ABSTRACT

The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.

CROSS-REFERENCE

This application is a continuation of U.S. application Ser. No. 16/244,497, filed on Jan. 10, 2019, now issued as U.S. Pat. No. 11,213,578 on Jan. 4, 2022, which is a continuation of U.S. application Ser. No. 15/910,988, filed on Mar. 2, 2018, now issued as U.S. Pat. No. 10,213,497 on Feb. 26, 2019, which claims the benefit of priority to European Application No. 17159242.1, filed on Mar. 3, 2017, European Application No. 17159243.9, filed on Mar. 3, 2017, and Great Britain Application No. 1703809.2, filed on Mar. 9, 2017, each of which is incorporated herein by reference in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created Dec. 18, 2021, is named “TBL_004C2_SL.txt” and is 269,433 bytes in size.

FIELD

The disclosure relates to polypeptides and vaccines that find use in the prevention or treatment of cancer, in particular most breast cancers, ovarian cancers and colorectal cancers.

BACKGROUND

Cancer is killing millions of people worldwide, because existing drugs do not enable effective prevention or treatment. Current checkpoint inhibitor immunotherapies that re-activate existing immune responses can provide clinical benefit for a fraction of cancer patients. Current cancer vaccines that induce new immune responses are poorly immunogenic and fail to benefit most patients.

Recent analyses of 63,220 unique tumors revealed that cancer vaccines need to be generated specifically for each patient because extensive inter-individual tumor genomic heterogeneity (Hartmaier et al. Genome Medicine 2017 9:16). Using state of art technologies it is currently not feasible to scale HLA-specific cancer vaccines to large populations.

SUMMARY

In antigen presenting cells (APC) protein antigens are processed into peptides. These peptides bind to human leukocyte antigen molecules (HLAs) and are presented on the cell surface as peptide-HLA complexes to T cells. Different individuals express different HLA molecules and different HLA molecules present different peptides. Therefore, according to the state of the art, a peptide, or a fragment of a larger polypeptide, is identified as immunogenic for a specific human subject if it is presented by a HLA molecule that is expressed by the subject. In other words, the state of the art describes immunogenic peptides as HLA-restricted epitopes. However, HLA restricted epitopes induce T cell responses in only a fraction of individuals who express the HLA molecule. Peptides that activate a T cell response in one individual are inactive in others despite HLA allele matching. Therefore, it was previously unknown how an individual's HLA molecules present the antigen-derived epitopes that positively activate T cell responses.

As provided herein multiple HLAs expressed by an individual need to present the same peptide in order to trigger a T cell response. The fragments of a polypeptide antigen that are immunogenic for a specific individual are those that can bind to multiple class I (activate cytotoxic T cells) or class II (activate helper T cells) HLAs expressed by that individual. For example, the inventors have discovered that the presence of a T cell epitope that binds to at least three HLA type I of a subject predicts an immune response in the subject to a polypeptide.

Based on this discovery the inventors have identified the T cell epitopes from certain breast, ovarian and/or colorectal cancer associated-polypeptide antigens (cancer testis antigens (CTA)) that are capable of binding to at least three class I HLA in a high proportion of individuals. These T cell epitopes, or fragments of the antigens comprising the T cell epitopes, are useful for inducing specific immune responses against tumor cells expressing these antigens and for treating or preventing cancer.

In a first aspect the disclosure provides a polypeptide that comprises a fragment of up to 50 consecutive amino acids of

(a) a colorectal cancer-associated antigen selected from TSP50, EpCAM, SPAG9, CAGE1, FBXO39, SURVIVIN, LEMD1, MAGE-A8, MAGE-A6 and MAGE-A3, wherein the fragment comprises an amino acid sequence selected from any one of SEQ ID NOs: 21 to 40 and 234 to 250;

(b) an ovarian cancer-associated antigen selected from PIWIL-4, WT1, EpCAM, BORIS, AKAP-4, OY-TES-1, SP17, PIWIL-2, PIWIL-3, SPAG9, PRAME, HIWI, SURVIVIN, and AKAP-3 wherein the fragment comprises the amino acid sequence of any one of SEQ ID NOs: 272 to 301; and/or

(c) a breast cancer associated antigen selected from PIWIL-2, AKAP-4, EpCAM, BORIS, HIWI, SPAG9, PLU-1, TSGA10, ODF-4, SP17, RHOXF-2, PRAME, NY-SAR-35, MAGE-A9, NY-BR-1, SURVIVIN, MAGE-A11, HOM-TES-85 and NY-ESO-1 wherein the fragment comprises an amino acid sequence selected from any one of SEQ ID NOs: 1 to 20, 24 and 172 to 194.

In some specific cases the disclosure provides a polypeptide that

-   -   (a) is a fragment of a colorectal cancer-associated antigen         selected from TSP50, EpCAM, SPAG9, CAGE1, FBXO39, SURVIVIN,         MAGE-A8, MAGE-A6, MAGE-A3 and LEMD1, wherein the fragment         comprises an amino acid sequence selected from any one of SEQ ID         NOs: 21 to 40 and 234 to 250; or     -   (b) comprises or consists of two or more fragments of one or         more colorectal cancer associated antigens selected from TSP50,         EpCAM, SPAG9, CAGE1, FBXO39, SURVIVIN, MAGE-A8, MAGE-A6, MAGE-A3         and LEMD1, wherein each fragment comprises a different amino         acid sequence selected from any one of SEQ ID NOs: 21 to 40 and         234 to 250, optionally wherein the fragments overlap or are         arranged end to end in the polypeptide; or     -   (c) is a fragment of a ovarian cancer-associated antigen         selected from PIWIL-4, WT1, EpCAM, BORIS, AKAP-4, OY-TES-1,         SP17, PIWIL-2, PIWIL-3, SPAG9, PRAME, HIWI, SURVIVIN and AKAP-3,         wherein the fragment comprises an amino acid sequence selected         from any one of SEQ ID NOs: 272 to 301; or     -   (d) comprises or consists of two or more fragments of one or         more ovarian cancer associated antigens selected from PIWIL-4,         WT1, EpCAM, BORIS, AKAP-4, OY-TES-1, SP17, PIWIL-2, PIWIL-3,         SPAG9, PRAME, HIWI, SURVIVIN and AKAP-3, wherein each fragment         comprises a different amino acid sequence selected from any one         of SEQ ID NOs: 272 to 301, optionally wherein the fragments         overlap or are arranged end to end in the polypeptide; or     -   (e) is a fragment of a breast cancer associated antigen selected         from SPAG9, AKAP-4, BORIS, NY-SAR-35, NY-BR-1, SURVIVIN,         MAGE-A11, PRAME, MAGE-A9, HOM-TES-85, PIWIL-2, EpCAM, HIWI,         PLU-1, TSGA10, ODF-4, SP17, RHOXF-2, wherein the fragment         comprises the amino acid sequence from any one of SEQ ID NOs: 1         to 20, 24 and 172 to 194; or     -   (f) comprises or consists of two or more fragments of one or         more breast cancer associated antigens selected from SPAG9,         AKAP-4, BORIS, NY-SAR-35, NY-BR-1, SURVIVIN, MAGE-A11, PRAME,         MAGE-A9, HOM-TES-8, PIWIL-2, EpCAM, HIWI, PLU-1, TSGA10, ODF-4,         SP17, RHOXF-2, wherein each fragment comprises a different amino         acid sequence selected from any one of SEQ ID NOs: 1 to 20, 24         and 172 to 194; optionally wherein the fragments overlap or are         arranged end to end in the polypeptide and.

In some specific cases the polypeptide comprises or consists of fragments of

-   -   (a) TSP50, EpCAM, SPAG9, CAGE1, FBXO39, SURVIVIN, MAGE-A8,         MAGE-A6, MAGE-A3 and LEMD1;     -   (b) PIWIL-4, WT1, EpCAM, BORIS, AKAP-4, OY-TES-1, SP17, PIWIL-2,         PIWIL-3, SPAG9, PRAME, HIWI, SURVIVIN and AKAP-3; and/or     -   (c) SPAG9, AKAP-4, BORIS, NY-SAR-35, NY-BR-1, SURVIVIN,         MAGE-A11, PRAME, MAGE-A9, HOM-TES-8, PIWIL-2, EpCAM, HIWI,         PLU-1, TSGA10, ODF-4, SP17, RHOXF-2;         wherein each fragment comprises a different amino acid sequence         selected from SEQ ID NOs: 21 to 40 and 234 to 250; SEQ ID NOs:         272 to 301; and/or SEQ ID NOs: 1 to 20, 24 and 172 to 194.

In some cases the polypeptide comprises or consists of one or more amino acid sequences selected from SEQ ID NOs: 41-80, 251 to 271, 302 to 331 and 196 to 233.

In some cases the polypeptide comprises or consists of one or more amino acid sequences selected from SEQ ID NOs: 41-80, 195-233, 251-271 and 302-331 or selected from SEQ ID NOs: 81-142, 332-346, and 435-449.

In a further aspect the disclosure provides a panel of two or more polypeptides as described above, wherein each peptide comprises or consists of a different amino acid sequence selected from SEQ ID NOs: 21 to 40 and 234 to 250; or selected from SEQ ID NOs: 272 to 301; or selected from SEQ ID NOs: 1 to 20, 24 and 172 to 194; or selected from SEQ ID NOs: 1 to 40, 234 to 250, 272 to 301 and 172 to 194. In some cases the panel of polypeptides comprises or consists of one or more peptides comprising or consisting of the amino acid sequences of SEQ ID NOs: 130, 121, 131, 124, 134, 126 and/or SEQ ID NOs: 435-449.

In a further aspect the disclosure provides a pharmaceutical composition or kit having one or more polypeptides or panels of peptides as described above as active ingredients, or having a polypeptide comprising at least two amino acid sequences selected from SEQ ID NOs: 21 to 40 and 234 to 250; SEQ ID NOs: 272 to 301; and/or SEQ ID NOs: 1 to 20, 24 and 172 to 194 as an active ingredient; or selected from SEQ ID NOs: 130, 121, 131, 124, 134, 126 and/or 435-449 as an active ingredient.

In a further aspect the disclosure provides a method of inducing immune responses, (e.g. vaccination, providing immunotherapy or inducing a cytotoxic T cell response in a subject), the method comprising administering to the subject a pharmaceutical composition, kit or the panel of polypeptides as described above. The method may be a method of treating cancer, such as breast cancer, ovarian cancer or colorectal cancer.

In further aspects, the disclosure provides

-   -   the pharmaceutical composition, kit or panel of polypeptides         described above for use in a method of inducing immune responses         or for use in a method of treating cancer, optionally breast         cancer, ovarian cancer or colorectal cancer; and     -   use of a peptide or a panel of peptides as described above in         the manufacture of a medicament for inducing immune responses or         for treating cancer, optionally breast cancer, ovarian cancer or         colorectal cancer.

In a further aspect the disclosure provides a method of identifying a human subject who will likely have a cytotoxic T cell response to administration of a pharmaceutical composition as described above, the method comprising

-   -   (i) determining that the active ingredient polypeptide(s) of the         pharmaceutical composition comprise a sequence that is a T cell         epitope capable of binding to at least three HLA class I of the         subject; and     -   (ii) identifying the subject as likely to have a cytotoxic T         cell response to administration of the pharmaceutical         composition.

In a further aspect the disclosure provides a method of identifying a subject who will likely have a clinical response to a method of treatment as described above, the method comprising

-   -   (i) determining that the active ingredient polypeptide(s)         comprise two or more different amino acid sequences each of         which is         -   a. a T cell epitope capable of binding to at least three HLA             class I of the subject; and         -   b. a fragment of a cancer-associated antigen expressed by             cancer cells of the subject; and     -   (ii) identifying the subject as likely to have a clinical         response to the method of treatment.

In a further aspect the disclosure provides a method of determining the likelihood that a specific human subject will have a clinical response to a method of treatment, wherein one or more of the following factors corresponds to a higher likelihood of a clinical response:

-   -   (a) presence in the active ingredient polypeptide(s) of a higher         number of amino acid sequences and/or different amino acid         sequences that are each a T cell epitope capable of binding to         at least three HLA class I of the subject;     -   (b) a higher number of target polypeptide antigens, comprising         at least one amino acid sequence that is both         -   A. comprised in an active ingredient polypeptide; and         -   B. a T cell epitope capable of binding to at least three HLA             class I of the subject; optionally wherein the target             polypeptide antigens are expressed in the subject, further             optionally wherein the target polypeptides antigens are in             one or more samples obtained from the subject;     -   (c) a higher probability that the subject expresses target         polypeptide antigens, optionally a threshold number of the         target polypeptide antigens and/or optionally target polypeptide         antigens that have been determined to comprise at least one         amino acid sequence that is both         -   A. comprised in in an active ingredient polypeptide; and         -   B. a T cell epitope capable of binding to at least three HLA             class I of the subject; and/or     -   (d) a higher number of target polypeptide antigens that the         subject is predicted to express, optionally a higher number of         target polypeptide antigens that the subject expresses with a         threshold probability, and/or optionally the target polypeptide         antigens that have been determined to comprise at least one         amino acid sequence that is both         -   A. comprised in in an active ingredient polypeptide; and         -   B. a T cell epitope capable of binding to at least three HLA             class I of the subject.

In some cases the cancer-associated antigens may be TSP50, EpCAM, SPAG9, CAGE1, FBXO39, SURVIVIN, LEMD1, MAGE-A8, MAGE-A6, MAGE-A3, PIWIL-4, WT1, BORIS, AKAP-4, OY-TES-1, SP17, PIWIL-2, PIWIL-3, PRAME, HIWI, PLU-1, TSGA10, ODF-4, RHOXF-2, NY-SAR-35, MAGE-A9, NY-BR-1, MAGE-A11, HOM-TES-85, NY-ESO-1 and AKAP-3. In some cases the methods above comprise the step of determining that one or more cancer-associated antigens is expressed by cancer cells of the subject. The cancer-associated antigen(s) may be present in one or more samples obtained from the subject

In some cases administration of the pharmaceutical composition or the active ingredient polypeptides of the kit may then be selected as a method of treatment for the subject. The subject may further be treated by administration of the pharmaceutical composition or the active ingredient polypeptides.

In a further aspect the disclosure provides a method of treatment as described above, wherein the subject has been identified as likely to have a clinical response or as having above a threshold minimum likelihood of having a clinical response to the treatment by the method described above.

In a further aspect the disclosure provides a method of identifying a human subject who will likely not have a clinical response to a method of treatment as described above, the method comprising

-   -   (i) determining that the active ingredient polypeptide(s) of the         pharmaceutical composition do not comprise two or more different         amino acid sequences each of which is a T cell epitope capable         of binding to at least three HLA class I of the subject; and     -   (ii) identifying the subject as likely not to have a clinical         response to the method of treatment.

The methods described above may comprise the step of determining the HLA class I genotype of the subject.

Disclosed herein in certain embodiments are pharmaceutical compositions comprising one or more peptides, wherein each peptide comprises a different one of the amino acid sequence of any one of SEQ ID NOs: 112 to 142. In some embodiments, the composition comprises 2 or more peptides, 3 or more peptides, 4 or more peptides, 5 or more peptides, or 6 or more peptides. In some embodiments, the composition comprises two peptides, wherein each peptide comprises a different one of the amino acid sequences of SEQ ID NOs: 121 and 124. In some embodiments, the composition comprises four peptides, wherein each peptide comprises a different one of the amino acid sequences of SEQ ID NOs: 126, 130, 131, and 134. In some embodiments, the composition comprises six peptides, wherein each peptide comprises a different one of the amino acid sequences of SEQ ID NOs: 121, 124, 126, 130, 131, and 134. In some embodiments, the composition further comprises at least one additional peptide comprising a fragment of an antigen selected from TSP50, EpCAM, SPAG9, CAGE1, FBXO39, SURVIVIN, MAGE-A8, and MAGE-A6. In some embodiments, the composition further comprises one or more additional peptides, each of the one or more additional peptides comprising a different one of the amino acid sequence of any one of SEQ ID NOs: 112-120, 122, 123, 125, 127-129, 132, 133, and 135-142. In some embodiments, the composition further comprises a pharmaceutically acceptable adjuvant, diluent, carrier, preservative, or combination thereof. In some embodiments, the adjuvant is selected from the group consisting of Montanide ISA-51, QS-21, GM-CSF, cyclophosamide, bacillus Calmette-Guerin (BCG), Corynbacterium parvum, levamisole, azimezone, isoprinisone, dinitrochlorobenezene (DNCB), keyhole limpet hemocyanins (KLH), Freunds adjuvant (complete), Freunds adjuvant (incomplete), mineral gels, aluminum hydroxide (Alum), lysolecithin, pluronic polyols, polyanions, oil emulsions, dinitrophenol, diphtheria toxin (DT), and combinations thereof.

Disclosed herein in certain embodiments are pharmaceutical compositions comprising one or more nucleic acid molecules encoding one or more peptides, wherein each peptide comprises a different one of the amino acid sequence of any one of SEQ ID NOs: 112 to 142.

Disclosed herein in certain embodiments are methods of identifying and treating a human subject having cancer who will likely have a clinical response to administration of a pharmaceutical composition of the disclosure, the method comprising (i) assaying a biological sample of the subject to determine HLA genotype of the subject; (ii) determining that the pharmaceutical composition comprises two or more sequences that are a T cell epitope capable of binding to at least three HLA class I molecules of the subject; (iii) determining the probability that a tumor of the subject expresses one or more antigen corresponding to the T cell epitopes identified in step (ii) using population expression data for each antigen, to identify the likelihood of the subject to have a clinical response to administration of the pharmaceutical composition; and (iv) administering the composition of the disclosure to the identified subject. In some embodiments, the subject has colorectal cancer. In some embodiments, the pharmaceutical composition comprises 2 or more peptides, 3 or more peptides, 4 or more peptides, 5 or more peptides, or 6 or more peptides. In some embodiments, the pharmaceutical composition comprises two peptides, wherein each peptide comprises a different one of the amino acid sequences of SEQ ID NOs: 121 and 124. In some embodiments, the pharmaceutical composition comprises four peptides, wherein each peptide comprises a different one of the amino acid sequences of SEQ ID NOs: 126, 130, 131, and 134. In some embodiments, the pharmaceutical composition comprises six peptides, wherein each peptide comprises a different one of the amino acid sequences of SEQ ID NOs: 121, 124, 126, 130, 131, and 134. In some embodiments, the pharmaceutical composition further comprises at least one additional peptide comprising a fragment of an antigen selected from TSP50, EpCAM, SPAG9, CAGE1, FBXO39, SURVIVIN, MAGE-A8, and MAGE-A6. In some embodiments, the pharmaceutical composition further comprises one or more additional peptides, each of the one or more additional peptides comprising a different one of the amino acid sequence of any one of SEQ ID NOs: 112-120, 122, 123, 125, 127-129, 132, 133, and 135-142. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable adjuvant, diluent, carrier, preservative, or combination thereof. In some embodiments, the adjuvant is selected from the group consisting of Montanide ISA-51, QS-21, GM-CSF, cyclophosamide, bacillus Calmette-Guerin (BCG), Corynbacterium parvum, levamisole, azimezone, isoprinisone, dinitrochlorobenezene (DNCB), keyhole limpet hemocyanins (KLH), Freunds adjuvant (complete), Freunds adjuvant (incomplete), mineral gels, aluminum hydroxide (Alum), lysolecithin, pluronic polyols, polyanions, oil emulsions, dinitrophenol, diphtheria toxin (DT), and combinations thereof. In some embodiments, the method further comprises administering a chemotherapeutic agent, a checkpoint inhibitor, a targeted therapy, radiation therapy, another immunotherapy, or combination thereof to the identified subject. In some embodiments, the method further comprises prior to the administering step, (i) assaying a tumor sample from the subject to determine that the three or more peptides of the pharmaceutical composition comprise two or more different amino acid sequences each of which is a) a fragment of a cancer-associated antigen expressed by cancer cells of the subject as determined in step (i); and b) a T cell epitope capable of binding to at least three HLA class I molecules of the subject; and (ii) confirming the subject as likely to have a clinical response to the method of treatment.

Disclosed herein in certain embodiments are kits comprising: a first pharmaceutical composition comprising one or more peptides, wherein each peptide comprises a different one of the amino acid sequence of any one of SEQ ID NOs: 112 to 142; and a second different pharmaceutical composition comprising one or more peptides, wherein each peptide comprises a different one of the amino acid sequence of any one of SEQ ID NOs: 112 to 142.

Disclosed herein in certain embodiments are pharmaceutical compositions comprising: a nucleic acid molecule expressing two or more polypeptides, each polypeptide comprising a fragment of up to 50 consecutive amino acids of an antigen selected from TSP50, EpCAM, SPAG9, CAGE1, FBXO39, SURVIVIN, MAGE-A8, and MAGE-A6, wherein each fragment comprises a different amino acid sequence selected from any one of SEQ ID NOs: 21-40 and 234 to 250. In some embodiments, the polypeptides do not comprise amino acid sequences that are adjacent to each other in a corresponding antigen.

Disclosed herein in certain embodiments are pharmaceutical compositions comprising one or more peptides, wherein each peptide comprises a different one of the amino acid sequence of any one of SEQ ID NOs: 81 to 111 and 435 to 449. In some embodiments, the composition comprises 2 or more peptides, 3 or more peptides, 4 or more peptides, 5 or more peptides, 6 or more peptides, 7 or more peptides, 8 or more peptides, 9 or more peptides, 10 or more peptides, 11 or more peptides, or 12 or more peptides. In some embodiments, the composition comprises 9 peptides, wherein each peptide comprises a different one of the amino acid sequences of SEQ ID NOs: 92, 93, 98, 99-101, and 103-105. In some embodiments, the composition further comprises at least one additional peptide comprising a fragment of an antigen selected from PIWIL-2, AKAP-4, EpCAM, BORIS, HIWI, SPAG9, PLU-1, TSGA10, ODF-4, SP17, RHOXF-2, PRAME, NY-SAR-35, MAGE-A9, NY-BR-1, SURVIVIN, MAGE-A11, HOM-TES-85 and NY-ESO-1. In some embodiments, the fragment of an antigen comprises an amino acid sequence selected from any one of SEQ ID NOs: 1 to 20, 24 and 172 to 194. In some embodiments, the fragment of an antigen comprises an amino acid sequence selected from any one of SEQ ID NOs:41-60 and 195-233. In some embodiments, the composition further comprises a pharmaceutically acceptable adjuvant, diluent, carrier, preservative, or combination thereof. In some embodiments, the adjuvant is selected from the group consisting of Montanide ISA-51, QS-21, GM-CSF, cyclophosamide, bacillus Calmette-Guerin (BCG), Corynbacterium parvum, levamisole, azimezone, isoprinisone, dinitrochlorobenezene (DNCB), keyhole limpet hemocyanins (KLH), Freunds adjuvant (complete), Freunds adjuvant (incomplete), mineral gels, aluminum hydroxide (Alum), lysolecithin, pluronic polyols, polyanions, oil emulsions, dinitrophenol, diphtheria toxin (DT), and combinations thereof.

Disclosed herein in certain embodiments are pharmaceutical compositions comprising one or more nucleic acid molecules encoding one or more peptides, wherein each peptide comprises a different one of the amino acid sequence of any one of SEQ ID NOs: 81 to 111 and 435 to 449 In some embodiments, the one or more nucleic acid molecules encode 2 or more peptides, 3 or more peptides, 4 or more peptides, 5 or more peptides, 6 or more peptides, 7 or more peptides, 8 or more peptides, 9 or more peptides, 10 or more peptides, 11 or more peptides, or 12 or more peptides. In some embodiments, the one or more nucleic acid molecules encode 9 peptides, wherein each peptide comprises a different one of the amino acid sequences of SEQ ID NOs: 92, 93, 98, 99-101, and 103-105. In some embodiments, the one or more nucleic acid molecules encode at least one additional peptide comprising a fragment of an antigen selected from PIWIL-2, AKAP-4, EpCAM, BORIS, HIWI, SPAG9, PLU-1, TSGA10, ODF-4, SP17, RHOXF-2, PRAME, NY-SAR-35, MAGE-A9, NY-BR-1, SURVIVIN, MAGE-A11, HOM-TES-85 and NY-ESO-1. In some embodiments, the fragment of an antigen comprises an amino acid sequence selected from any one of SEQ ID NOs: 1 to 20, 24 and 172 to 194. In some embodiments, the fragment of an antigen comprises an amino acid sequence selected from any one of SEQ ID NOs:41-60 and 195-233. In some embodiments, the composition further comprises a pharmaceutically acceptable adjuvant, diluent, carrier, preservative, or combination thereof. In some embodiments, the adjuvant is selected from the group consisting of Montanide ISA-51, QS-21, GM-CSF, cyclophosamide, bacillus Calmette-Guerin (BCG), Corynbacterium parvum, levamisole, azimezone, isoprinisone, dinitrochlorobenezene (DNCB), keyhole limpet hemocyanins (KLH), Freunds adjuvant (complete), Freunds adjuvant (incomplete), mineral gels, aluminum hydroxide (Alum), lysolecithin, pluronic polyols, polyanions, oil emulsions, dinitrophenol, diphtheria toxin (DT), and combinations thereof.

Disclosed herein in certain embodiments are methods of identifying and treating a human subject having cancer who will likely have a clinical response to administration of a pharmaceutical composition of the disclosure, the method comprising (i) assaying a biological sample of the subject to determine HLA genotype of the subject; (ii) determining that the pharmaceutical composition comprises two or more sequences that are a T cell epitope capable of binding to at least three HLA class I molecules of the subject; (iii) determining the probability that a tumor of the subject expresses one or more antigen corresponding to the T cell epitopes identified in step (ii) using population expression data for each antigen, to identify the likelihood of the subject to have a clinical response to administration of the pharmaceutical composition; and (iv) administering the composition of the disclosure to the identified subject. In some embodiments, the subject has breast cancer. In some embodiments, the pharmaceutical composition comprises 2 or more peptides, 3 or more peptides, 4 or more peptides, 5 or more peptides, 6 or more peptides, 7 or more peptides, 8 or more peptides, 9 or more peptides, 10 or more peptides, 11 or more peptides, or 12 or more peptides. In some embodiments, the pharmaceutical composition comprises 9 peptides, wherein each peptide comprises a different one of the amino acid sequences of SEQ ID NOs: 92, 93, 98, 99-101, and 103-105. In some embodiments, the pharmaceutical composition further comprises comprising at least one additional peptide comprising a fragment of an antigen selected from PIWIL-2, AKAP-4, EpCAM, BORIS, HIWI, SPAG9, PLU-1, TSGA10, ODF-4, SP17, RHOXF-2, PRAME, NY-SAR-35, MAGE-A9, NY-BR-1, SURVIVIN, MAGE-A11, HOM-TES-85 and NY-ESO-1. In some embodiments, the fragment of an antigen comprises an amino acid sequence selected from any one of SEQ ID NOs: 1 to 20, 24 and 172 to 194. In some embodiments, the fragment of an antigen comprises an amino acid sequence selected from any one of SEQ ID NOs:41-60 and 195-233. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable adjuvant, diluent, carrier, preservative, or combination thereof. In some embodiments, the adjuvant is selected from the group consisting of Montanide ISA-51, QS-21, GM-CSF, cyclophosamide, bacillus Calmette-Guerin (BCG), Corynbacterium parvum, levamisole, azimezone, isoprinisone, dinitrochlorobenezene (DNCB), keyhole limpet hemocyanins (KLH), Freunds adjuvant (complete), Freunds adjuvant (incomplete), mineral gels, aluminum hydroxide (Alum), lysolecithin, pluronic polyols, polyanions, oil emulsions, dinitrophenol, diphtheria toxin (DT), and combinations thereof. In some embodiments, the method further comprises administering a chemotherapeutic agent, a checkpoint inhibitor, a targeted therapy, radiation therapy, another immunotherapy, or combination thereof to the identified subject. In some embodiments, the method further comprises prior to the administering step, (i) assaying a tumor sample from the subject to determine that the three or more peptides of the pharmaceutical composition comprise two or more different amino acid sequences each of which is a) a fragment of a cancer-associated antigen expressed by cancer cells of the subject as determined in step (i); and b) a T cell epitope capable of binding to at least three HLA class I molecules of the subject; and confirming the subject as likely to have a clinical response to the method of treatment.

Disclosed herein in certain embodiments are methods of identifying and treating a human subject having cancer who will likely have an immune response to administration of a pharmaceutical composition of the disclosure, the method comprising (i) assaying a biological sample of the subject to determine HLA genotype of the subject; (ii) determining that the pharmaceutical composition comprises one or more sequences that are a T cell epitope capable of binding to at least three HLA class I molecules of the subject; and (iii) administering the composition of the disclosure to the identified subject.

Disclosed herein in certain embodiments are kits comprising: a first pharmaceutical composition comprising one or more peptides, wherein each peptide comprises a different one of the amino acid sequence of any one of SEQ ID NOs: 81-111 and 435 to 449; and a second different pharmaceutical composition comprising one or more peptides, wherein each peptide comprises a different one of the amino acid sequence of any one of SEQ ID NOs: 81-111 and 435 to 449.

Disclosed herein in certain embodiments are pharmaceutical compositions comprising: a nucleic acid molecule expressing two or more polypeptides, each polypeptide comprising a fragment of up to 50 consecutive amino acids of an antigen selected from PIWIL-2, AKAP-4, EpCAM, BORIS, HIWI, SPAG9, PLU-1, TSGA10, ODF-4, SP17, RHOXF-2, PRAME, NY-SAR-35, MAGE-A9, NY-BR-1, SURVIVIN, MAGE-A11, HOM-TES-85 and NY-ESO-1, wherein each fragment comprises a different amino acid sequence selected from any one of SEQ ID NOs: 1 to 20, 24, and 172 to 194. In some embodiments, the polypeptides do not comprise amino acid sequences that are adjacent to each other in a corresponding antigen.

Disclosed herein in certain embodiments are pharmaceutical compositions comprising one or more peptides, wherein each peptide comprises a different one of the amino acid sequence of any one of SEQ ID NOs: 332-346. In some embodiments, the composition comprises 2 or more peptides, 3 or more peptides, 4 or more peptides, 5 or more peptides, 6 or more peptides, 7 or more peptides, 8 or more peptides, 9 or more peptides, 10 or more peptides, 11 or more peptides, 12 or more peptides, 13 or more peptides, 14 or more peptides, or 15 or more peptides. In some embodiments, the composition comprises 15 peptides, wherein each peptide comprises a different one of the amino acid sequences of SEQ ID NOs: 332-346. In some embodiments, the composition further comprises at least one additional peptide comprising a fragment of an antigen selected from PIWIL-4, WT1, EpCAM, BORIS, AKAP-4, OY-TES-1, SP17, PIWIL-2, PIWIL-3, SPAG9, PRAME, HIWI, SURVIVIN, and AKAP-3. In some embodiments, the fragment comprises an amino acid sequence selected from any one of SEQ ID NOs: 272-301. In some embodiments, the fragment comprises an amino acid sequence selected from any one of SEQ ID NOs:302-331. In some embodiments, the composition further comprises a pharmaceutically acceptable adjuvant, diluent, carrier, preservative, or combination thereof. In some embodiments, the adjuvant is selected from the group consisting of Montanide ISA-51, QS-21, GM-CSF, cyclophosamide, bacillus Calmette-Guerin (BCG), Corynbacterium parvum, levamisole, azimezone, isoprinisone, dinitrochlorobenezene (DNCB), keyhole limpet hemocyanins (KLH), Freunds adjuvant (complete), Freunds adjuvant (incomplete), mineral gels, aluminum hydroxide (Alum), lysolecithin, pluronic polyols, polyanions, oil emulsions, dinitrophenol, diphtheria toxin (DT), and combinations thereof.

Disclosed herein in certain embodiments are pharmaceutical compositions comprising one or more nucleic acid molecules encoding one or more peptides, wherein each peptide comprises a different one of the amino acid sequence of any one of SEQ ID NOs: 332-346. In some embodiments, the one or more nucleic acid molecules encode 2 or more peptides, 3 or more peptides, 4 or more peptides, 5 or more peptides, 6 or more peptides, 7 or more peptides, 8 or more peptides, 9 or more peptides, 10 or more peptides, 11 or more peptides, 12 or more peptides, 13 or more peptides, 14 or more peptides, or 15 or more peptides. In some embodiments, the one or more nucleic acid molecules encode 15 peptides, wherein each peptide comprises a different one of the amino acid sequences of SEQ ID NOs: 332-346. In some embodiments, the one or more nucleic acid molecules encode at least one additional peptide comprising a fragment of an antigen selected from PIWIL-4, WT1, EpCAM, BORIS, AKAP-4, OY-TES-1, SP17, PIWIL-2, PIWIL-3, SPAG9, PRAME, HIWI, SURVIVIN, and AKAP-3. In some embodiments, the fragment comprises an amino acid sequence selected from any one of SEQ ID NOs: 272-301. In some embodiments, the fragment comprises an amino acid sequence selected from any one of SEQ ID NOs:302-331. In some embodiments, the composition further comprises a pharmaceutically acceptable adjuvant, diluent, carrier, preservative, or combination thereof. In some embodiments, the adjuvant is selected from the group consisting of Montanide ISA-51, QS-21, GM-CSF, cyclophosamide, bacillus Calmette-Guerin (BCG), Corynbacterium parvum, levamisole, azimezone, isoprinisone, dinitrochlorobenezene (DNCB), keyhole limpet hemocyanins (KLH), Freunds adjuvant (complete), Freunds adjuvant (incomplete), mineral gels, aluminum hydroxide (Alum), lysolecithin, pluronic polyols, polyanions, oil emulsions, dinitrophenol, diphtheria toxin (DT), and combinations thereof.

Disclosed herein in certain embodiments are methods of identifying and treating a human subject having cancer who will likely have a clinical response to administration of a pharmaceutical composition according of the disclosure, the method comprising (i) assaying a biological sample of the subject to determine HLA genotype of the subject; (ii) determining that the pharmaceutical composition comprises two or more sequences that are a T cell epitope capable of binding to at least three HLA class I molecules of the subject; (iii) determining the probability that a tumor of the subject expresses one or more antigen corresponding to the T cell epitopes identified in step (ii) using population expression data for each antigen, to identify the likelihood of the subject to have a clinical response to administration of the pharmaceutical composition; and (iv) administering the composition of of the disclosure to the identified subject. In some embodiments, the subject has ovarian cancer. In some embodiments, the pharmaceutical composition comprises 2 or more peptides, 3 or more peptides, 4 or more peptides, 5 or more peptides, 6 or more peptides, 7 or more peptides, 8 or more peptides, 9 or more peptides, 10 or more peptides, 11 or more peptides, 12 or more peptides, 13 or more peptides, 14 or more peptides, or 15 or more peptides. In some embodiments, the pharmaceutical composition comprises 15 peptides, wherein each peptide comprises a different one of the amino acid sequences of SEQ ID NOs: 332-346. In some embodiments, the pharmaceutical composition further comprises comprising at least one additional peptide comprising a fragment of an antigen selected from PIWIL-4, WT1, EpCAM, BORIS, AKAP-4, OY-TES-1, SP17, PIWIL-2, PIWIL-3, SPAG9, PRAME, HIWI, SURVIVIN, and AKAP-3. In some embodiments, the fragment comprises an amino acid sequence selected from any one of SEQ ID NOs: 272-301 In some embodiments, the fragment comprises an amino acid sequence selected from any one of SEQ ID NOs:302-331. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable adjuvant, diluent, carrier, preservative, or combination thereof. In some embodiments, the adjuvant is selected from the group consisting of Montanide ISA-51, QS-21, GM-CSF, cyclophosamide, bacillus Calmette-Guerin (BCG), Corynbacterium parvum, levamisole, azimezone, isoprinisone, dinitrochlorobenezene (DNCB), keyhole limpet hemocyanins (KLH), Freunds adjuvant (complete), Freunds adjuvant (incomplete), mineral gels, aluminum hydroxide (Alum), lysolecithin, pluronic polyols, polyanions, oil emulsions, dinitrophenol, diphtheria toxin (DT), and combinations thereof. In some embodiments, the method further comprises administering a chemotherapeutic agent, a checkpoint inhibitor, a targeted therapy, radiation therapy, another immunotherapy, or combination thereof to the identified subject. In some embodiments, the method further comprises prior to the administering step, (i) assaying a tumor sample from the subject to determine that the three or more peptides of the pharmaceutical composition comprise two or more different amino acid sequences each of which is a) a fragment of a cancer-associated antigen expressed by cancer cells of the subject as determined in step (i); and b) a T cell epitope capable of binding to at least three HLA class I molecules of the subject; and (ii) confirming the subject as likely to have a clinical response to the method of treatment. Disclosed herein in certain embodiments are methods of identifying and treating a human subject having cancer who will likely have an immune response to administration of a pharmaceutical composition of the disclosure, the method comprising (i) assaying a biological sample of the subject to determine HLA genotype of the subject; (ii) determining that the pharmaceutical composition comprises one or more sequences that are a T cell epitope capable of binding to at least three HLA class I molecules of the subject; and (iii) administering the composition of the disclosure to the identified subject.

Disclosed herein in certain embodiments are kits comprising: a first pharmaceutical composition comprising one or more peptides, wherein each peptide comprises a different one of the amino acid sequence of any one of SEQ ID NOs: 332-346; and a second different pharmaceutical composition comprising one or more peptides, wherein each peptide comprises a different one of the amino acid sequence of any one of SEQ ID NOs: 332-346.

Disclosed herein in certain embodiments are pharmaceutical compositions comprising: a nucleic acid molecule expressing two or more polypeptides, each polypeptide comprising a fragment of up to 50 consecutive amino acids of an antigen selected from PIWIL-4, WT1, EpCAM, BORIS, AKAP-4, OY-TES-1, SP17, PIWIL-2, PIWIL-3, SPAG9, PRAME, HIWI, SURVIVIN, and AKAP-3, wherein each fragment comprises a different amino acid sequence selected from any one of SEQ ID NOs: 272-301. In some embodiments, the polypeptides do not comprise amino acid sequences that are adjacent to each other in a corresponding antigen.

DISCLOSURE

The disclosure will now be described in more detail, by way of example and not limitation, and by reference to the accompanying drawings. Many equivalent modifications and variations will be apparent, to those skilled in the art when given this disclosure. Accordingly, the exemplary embodiments of the disclosure set forth are considered to be illustrative and not limiting. Various changes to the described embodiments may be made without departing from the scope of the disclosure. All documents cited herein, whether supra or infra, are expressly incorporated by reference in their entirety.

The present disclosure includes the combination of the aspects and preferred features described except where such a combination is clearly impermissible or is stated to be expressly avoided. As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a peptide” includes two or more such peptides.

Section headings are used herein for convenience only and are not to be construed as limiting in any way.

DESCRIPTION OF THE FIGURES

FIG. 1—ROC curve of HLA restricted PEPI biomarkers.

FIG. 2—ROC curve of ≥1 PEPI3+ Test for the determination of the diagnostic accuracy.

FIGS. 3A-B—Distribution of HLA class I PEPI3+ compared to CD8+ T cell responses measured by a state of art assay among peptide pools used in the CD8+ T cell response assays. FIG. 3A: HLA class I restricted PEPI3+s. The 90% Overall Percent of Agreement (OPA) among the T cell responses and PEPI3+ peptides demonstrate the utility of the invented peptides for prediction of vaccine induced T cell response set of individuals. FIG. 3B: Class I HLA restricted epitopes (PEPI1+). The OPA between predicted epitopes and CD8+ T cell responses was 28% (not statistically significant). Darkest grey: True positive (TP), both peptide and T cell responses were detected; Light grey: False negative (FN), only T cell responses were detected; Lightest grey: False positive (FP), only peptide were detected; Dark grey: True negative (TN): neither peptides nor T cell responses were detected.

FIGS. 4A-B—Distribution of HLA class II PEPIs compared to CD4+ T cell responses measured by a state of art assay among peptide pools used in the assays. FIG. 4A: HLA class II restricted PEPI4+s. 67% OPA between PEPI4+ and CD4+ T-cell responses (p=0.002). FIG. 4B: The class II HLA restricted epitopes. OPA between class II HLA restricted epitopes and CD4+ T cell responses was 66% (not statistically significant). Darkest grey: True positive (TP), both peptide and T cell responses were detected; Light grey: False negative (FN), only T cell responses were detected; Lightest grey: False positive (FP), only peptide were detected; Dark grey: True negative (TN): neither peptides nor T cell responses were detected.

FIGS. 5A-D—Multiple HLA binding peptides that define the HPV-16 LPV vaccine specific T cell response set of 18 VIN-3 and 5 cervical cancer patients. HLA class I restricted PEPI3 counts (FIGS. 5A and 5B) and HLA class II restricted PEPI3 counts (FIGS. 5C and 5C) derived from LPV antigens of each patient. Light grey: immune responders measured after vaccination in the clinical trial; Dark grey: Immune non-responders measured after vaccination in the clinical trial. Results show that ≥3 HLA class I binding peptides predict the CD8+ T cell reactivity and ≥4 HLA class II binding peptides predict the CD4+ T cell reactivity.

FIG. 6—The multiple HLA class I binding peptides that define the HPV vaccine specific T cell response set of 2 patients. Panel A: Four HPV antigens in the HPV vaccine. Boxes represent the length of the amino acid sequences from the N terminus to the C terminus. Panel B: Process to identify the multiple HLA binding peptides of two patients: HLA sequences of the patients labelled as 4-digit HLA genotype right from the patient's ID. The location of the 1^(st) amino acid of the 54 and 91 epitopes that can bind to the patient 12-11 and patient 14-5 HLAs (PEPI1+) respectively are depicted with lines. PEPI2 represents the peptides selected from PEPI1+s that can bind to multiple HLAs of a patient (PEPI2+). PEPI3 represent peptides that can bind to ≥3 HLAs of a patient (PEPI3+). PEPI4 represent peptides that can bind to ≥4 HLAs of a patient (PEPI4+). PEPI5 represent peptides that can bind to ≥5 HLAs of a patient (PEPI5+). PEPI6 represent peptides that can bind to 6 HLAs of a patient (PEPI6). Panel C: The DNA vaccine specific PEPI3+ set of two patients characterizes their vaccine specific T cell responses.

FIG. 7—Correlation between the ≥1 PEPI3+ Score and CTL response rates of peptide targets determined in clinical trials.

FIG. 8—Correlation between the ≥1 PEPI3+ Score and the clinical Immune Response Rate (IRR) of immunotherapy vaccines. Dashed lines: 95% confidence band.

FIG. 9—Correlation between the ≥2 PEPI3+ Score and Disease Control Rate (DCR) of immunotherapy vaccines. Dashed lines: 95% confidence band.

FIG. 10—Peptide hotspot analysis example: PRAME antigen hotspot on 433 patients of the Model Population. On the y axis are the 433 patients of the Model Population, on the x axis is the amino acid sequence of the PRAME antigen (CTA). Each data point represents a PEPI presented by ≥3 HLA class I of one patient starting at the specified amino acid position. The two most frequent PEPIs (called bestEPIs) of the PRAME antigen are highlighted in dark gray (peptide hotspots=PEPI Hotspots).

FIG. 11—CTA Expression Curve calculated by analyzing expression frequency data of tumor specific antigens (CTAs) in human breast cancer tissues. (No cell line data were included.)

FIGS. 12A-B—Antigen expression distribution for breast cancer based on the calculation of multi-antigen responses from expression frequencies of the selected 10 different CTAs. FIG. 12A: non-cumulative distribution to calculate the expected value for the number of expressed antigens (AG50). This value shows that probably 6.14 vaccine antigens will be expressed by breast tumor cells. FIG. 12B: cumulative distribution curve of the minimum number of expressed antigens (CTA expression curve). This shows that minimum 4 vaccine antigens will be expressed with 95% probability in breast cancer cell (AG95).

FIGS. 13A-B—PEPI representing antigens: breast cancer vaccine-specific CTA antigens with ≥1 PEPI, called as “AP”) distribution within the Model Population (n=433) for breast cancer vaccine. FIG. 13A: non-cumulative distribution of AP where the average number of APs is: AP50=5.30, meaning that in average almost 6 CTAs will have PEPIs in the Model Population. FIG. 13B: cumulative distribution curve of the minimum number of APs in the Model Population (n=433). This shows that at least one vaccine antigen will have PEPIs in 95% of the Model Population (n=433) (AP95=1).

FIGS. 14A-B—PEPI represented expressed antigen (breast cancer vaccine-specific CTA antigens expressed by the tumor, for which ≥1 PEPI is predicted, called as “AGP”) distribution within the model population (n=433) calculated with CTA expression rates for breast cancer. FIG. 14A: non-cumulative distribution of AGP where the expected value for number expressed CTAs represented by PEPI is AGP50=3.37. AGP50 is a measure of the effectiveness of the disclosed breast cancer vaccine in attacking breast tumor in an unselected patient population. AGP50=3.37 means that at least 3 CTAs from the vaccine will probably be expressed by the breast tumor cells and present PEPIs in the Model Population. FIG. 14B: cumulative distribution curve of the minimum number of AGPs in the Model Population (n=433) shows that at least 1 of the vaccine CTAs will present PEPIs in 92% of the population and the remaining 8% of the population will likely have no AGP at all (AGP95=0, AGP92=1).

FIG. 15—CTA Expression Curve calculated by analyzing expression frequency data of tumor specific antigens (CTAs) in human colorectal cancer tissues. (No cell line data were included.)

FIGS. 16A-B—Antigen expression distribution for colorectal cancer based on the calculation of multi-antigen responses from expression frequencies of the selected 7 different CTAs. FIG. 16A: non-cumulative distribution to calculate the expected vale for the number of expressed vaccine antigens in colorectal cancers (AG50). This value shows that probably 4.96 vaccine antigens will be expressed by colorectal tumor cells. FIG. 16B: cumulative distribution curve of the minimum number of expressed antigens (CTA expression curve). This shows that minimum 3 antigens will be expressed with 95% probability in the colorectal cancer cell (AG95).

FIGS. 17A-B—PEPI represented antigen (colorectal cancer vaccine-specific CTA antigens for which ≥1 PEPI is predicted. Called as “AP”) distribution within the model population (n=433) for colorectal cancer. FIG. 17A: non-cumulative distribution of AP where the average number of APs is: AP50=4.73, meaning that in average 5 CTAs will be represented by PEPIs in the model population FIG. 17B: cumulative distribution curve of the minimum number of APs in the model population (n=433). This shows that 2 or more antigens will be represented by PEPIs in 95% of the model population (n=433) (AP95=2).

FIGS. 18A-B—PEPI represented expressed antigen (colorectal cancer vaccine-specific CTA antigens expressed by the tumor, for which ≥1 PEPI is predicted. Called as “AGP”) distribution within the model population (n=433) calculated with CTA expression rates for colorectal cancer. FIG. 18A: non-cumulative distribution of AGP where the expected value for number expressed CTAs represented by PEPI is AGP50=2.54. AGP50 is a measure of the effectiveness of the disclosed colorectal cancer vaccine in attacking colorectal tumors in an unselected patient population. AGP50=2.54 means that at least 2-3 CTAs from the vaccine will probably be expressed by the colorectal tumor cells and present PEPIs in the Model Population. FIG. 18B: cumulative distribution curve of the minimum number of AGPs in the Model Population (n=433) shows that at least 1 of the vaccine CTAs will be expressed and also present PEPIs in 93% of the population (AGP93=1).

FIG. 19—Schematic showing exemplary positions of amino acids in overlapping HLA class I- and HLA class-II binding epitopes in a 30-mer peptide.

FIGS. 20A-B—Antigenicity of PolyPEPI1018 CRC Vaccine in a general population. The antigenicity of PolyPEPI1018 in a subject is determined by the AP count, which indicates the number of vaccine antigens that induce T cell responses in a subject. The AP count of PolyPEPI1018 was determined in each of the 433 subjects in the Model Population using the PEPI Test, and the AP50 count was then calculated for the Model Population. The AP50 of PolyPEPI1018 in the Model Population is 4.73. The mean number of immunogenic antigens (i.e., antigens with ≥1 PEPI) in PolyPEPI1018 in a general population is 4.73. Abbreviations: AP=antigens with ≥1 PEPI. Left Panel: Cumulative distribution curve. Right Panel: Distinct distribution curve.

FIGS. 21A-B—Effectiveness of PolyPEPI1018 CRC Vaccine in a general population. Vaccine induced T cells can recognize and kill tumor cells if a PEPI in the vaccine is presented by the tumor cell. The number of AGPs (expressed antigens with PEPI) is an indicator of vaccine effectiveness in an individual, and is dependent on both the potency and antigenicity of PolyPEPI1018. The mean number of immunogenic CTAs (i.e., AP [expressed antigens with ≥1 PEPI]) in PolyPEPI1018 is 2.54 in the Model Population. The likelihood that PolyPEPI1018 induces T cell responses against multiple antigens in a subject (i.e., mAGP) in the Model Population is 77%.

FIGS. 22A-B—Probability of vaccine antigen expression in the XYZ patient's tumor cells. There is over 95% probability that 5 out of the 12 target antigens in the vaccine regimen is expressed in the patient's tumor. Consequently, the 12 peptide vaccines together can induce immune responses against at least 5 ovarian cancer antigens with 95% probability (AGP95). It has 84% probability that each peptide will induce immune responses in the XYZ patient. AGP50 is the mean (expected value)=7.9 (it is a measure of the effectiveness of the vaccine in attacking the tumor of XYZ patient).

FIG. 23—MRI findings of patient XYZ treated with personalised (PIT) vaccine. This late stage, heavily pretreated ovarian cancer patient had an unexpected objective response after the PIT vaccine treatment. These MRI findings suggest that PIT vaccine in combination with chemotherapy significantly reduced her tumor burden. The patient now continues the PIT vaccine treatment.

FIGS. 24A-B—Probability of vaccine antigen expression in the ABC patient's tumor cells. There is over 95% probability that 4 out of the 13 target antigens in the vaccine is expressed in the patient's tumor. Consequently, the 12 peptide vaccines together can induce immune responses against at least 4 breast cancer antigens with 95% probability (AGP95). It has 84% probability that each peptide will induce immune responses in the ABC patient. AGP50 is the mean (expected value) of the discrete probability distribution=6.45 (it is a measure of the effectiveness of the vaccine in attacking the tumor of ABC patient).

DESCRIPTION OF THE SEQUENCES

SEQ ID NOs: 1 to 20 set forth 9 mer T cell epitopes described in Table 17.

SEQ ID NOs: 21 to 40 set forth 9 mer T cell epitopes described in Table 20.

SEQ ID NOs 41 to 60 set forth 15 mer T cell epitopes described in Table 17.

SEQ ID NOs 61 to 80 set forth 15 mer T cell epitopes described in Table 20.

SEQ ID NOs: 81 to 111 set forth breast cancer vaccine peptides described in Table 18a.

SEQ ID NOs 112 to 142 set forth the colorectal cancer vaccine peptides described in Table 21a.

SEQ ID NOs 143 to 158 set forth breast cancer, colorectal cancer and/or ovarian cancer associated antigens.

SEQ ID NOs 159 to 171 set forth the additional peptide sequences described in Table 10.

SEQ ID NOs 172 to 194 set forth further 9 mer T cell epitopes described in Table 17.

SEQ ID NOs 195 to 233 set forth further 15 mer T cell epitopes described in Table 17.

SEQ ID NOs 234 to 250 set forth further 9 mer T cell epitopes described in Table 20.

SEQ ID NOs 251 to 271 set forth further 15 mer T cell epitopes described in Table 20.

SEQ ID NOs: 272 to 301 set forth the 9 mer T cell epitopes described in Table 23.

SEQ ID NOs: 302 to 331 set forth the 15 mer T cell epitopes described in Table 23.

SEQ ID NOs: 332 to 346 set forth the ovarian cancer vaccine peptides set forth in Table 24.

SEQ ID NOs: 347 to 361 set forth further breast cancer, colorectal cancer and/or ovarian cancer associated antigens.

SEQ ID NOs: 362 to 374 set forth personalised vaccine peptides designed for patient XYZ described in Table 38.

SEQ ID NOs: 375 to 386 set forth personalised vaccine peptides designed for patient ABC described in Table 41.

SEQ ID NOs 387 to 434 set forth further 9 mer T cell epitopes described in Table 32

SEQ ID NOs: 435 to 449 set forth further breast cancer vaccine peptides described in Table 18a.

DETAILED DESCRIPTION

HLA Genotypes

HLAs are encoded by the most polymorphic genes of the human genome. Each person has a maternal and a paternal allele for the three HLA class I molecules (HLA-A*, HLA-B*, HLA-C*) and four HLA class II molecules (HLA-DP*, HLA-DQ*, HLA-DRB1*, HLA-DRB3*/4*/5*). Practically, each person expresses a different combination of 6 HLA class I and 8 HLA class II molecules that present different epitopes from the same protein antigen. The function of HLA molecules is to regulate T cell responses. However up to date it was unknown how the HLAs of a person regulate T cell activation.

The nomenclature used to designate the amino acid sequence of the HLA molecule is as follows: gene name*allele:protein number, which, for instance, can look like: HLA-A*02:25. In this example, “02” refers to the allele. In most instances, alleles are defined by serotypes—meaning that the proteins of a given allele will not react with each other in serological assays. Protein numbers (“25” in the example above) are assigned consecutively as the protein is discovered. A new protein number is assigned for any protein with a different amino acid sequence (e.g. even a one amino acid change in sequence is considered a different protein number). Further information on the nucleic acid sequence of a given locus may be appended to the HLA nomenclature, but such information is not required for the methods described herein.

The HLA class I genotype or HLA class II genotype of an individual may refer to the actual amino acid sequence of each class I or class II HLA of an individual, or may refer to the nomenclature, as described above, that designates, minimally, the allele and protein number of each HLA gene. An HLA genotype may be determined using any suitable method. For example, the sequence may be determined via sequencing the HLA gene loci using methods and protocols known in the art. Alternatively, the HLA set of an individual may be stored in a database and accessed using methods known in the art.

Some subjects may have two HLA alleles that encode the same HLA molecule (for example, two copies for HLA-A*02:25 in case of homozygosity). The HLA molecules encoded by these alleles bind all of the same T cell epitopes. For the purposes of this disclosure “binding to at least two HLA molecules of the subject” as used herein includes binding to the HLA molecules encoded by two identical HLA alleles in a single subject. In other words, “binding to at least two HLA molecules of the subject” and the like could otherwise be expressed as “binding to the HLA molecules encoded by at least two HLA alleles of the subject”.

Polypeptides

The disclosure relates to polypeptides that are derived from CTAs and that are immunogenic for a high proportion of the human population.

As used herein, the term “polypeptide” refers to a full-length protein, a portion of a protein, or a peptide characterized as a string of amino acids. As used herein, the term “peptide” refers to a short polypeptide comprising between 2, or 3, or 4, or 5, or 6, or 7, or 8, or 9, or 10, or 11, or 12, or 13, or 14, or 15 and 10, or 11, or 12, or 13, or 14, or 15, or 20, or 25, or 30, or 35, or 40, or 45, or 50 or 55 or 60 amino acids.

The terms “fragment” or “fragment of a polypeptide” as used herein refer to a string of amino acids or an amino acid sequence typically of reduced length relative to the or a reference polypeptide and comprising, over the common portion, an amino acid sequence identical to the reference polypeptide. Such a fragment according to the disclosure may be, where appropriate, included in a larger polypeptide of which it is a constituent. In some cases the fragment may comprise the full length of the polypeptide, for example where the whole polypeptide, such as a 9 amino acid peptide, is a single T cell epitope. In some cases the fragments referred to herein may be between 2, or 3, or 4, or 5 or 6 or 7 or 8 or 9 and 20, or 25, or 30, or 35, or 40, or 45, or 50 amino acids.

As used herein, the term “epitope” or “T cell epitope” refers to a sequence of contiguous amino acids contained within a protein antigen that possess a binding affinity for (is capable of binding to) one or more HLAs. An epitope is HLA- and antigen-specific (HLA-epitope pairs, predicted with known methods), but not subject specific. An epitope, a T cell epitope, a polypeptide, a fragment of a polypeptide or a composition comprising a polypeptide or a fragment thereof is “immunogenic” for a specific human subject if it is capable of inducing a T cell response (a cytotoxic T cell response or a helper T cell response) in that subject. In some cases the helper T cell response is a Th1-type helper T cell response. In some cases an epitope, a T cell epitope, a polypeptide, a fragment of a polypeptide or a composition comprising a polypeptide or a fragment thereof is “immunogenic” for a specific human subject if it is more likely to induce a T cell response or immune response in the subject than a different T cell epitope (or in some cases two different T cell epitopes each) capable of binding to just one HLA molecule of the subject.

The terms “T cell response” and “immune response” are used herein interchangeably, and refer to the activation of T cells and/or the induction of one or more effector functions following recognition of one or more HLA-epitope binding pairs. In some cases an “immune response” includes an antibody response, because HLA class II molecules stimulate helper responses that are involved in inducing both long lasting CTL responses and antibody responses. Effector functions include cytotoxicity, cytokine production and proliferation. According to the present disclosure, an epitope, a T cell epitope, or a fragment of a polypeptide is immunogenic for a specific subject if it is capable of binding to at least two, or in some cases at least three, class I or at least two, or in some cases at least three or at least four class II HLAs of the subject.

For the purposes of this disclosure we have coined the term “personal epitope”, or “PEPI” to distinguish subject specific epitopes from HLA specific epitopes. A “PEPI” is a fragment of a polypeptide consisting of a sequence of contiguous amino acids of the polypeptide that is a T cell epitope capable of binding to one or more HLA class I molecules of a specific human subject. In other cases a “PEPI” is a fragment of a polypeptide consisting of a sequence of contiguous amino acids of the polypeptide that is a T cell epitope capable of binding to one or more HLA class II molecules of a specific human subject. In other words a “PEPI” is a T cell epitope that is recognised by the HLA set of a specific individual, and is consequently specific to the subject in addition to the HLA and the antigen. In contrast to an “epitope”, which is specific only to HLA and the antigen, PEPIs are specific to an individual because different individuals have different HLA molecules which each bind to different T cell epitopes. This subject specificity of the PEPIs allows to make personalized cancer vaccines.

“PEPI1” as used herein refers to a peptide, or a fragment of a polypeptide, that can bind to one HLA class I molecule (or, in specific contexts, HLA class II molecule) of an individual. “PEPI1+” refers to a peptide, or a fragment of a polypeptide, that can bind to one or more HLA class I molecule of an individual.

“PEPI2” refers to a peptide, or a fragment of a polypeptide, that can bind to two HLA class I (or II) molecules of an individual. “PEPI2+” refers to a peptide, or a fragment of a polypeptide, that can bind to two or more HLA class I (or II) molecules of an individual, i.e. a fragment identified according to a method of the disclosure.

“PEPI3” refers to a peptide, or a fragment of a polypeptide, that can bind to three HLA class I (or II) molecules of an individual. “PEPI3+” refers to a peptide, or a fragment of a polypeptide, that can bind to three or more HLA class I (or II) molecules of an individual.

“PEPI4” refers to a peptide, or a fragment of a polypeptide, that can bind to four HLA class I (or II) molecules of an individual. “PEPI4+” refers to a peptide, or a fragment of a polypeptide, that can bind to four or more HLA class I (or II) molecules of an individual.

“PEPI5” refers to a peptide, or a fragment of a polypeptide, that can bind to five HLA class I (or II) molecules of an individual. “PEPI5+” refers to a peptide, or a fragment of a polypeptide, that can bind to five or more HLA class I (or II) molecules of an individual.

“PEPI6” refers to a peptide, or a fragment of a polypeptide, that can bind to all six HLA class I (or six HLA class II) molecules of an individual.

Generally speaking, epitopes presented by HLA class I molecules are about nine amino acids long and epitopes presented by HLA class II molecules are about fifteen amino acids long. For the purposes of this disclosure, however, an epitope may be more or less than nine (for HLA Class I) or fifteen (for HLA Class II) amino acids long, as long as the epitope is capable of binding HLA. For example, an epitope that is capable of binding to class I HLA may be between 7, or 8 or 9 and 9 or 10 or 11 amino acids long. An epitope that is capable of binding to a class II HLA may be between 13, or 14 or 15 and 15 or 16 or 17 amino acids long.

A given HLA of a subject will only present to T cells a limited number of different peptides produced by the processing of protein antigens in an APC. As used herein, “display” or “present”, when used in relation to HLA, references the binding between a peptide (epitope) and an HLA. In this regard, to “display” or “present” a peptide is synonymous with “binding” a peptide.

Using techniques known in the art, it is possible to determine the epitopes that will bind to a known HLA. Any suitable method may be used, provided that the same method is used to determine multiple HLA-epitope binding pairs that are directly compared. For example, biochemical analysis may be used. It is also possible to use lists of epitopes known to be bound by a given HLA. It is also possible to use predictive or modelling software to determine which epitopes may be bound by a given HLA. Examples are provided in Table 1. In some cases a T cell epitope is capable of binding to a given HLA if it has an IC50 or predicted IC50 of less than 5000 nM, less than 2000 nM, less than 1000 nM, or less than 500 nM.

TABLE 1 Example software for determining epitope-HLA binding EPITOPE PREDICTION TOOLS WEB ADDRESS BIMAS, NIH www-bimas.cit.nih.gov/molbio/hla_bind/ PPAPROC, Tubingen Univ. MHCPred, Edward Jenner Inst. of Vaccine Res. EpiJen, Edward Jenner Inst. of Vaccine www.ddg-pharmfac.net/epijen/EpiJen/EpiJen.htm Res. NetMHC, Center for Biological www.cbs.dtu.dk/services/NetMHC/ Sequence Analysis SVMHC, Tubingen Univ. abi.inf.uni-tuebingen.de/Services/SVMHC/ SYFPEITHI, Biomedical Informatics, www.syfpeithi.de/bin/MHCServer.dll/EpitopePrediction.htm Heidelberg ETK EPITOOLKIT, Tubingen Univ. etk.informatik.uni-tuebingen.de/epipred/ PREDEP, Hebrew Univ. Jerusalem margalit.huji.ac.il/Teppred/mhc-bind/index.html RANKPEP, MIF Bioinformatics bio.dfci.harvard.edu/RANKPEP/ IEDB, Immune Epitope Database tools.immuneepitope.org/main/html/tcell_tools.html EPITOPE DATABASES WEB ADDRESS MHCBN, Institute of Microbial www.imtech.res.in/raghava/mhcbn/ Technology, Chandigarh, INDIA SYFPEITHI, Biomedical Informatics, www.syfpeithi.de/ Heidelberg AntiJen, Edward Jenner Inst. of www.ddg-pharmfac.net/antijen/AntiJen/antijenhomepage.htm Vaccine Res. EPIMHC database of MHC ligands, immunax.dfci.harvard.edu/epimhc/ MIF Bioinformatics IEDB, Immune Epitope Database www.iedb.ord

In some embodiments the peptides of the disclosure may comprise or consist of one or more fragments of one or more CTAs. CTAs are not typically expressed beyond embryonic development in healthy cells. In healthy adults, CTA expression is limited to male germ cells that do not express HLAs and cannot present antigens to T cells. Therefore, CTAs are considered expressional neoantigens when expressed in cancer cells.

CTAs are a good choice for cancer vaccine targets because their expression is (i) specific for tumor cells, (ii) more frequent in metastases than in primary tumors and (iii) conserved among metastases of the same patient (Gajewski ed. Targeted Therapeutics in Melanoma. Springer New York. 2012).

The peptides of the disclosure may comprise or consist of one or more fragments of one or more breast cancer associated antigens selected from SPAG9 (SEQ ID NO: 143), AKAP-4 (SEQ ID NO: 144), BORIS (SEQ ID NO: 145), NY-SAR-35 (SEQ ID NO: 146), NY-BR-1 (SEQ ID NO: 147), SURVIVIN (SEQ ID NO: 148), MAGE-A11 (SEQ ID NO: 149), PRAME (SEQ ID NO: 150), MAGE-A9 (SEQ ID NO: 151), HOM-TES-85 (SEQ ID NO: 152), PIWIL-2 (SEQ ID NO: 349), EpCAM (SEQ ID NO: 154), HIWI (SEQ ID NO: 350), PLU-1 (SEQ ID NO: 351), TSGA10 (SEQ ID NO: 351), ODF-4 (SEQ ID NO: 352), SP17 (SEQ ID NO:354), RHOXF-2 (SEQ ID NO: 355), and NY-ESO-1 (SEQ ID NO: 356); one or more ovarian cancer-associated antigens selected from PIWIL-4 (SEQ ID NO: 357), WT1 (SEQ ID NO: 358), EpCAM (SEQ ID NO: 154), BORIS (SEQ ID NO: 145), AKAP-4 (SEQ ID NO: 144), OY-TES-1 (SEQ ID NO: 359), SP17 (SEQ ID NO: 354), PIWIL-2 (SEQ ID NO: 349), PIWIL-3 (SEQ ID NO: 360), SPAG9 (SEQ ID NO: 143), PRAME (SEQ ID NO: 150), HIWI (SEQ ID NO: 350), SURVIVIN (SEQ ID NO: 148), and AKAP-3 (SEQ ID NO: 361); and/or one or more colorectal cancer-associated antigens selected from TSP50 (SEQ ID NO: 153), EpCAM (SEQ ID NO: 154), SPAG9 (SEQ ID NO: 143), CAGE1 (SEQ ID NO: 155), FBXO39 (SEQ ID NO: 156), SURVIVIN (SEQ ID NO: 148), MAGE-A8 (SEQ ID NO 157), MAGE-A6 (SEQ ID NO: 158), LEMD1 (SEQ ID NO:348) and MAGE-A3 (SEQ ID NO: 347). In some cases the peptide comprises or consists of one or more amino acid sequences selected from SEQ ID NOs: 41-80, or from SEQ ID NOs: 41-80, 195-233, 251-271 and 302-331 that are optimised for T cell activation/binding to all HLA types across the population.

In some cases the amino acid sequence is flanked at the N and/or C terminus by additional amino acids that are not part of the sequence of the target polypeptide antigen, in other words that are not the same sequence of consecutive amino acids found adjacent to the selected fragments in the target polypeptide antigen. In some cases the sequence is flanked by up to 41 or 35 or 30 or 25 or 20 or 15 or 10, or 9 or 8 or 7 or 6 or 5 or 4 or 3 or 2 or 1 additional amino acid at the N and/or C terminus or between target polypeptide fragments. In other cases each polypeptide either consists of a fragment of a target polypeptide antigen, or consists of two or more such fragments arranged end to end (arranged sequentially in the peptide end to end) or overlapping in a single peptide (where two or more of the fragments comprise partially overlapping sequences, for example where two PEPIs in the same polypeptide are within 50 amino acids of each other).

When fragments of different polypeptides or from different regions of the same polypeptide are joined together in an engineered peptide there is the potential for neoepitopes to be generated around the join or junction. Such neoepitopes encompass at least one amino acid from each fragment on either side of the join or junction, and may be referred to herein as junctional amino acid sequences. The neoepitopes may induce undesired T cell responses against healthy cells (autoimmunity). The polypeptides may be designed, or the polypeptides may be screened, to avoid, eliminate or minimise neoepitopes that correspond to a fragment of a protein expressed in normal healthy human cells and/or neoepitopes that are capable of binding to at least two, or in some cases at least three, or at least four HLA class I molecules of the subject, or in some cases at least two, or at least three or four or five HLA class II molecules of the subject. In some cases the peptide is designed, or the polypeptide screened, to eliminate polypeptides having a junctional neoepitope that is capable of binding in more than a threshold percentage of human subjects in an intent-to-treat population, to at least two HLA class I molecules expressed by individual subjects of the population. In some cases the threshold is 20%, or 15%, or 10%, or 5%, or 2%, or 1%, or 0.5% of said population. Alignment may be determined using known methods such as BLAST algorithms. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/).

The presence in a vaccine or immunotherapy composition of at least two polypeptide fragments (epitopes) that can bind to at least three HLA class I of an individual (≥2 PEPI3+) is predictive for a clinical response. In other words, if ≥2 PEPI3+ can be identified within the active ingredient polypeptide(s) of a vaccine or immunotherapy composition, then an individual is a likely clinical responder. The at least two multiple HLA-binding PEPIs of the composition polypeptides may both target a single antigen (e.g a polypeptide vaccine comprising two multiple HLA-binding PEPIs derived from a single tumor associated antigen targeted by the vaccine) or may target different antigens (e.g. a polypeptide vaccine comprising one multiple HLA-binding PEPI derived from one tumor associated antigen and a second multiple HLA-binding PEPI derived from a different tumor associated antigen).

Without wishing to be bound by theory, the inventors believe that one reason for the increased likelihood of deriving clinical benefit from a vaccine/immunotherapy comprising at least two multiple-HLA binding PEPIs, is that diseased cell populations, such as cancer or tumor cells or cells infected by viruses or pathogens such as HIV, are often heterogenous both within and between effected subjects. A specific cancer patient, for example, may or may not express or overexpress a particular cancer associated target polypeptide antigen of a vaccine, or their cancer may comprise heterogeneous cell populations, some of which (over-)express the antigen and some of which do not. In addition, the likelihood of developing resistance is decreased when more multiple HLA-binding PEPIs are included or targeted by a vaccine/immunotherapy because a patient is less likely to develop resistance to the composition through mutation of the target PEPI(s).

Currently most vaccines and immunotherapy compositions target only a single polypeptide antigen. However according to the present disclosure it is in some cases beneficial to provide a pharmaceutical composition that targets two or more different polypeptide antigens. For example, most cancers or tumors are heterogeneous, meaning that different cancer or tumor cells of a subject (over-)express different antigens. The tumour cells of different cancer patients also express different combinations of tumour-associated antigens. The anti-cancer immunogenic compositions that are most likely to be effective are those that target multiple antigens expressed by the tumor, and therefore more cancer or tumor cells, in an individual human subject or in a population.

The beneficial effect of combining multiple bestEPIs in a single treatment (administration of one or more pharmaceutical compositions that together comprise multiple PEPIs), can be illustrated by the personalised vaccine polypeptides described in Examples 15 and 16 below. Exemplary CTA expression probabilities in ovarian cancer are as follows: BAGE: 30%; MAGE A9: 37%; MAGE A4: 34%; MAGE A10: 52%. If patient XYZ were treated with a vaccine comprising PEPIs in only BAGE and MAGE A9, then the probability of having a mAGP (multiple expressed antigens with PEPI) would be 11%. If patent XYZ were treated with a vaccine comprising only PEPIs for the MAGE A4 and MAGE A10 CTAs, then the probability of having a multi AGP would be 19%. However if a vaccine contained all 4 of these CTAs (BAGE, MAGE A9, MAGE A4 and MAGE A10), then the probability of having a mAGP would be 50%. In other words the effect would be greater than the combined probabilities of mAGP for both two-PEPI treatments (probability mAGP for BAGE/MAGE+ probability mAGP for MAGE A4 and MAGE A10). Patient XYZ's PIT vaccine described in Example 21 contains a further 9 PEPIs, and thus, the probability of having a mAGP is over 99.95%.

Likewise exemplary CTA expression probabilities in breast cancer are as follows: MAGE C2: 21%; MAGE A1: 37%; SPC1: 38%; MAGE A9: 44%. Treatment of patient ABC with a vaccine comprising PEPIs in only MAGE C2: 21% and MAGE A1 has a mAGP probability of 7%. Treatment of patient ABC with a vaccine comprising PEPIs in only SPC1: 38%; MAGE A9 has a mAGP probability of 11%. Treatment of patient ABC with a vaccine comprising PEPIs in MAGE C2: 21%; MAGE A1: 37%; SPC1: 38%; MAGE A9 has a mAGP probability of 44% (44>7+11). Patient ABC's PIT vaccine described in Example 22 contains a further 8 PEPIs, and thus, the probability of having a mAGP is over 99.93%.

Accordingly in some cases, the polypeptide or panel of polypeptides of the disclosure or an active ingredient polypeptide of a pharmaceutical composition or kit of the disclosure may comprise or consist of any combination of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 fragments of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 one or more of the cancer associated antigens, or CTAs, such as the CTA discussed above. Each fragment comprises or consists of a different target epitope having an amino acid sequence selected from SEQ ID NOs: 1-40; or selected from SEQ ID NOs: 1 to 20; or selected from SEQ ID NOs: 21 to 40; or selected from SEQ ID NOs: 1-20, 24 and 172-194; or selected from SEQ ID NOs: 21-40 and 234-250; or selected from SEQ ID NOs: 272-301; or selected from SEQ ID NOs: 1-40, 172-194 and 234-250; or selected from SEQ ID NOs: 21-40, 234-250 and 272-301; or selected from SEQ ID NOs: 1-20, 24, 172-194 and 272-301; or selected from SEQ ID NOs: 1-40, 172-194, 234-250 and 272-301; or selected from SEQ ID NOs: 41-60, 64 and 195-233; or selected from SEQ ID NOs: 61-80 and 251-271; or selected from SEQ ID NOs: 302-331; or selected from SEQ ID NOs: 41-80, 195-233 and 251-271; or selected from SEQ ID NOs: 61-80, 251-271 and 302 to 331; or selected from SEQ ID NOs: 41-60, 64, 191-233 and 302 to 331; or selected from SEQ ID NOs: 41-80, 195-233, 251-271 and 332-346; or selected from SEQ ID NOs: 1-20, 24, 41-60, 64, 172-194 and 195-233; or selected from SEQ ID NOs: 21-40, 61-80, 234-250 and 251-271; or selected from SEQ ID NOs: 271-331; or selected from SEQ ID NOs: 1-80, 172-194, 195-233, 234-250 and 251-271; or selected from SEQ ID NOs: 21-40, 61-80, 234-250, 251-271, 272-301 and 302-331; or selected from SEQ ID NOs: 1-80, 172-233, 234-271 and 272-331; or selected from SEQ ID NOs: 81-111 and 435-449; or selected from SEQ ID NOs: 112-142; or selected from SEQ ID NOs: 332-346; or selected from SEQ ID NOs: 81-142; or selected from SEQ ID NOs: 112-142 and 332-346; or selected from SEQ ID NOs: 81-111, 435-449 and 332-346; or selected from SEQ ID NOs: 81-142 and 332-346; or selected from SEQ ID NOs: 41-60, 64, 81-111, 435-449 and 195-233; or selected from SEQ ID NOs: 61-80, 112-142 and 251-271; or selected from SEQ ID NOs: 302-346; or selected from SEQ ID NOs: 41-142, 195-233 and 251-271; or selected from SEQ ID NOs: 61-80, 112-142, 251-271 and 302-346; or selected from SEQ ID NOs: 41-60, 64, 81-111, 435-449, 195-233 and 302-346; or selected from SEQ ID NOs: 41-142, 195-233, 251-271 and 302-346; or selected from SEQ ID NOs: 1-20, 24, 41-60, 64, 81-111, 435-449 and 172-233; or selected from SEQ ID NOs: 21-40, 61-80, 112-142, or 234-271; or selected from SEQ ID NOs: 272-346; or selected from SEQ ID NOs: 1-142 and 172-271; or selected from SEQ ID NOs: 21-40, 61-80, 112-142 and 234-346; or selected from SEQ ID NOs: 1-20, 24, 41-60, 64, 81-111, 435-449, 172-233 and 272 to 346; or selected from SEQ ID NOs: 1-142 and 172-346; or selected from SEQ ID NOs: 1 to 2, or to 3, or 4, or 5, or 6, or 7, or 8, or 9, or 10, or 11, or 12, or 13, or 14, or 15, or 16, or 17, or 18, or 19, or SEQ ID NOs: 20 to 21, or to 22, or 23, or 24, or 25, or 26, or 27, or 28, or 29, or 30, or 31, or 32, or 33, or 34, or 35, or 36, or 37, or 38, or 39; or a different amino acid sequences selected from SEQ ID NOs: 41 to 80, or SEQ ID NOs: 41 to 60, or SEQ ID NOs: 61-80; or SEQ ID NOs: 41 to 42, or to 43, or to 44, or to 45, or to 46, or to 47, or to 48, or to 49, or 50, or 51, or 52, or 53, or 54, or 55, or 56, or 57, or 58, or 59, SEQ ID NOs: 60 to 61, or to 62, or to 63, or to 64, or to 65, or to 66, or to 67, or to 68, or to 69, or to 70, or to 71, or to 72, or to 73, or to 74, or to 75, or to 76, or to 77, or to 78, or to 79; a different amino acid sequences selected from SEQ ID NOs: 81 to 142; or selected from SEQ ID NOs: 81 to 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 105, 106, 107, 108, 109, 110, or 111; or selected from SEQ ID NOs: 81 to 105; or selected from SEQ ID NOs: 99, 100, 92, 93, 101, 103, 104, 105 and 98; or selected from SEQ ID NOs: 112 to 142; or selected from SEQ ID NOs: 112 to 113, 114, 115, 116, 117, 118, 119, 120, 121, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141 or 142; or selected from SEQ ID NOs: 112 to 134; or selected from SEQ ID NOs: 121, 124, 126, 127, 130, 131, 132, 133 and 134; or selected from SEQ ID NOs: 1 to 2, or to 3, or 4, or 5, or 6, or 7, or 8, or 9, or 10, or 11, or 12, or 13, or 14, or 15, or 16, or 17, or 18, or 19, or SEQ ID NOs: 20 to 21, or to 22, or 23, or 24, or 25, or 26, or 27, or 28, or 29, or 30, or 31, or 32, or 33, or 34, or 35, or 36, or 37, or 38, or 39; or a different amino acid sequences selected from SEQ ID NOs: 41 to 80, or SEQ ID NOs: 41 to 60, or SEQ ID NOs: 61-80; or SEQ ID NOs: 41 to 42, or to 43, or to 44, or to 45, or to 46, or to 47, or to 48, or to 49, or 50, or 51, or 52, or 53, or 54, or 55, or 56, or 57, or 58, or 59, SEQ ID NOs: 60 to 61, or to 62, or to 63, or to 64, or to 65, or to 66, or to 67, or to 68, or to 69, or to 70, or to 71, or to 72, or to 73, or to 74, or to 75, or to 76, or to 77, or to 78, or to 79; a different amino acid sequences selected from SEQ ID NOs: 81 to 142; or selected from SEQ ID NOs: 81 to 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 105, 106, 107, 108, 109, 110, or 111; or selected from SEQ ID NOs: 81 to 105; or selected from SEQ ID NOs: 99, 100, 92, 93, 101, 103, 104, 105 and 98; or selected from SEQ ID NOs: 112 to 142; or selected from SEQ ID NOs: 112 to 113, 114, 115, 116, 117, 118, 119, 120, 121, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141 or 142; or selected from SEQ ID NOs: 112 to 134; or selected from SEQ ID NOs: 121, 124, 126, 127, 130, 131, 132, 133 and 134; or selected from SEQ ID Nos: 130, 121, 131, 124, 134, 126; or selected from SEQ ID NO: 435-449; or selected from any of these groups of sequences excluding SEQ ID NOs: 12, 32, 19 and/or 39, and/or SEQ ID NOs: 21, 41, 23 and/or 43 and/or SEQ ID NOs: 172, 177, 195 and/or 203, and/or SEQ ID NOs: 1, 41 and/or 197, and/or SEQ ID NOs: 4, 44 and/or 201, and/or SEQ ID NOs: 1, 4, 44, 197 and/or 201, and/or SEQ ID NOs: 1, 41, 197, 184 and/or 212, and/or SEQ ID NOs: 3, 43 and/or 200, and/or SEQ ID NOs: 3, 43, 200, 7 and/or 47, and/or SEQ ID NOs: 10, 50 and/or 220, and/or SEQ ID NOs: 24, 64 and/or 202, and/or SEQ ID NOs: 6, 46 and/or 209, and/or SEQ ID NOs: 182, 210, 185 and/or 213, and/or SEQ ID NOs: 14, 54, 225 and 226, and/or SEQ ID NOs: 190, 218, 11, 51 and/or 219, and/or SEQ ID NOs: 12, 224 and/or 52, and/or SEQ ID NOs: 192, 227 and/or 228, and/or SEQ ID NOs: 17, 229, 230 and/or 57, and/or SEQ ID NOs: 21, 252, 61 and/or 253, and/or SEQ ID NOs: 23, 63 and/or 256, and/or SEQ ID NOs: 21, 252, 61, 253, 23, 63 and/or 256, and/or SEQ ID NOs: 237 and/or 238, and/or SEQ ID NOs: 26 and/or 240, and/or SEQ ID NOs: 242, 244, 263 and/or 265, and/or SEQ ID NOs: 29, 69 and/or 259, and/or SEQ ID NOs: 24, 64 and/or 255, and/or SEQ ID NOs: 236, 257 and/or 258, and/or SEQ ID NOs: 27, 67, 241 and/or 262, and/or SEQ ID NOs: 252, 249 and/or 264, and/or SEQ ID NOs: 35, 250 and/or 75, and/or SEQ ID NOs: 252, 249, 264, 35, 250 and/or 75, and/or SEQ ID NOs: 36, 266 and/or 76, and/or SEQ ID NOs: 36, 266, 76, 39 and/or 79, and/or SEQ ID NOs: 38, 268 and/or 78, and/or SEQ ID NOs: 38, 268, 78, 246 and/or 270, and/or SEQ ID NOs: 245, 269, and/or 248, and/or SEQ ID NOs: 245, 269, 248, 40 and/or 80, and/or SEQ ID NOs: 272, 302, 281 and/or 311, and/or SEQ ID NOs: 276, 306, 300 and/or 330, and/or SEQ ID NOs: 276, 306, 289 and/or 319, and/or SEQ ID NOs: 277, 307, 283 and/or 313, and/or SEQ ID NOs: 277, 307, 290 and/or 320, and/or SEQ ID NOs: 282, 312, 297 and/or 327, or any other combinations of the sequences disclosed herein that are within 50-60 amino acids of each other in any one or more of the antigens of SEQ ID NOs: 143-158 and 347 to 351; and/or SEQ ID NOs: 18, 19 and/or 20 and/or SEQ ID NOs: 34-40; and/or SEQ ID NOs corresponding to peptides shown in Table 17, 20 and/or 23 having a N %*B % value of less than 12% or 13% or 14% or 17.6% or 17.8% or 18% or 20% or 21% or 22% or 22.2% or 24% or 25% or 27% or 28% or 30% or 31% or 31.5% or 32% or 32.5% or 35%. In some cases the panel of peptides comprises or consists of one or more polypeptides comprising or consisting of the amino acid sequences of SEQ ID NOs: 130, 121, 131, 124, 134, 126 and/or SEQ ID NOs: 435-449.

In some cases the disclosure provides a panel of any two or more of the peptides or groups of peptides described above. For example the panel may comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more such peptides. In some cases the panel comprises or consists of peptides comprising or consisting of all or any combination of the amino acid sequences of SEQ ID NOs: 99, 100, 92, 93, 101, 103, 104, 105 and 98; or the amino acid sequences of SEQ ID NOs: 121, 124, 126, 127, 130, 131, 132, 133 and 134. In some cases the panel comprises or consists of peptides comprising or consisting of all or any combination of the amino acid sequences of SEQ ID NOs: SEQ ID NOs: 130, 121, 131, 124, 134, 126 and/or SEQ ID NOs: 435-449.

Pharmaceutical Compositions, Methods of Treatment and Modes of Administration

In some aspects the disclosure relates to a pharmaceutical composition, kit, or panels of polypeptides as described above having one or more polypeptides as active ingredient(s). These may be for use in a method of inducing an immune response, treating, vaccinating or providing immunotherapy to a subject, and the pharmaceutical composition may be a vaccine or immunotherapy composition. Such a treatment comprises administering one or more polypeptides or pharmaceutical compositions that together comprise all of the active ingredient polypeptides of the treatment to the subject. Multiple polypeptides or pharmaceutical compositions may be administered together or sequentially, for example all of the pharmaceutical compositions or polypeptides may be administered to the subject within a period of 1 year, or 6 months, or 3 months, or 60 or 50 or 40 or 30 days.

The term “active ingredient” as used herein refers to a polypeptide that is intended to induce an immune response and may include a polypeptide product of a vaccine or immunotherapy composition that is produced in vivo after administration to a subject. For a DNA or RNA immunotherapy composition, the polypeptide may be produced in vivo by the cells of a subject to whom the composition is administered. For a cell-based composition, the polypeptide may be processed and/or presented by cells of the composition, for example autologous dendritic cells or antigen presenting cells pulsed with the polypeptide or comprising an expression construct encoding the polypeptide. The pharmaceutical composition may comprise a polynucleotide or cell encoding one or more active ingredient polypeptides.

The composition/kit may optionally further comprise at least one pharmaceutically acceptable diluent, carrier, or preservative and/or additional polypeptides that do not comprise any PEPIs. The polypeptides may be engineered or non-naturally occurring. The kit may comprise one or more separate containers each containing one or more of the active ingredient peptides. The composition/kit may be a personalised medicine to prevent, diagnose, alleviate, treat, or cure a disease of an individual, such as a cancer.

The immunogenic or pharmaceutical compositions or kits described herein may comprise, in addition to one or more immunogenic peptides, a pharmaceutically acceptable excipient, carrier, diluent, buffer, stabiliser, preservative, adjuvant or other materials well known to those skilled in the art. Such materials are preferably non-toxic and preferably do not interfere with the pharmaceutical activity of the active ingredient(s). The pharmaceutical carrier or diluent may be, for example, water containing solutions. The precise nature of the carrier or other material may depend on the route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intradermal, and intraperitoneal routes.

The pharmaceutical compositions of the disclosure may comprise one or more “pharmaceutically acceptable carriers”. These are typically large, slowly metabolized macromolecules such as proteins, saccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, sucrose (Paoletti et al., 2001, Vaccine, 19:2118), trehalose (WO 00/56365), lactose and lipid aggregates (such as oil droplets or liposomes). Such carriers are well known to those of ordinary skill in the art. The pharmaceutical compositions may also contain diluents, such as water, saline, glycerol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present. Sterile pyrogen-free, phosphate buffered physiologic saline is a typical carrier (Gennaro, 2000, Remington: The Science and Practice of Pharmacy, 20th edition, ISBN:0683306472).

The pharmaceutical compositions of the disclosure may be lyophilized or in aqueous form, i.e. solutions or suspensions. Liquid formulations of this type allow the compositions to be administered direct from their packaged form, without the need for reconstitution in an aqueous medium, and are thus ideal for injection. The pharmaceutical compositions may be presented in vials, or they may be presented in ready filled syringes. The syringes may be supplied with or without needles. A syringe will include a single dose, whereas a vial may include a single dose or multiple doses.

Liquid formulations of the disclosure are also suitable for reconstituting other medicaments from a lyophilized form. Where a pharmaceutical composition is to be used for such extemporaneous reconstitution, the disclosure provides a kit, which may comprise two vials, or may comprise one ready-filled syringe and one vial, with the contents of the syringe being used to reconstitute the contents of the vial prior to injection.

The pharmaceutical compositions of the disclosure may include an antimicrobial, particularly when packaged in a multiple dose format. Antimicrobials may be used, such as 2-phenoxyethanol or parabens (methyl, ethyl, propyl parabens). Any preservative is preferably present at low levels. Preservative may be added exogenously and/or may be a component of the bulk antigens which are mixed to form the composition (e.g. present as a preservative in pertussis antigens).

The pharmaceutical compositions of the disclosure may comprise detergent e.g. Tween (polysorbate), DMSO (dimethyl sulfoxide), DMF (dimethylformamide). Detergents are generally present at low levels, e.g. <0.01%, but may also be used at higher levels, e.g. 0.01-50%.

The pharmaceutical compositions of the disclosure may include sodium salts (e.g. sodium chloride) and free phosphate ions in solution (e.g. by the use of a phosphate buffer).

In certain embodiments, the pharmaceutical composition may be encapsulated in a suitable vehicle either to deliver the peptides into antigen presenting cells or to increase the stability. As will be appreciated by a skilled artisan, a variety of vehicles are suitable for delivering a pharmaceutical composition of the disclosure. Non-limiting examples of suitable structured fluid delivery systems may include nanoparticles, liposomes, microemulsions, micelles, dendrimers and other phospholipid-containing systems. Methods of incorporating pharmaceutical compositions into delivery vehicles are known in the art.

In order to increase the immunogenicity of the composition, the pharmacological compositions may comprise one or more adjuvants and/or cytokines.

Suitable adjuvants include an aluminum salt such as aluminum hydroxide or aluminum phosphate, but may also be a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, or may be cationically or anionically derivatised saccharides, polyphosphazenes, biodegradable microspheres, monophosphoryl lipid A (MPL), lipid A derivatives (e.g. of reduced toxicity), 3-O-deacylated MPL [3D-MPL], quil A, Saponin, QS21, Freund's Incomplete Adjuvant (Difco Laboratories, Detroit, Mich.), Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.), AS-2 (Smith-Kline Beecham, Philadelphia, Pa.), CpG oligonucleotides, bioadhesives and mucoadhesives, microparticles, liposomes, polyoxyethylene ether formulations, polyoxyethylene ester formulations, muramyl peptides or imidazoquinolone compounds (e.g. imiquamod and its homologues). Human immunomodulators suitable for use as adjuvants in the disclosure include cytokines such as interleukins (e.g. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc), macrophage colony stimulating factor (M-CSF), tumour necrosis factor (TNF), granulocyte, macrophage colony stimulating factor (GM-CSF) may also be used as adjuvants.

In some embodiments, the compositions comprise an adjuvant selected from the group consisting of Montanide ISA-51 (a water-in-oil emulsion, Seppic, Inc., Fairfield, N.J., United States of America), QS-21 (Aquila Biopharmaceuticals, Inc., Lexington, Mass., United States of America), GM-CSF, cyclophosamide, bacillus Calmette-Guerin (BCG), Corynbacterium parvum, levamisole, azimezone, isoprinisone, dinitrochlorobenezene (DNCB), keyhole limpet hemocyanins (KLH), Freunds adjuvant (complete and incomplete), mineral gels, aluminum hydroxide (Alum), lysolecithin, pluronic polyols, polyanions, oil emulsions, dinitrophenol, diphtheria toxin (DT).

By way of example, the cytokine may be selected from the group consisting of a transforming growth factor (TGF) such as but not limited to TGF-α and TGF-β insulin-like growth factor-I and/or insulin-like growth factor-II; erythropoietin (EPO); an osteoinductive factor; an interferon such as but not limited to interferon-.α, -β, and -γ; a colony stimulating factor (CSF) such as but not limited to macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF). In some embodiments, the cytokine is selected from the group consisting of nerve growth factors such as NGF-β; platelet-growth factor; a transforming growth factor (TGF) such as but not limited to TGF-α. and TGF-β; insulin-like growth factor-I and insulin-like growth factor-II; erythropoietin (EPO); an osteoinductive factor; an interferon (IFN) such as but not limited to IFN-α, IFN-β, and IFN-γ; a colony stimulating factor (CSF) such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); an interleukin (II) such as but not limited to IL-1, IL-1.alpha., IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; IL-13, IL-14, IL-15, IL-16, IL-17, IL-18; LIF; kit-ligand or FLT-3; angiostatin; thrombospondin; endostatin; a tumor necrosis factor (TNF); and LT.

It is expected that an adjuvant or cytokine can be added in an amount of about 0.01 mg to about 10 mg per dose, preferably in an amount of about 0.2 mg to about 5 mg per dose. Alternatively, the adjuvant or cytokine may be at a concentration of about 0.01 to 50%, preferably at a concentration of about 2% to 30%.

In certain aspects, the pharmaceutical compositions of the disclosure are prepared by physically mixing the adjuvant and/or cytokine with the peptides of the disclosure under appropriate sterile conditions in accordance with known techniques to produce the final product.

Examples of suitable compositions of the invented polypeptide fragments and methods of administration are provided in Esseku and Adeyeye (2011) and Van den Mooter G. (2006). Vaccine and immunotherapy composition preparation is generally described in Vaccine Design (“The subunit and adjuvant approach” (eds Powell M. F. & Newman M. J. (1995) Plenum Press New York). Encapsulation within liposomes, which is also envisaged, is described by Fullerton, U.S. Pat. No. 4,235,877.

In some embodiments, the compositions disclosed herein are prepared as a nucleic acid vaccine. In some embodiments, the nucleic acid vaccine is a DNA vaccine. In some embodiments, DNA vaccines, or gene vaccines, comprise a plasmid with a promoter and appropriate transcription and translation control elements and a nucleic acid sequence encoding one or more polypeptides of the disclosure. In some embodiments, the plasmids also include sequences to enhance, for example, expression levels, intracellular targeting, or proteasomal processing. In some embodiments, DNA vaccines comprise a viral vector containing a nucleic acid sequence encoding one or more polypeptides of the disclosure. In additional aspects, the compositions disclosed herein comprise one or more nucleic acids encoding peptides determined to have immunoreactivity with a biological sample. For example, in some embodiments, the compositions comprise one or more nucleotide sequences encoding 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more peptides comprising a fragment that is a T cell epitope capable of binding to at least three HLA class I molecules and/or at least three HLA class II molecules of a patient. In some embodiments, the peptides are derived from an antigen that is expressed in cancer. In some embodiments the DNA or gene vaccine also encodes immunomodulatory molecules to manipulate the resulting immune responses, such as enhancing the potency of the vaccine, stimulating the immune system or reducing immunosuppression. Strategies for enhancing the immunogenicity of DNA or gene vaccines include encoding of xenogeneic versions of antigens, fusion of antigens to molecules that activate T cells or trigger associative recognition, priming with DNA vectors followed by boosting with viral vector, and utilization of immunomodulatory molecules. In some embodiments, the DNA vaccine is introduced by a needle, a gene gun, an aerosol injector, with patches, via microneedles, by abrasion, among other forms. In some forms the DNA vaccine is incorporated into liposomes or other forms of nanobodies. In some embodiments, the DNA vaccine includes a delivery system selected from the group consisting of a transfection agent; protamine; a protamine liposome; a polysaccharide particle; a cationic nanoemulsion; a cationic polymer; a cationic polymer liposome; a cationic nanoparticle; a cationic lipid and cholesterol nanoparticle; a cationic lipid, cholesterol, and PEG nanoparticle; a dendrimer nanoparticle. In some embodiments, the DNA vaccines is administered by inhalation or ingestion. In some embodiments, the DNA vaccine is introduced into the blood, the thymus, the pancreas, the skin, the muscle, a tumor, or other sites.

In some embodiments, the compositions disclosed herein are prepared as an RNA vaccine. In some embodiments, the RNA is non-replicating mRNA or virally derived, self-amplifying RNA. In some embodiments, the non-replicating mRNA encodes the peptides disclosed herein and contains 5′ and 3′ untranslated regions (UTRs). In some embodiments, the virally derived, self-amplifying RNA encodes not only the peptides disclosed herein but also the viral replication machinery that enables intracellular RNA amplification and abundant protein expression. In some embodiments, the RNA is directly introduced into the individual. In some embodiments, the RNA is chemically synthesized or transcribed in vitro. In some embodiments, the mRNA is produced from a linear DNA template using a T7, a T3, or an Sp6 phage RNA polymerase, and the resulting product contains an open reading frame that encodes the peptides disclosed herein, flanking UTRs, a 5′ cap, and a poly(A) tail. In some embodiments, various versions of 5′ caps are added during or after the transcription reaction using a vaccinia virus capping enzyme or by incorporating synthetic cap or anti-reverse cap analogues. In some embodiments, an optimal length of the poly(A) tail is added to mRNA either directly from the encoding DNA template or by using poly(A) polymerase. The RNA encodes one or more peptides comprising a fragment that is a T cell epitope capable of binding to at least three HLA class I and/or at least three HLA class II molecules of a patient. In some embodiments, the fragments are derived from an antigen that is expressed in cancer. In some embodiments, the RNA includes signals to enhance stability and translation. In some embodiments, the RNA also includes unnatural nucleotides to increase the half-life or modified nucleosides to change the immunostimulatory profile. In some embodiments, the RNAs is introduced by a needle, a gene gun, an aerosol injector, with patches, via microneedles, by abrasion, among other forms. In some forms the RNA vaccine is incorporated into liposomes or other forms of nanobodies that facilitate cellular uptake of RNA and protect it from degradation. In some embodiments, the RNA vaccine includes a delivery system selected from the group consisting of a transfection agent; protamine; a protamine liposome; a polysaccharide particle; a cationic nanoemulsion; a cationic polymer; a cationic polymer liposome; a cationic nanoparticle; a cationic lipid and cholesterol nanoparticle; a cationic lipid, cholesterol, and PEG nanoparticle; a dendrimer nanoparticle; and/or naked mRNA; naked mRNA with in vivo electroporation; protamine-complexed mRNA; mRNA associated with a positively charged oil-in-water cationic nanoemulsion; mRNA associated with a chemically modified dendrimer and complexed with polyethylene glycol (PEG)-lipid; protamine-complexed mRNA in a PEG-lipid nanoparticle; mRNA associated with a cationic polymer such as polyethylenimine (PEI); mRNA associated with a cationic polymer such as PEI and a lipid component; mRNA associated with a polysaccharide (for example, chitosan) particle or gel; mRNA in a cationic lipid nanoparticle (for example, 1,2-dioleoyloxy-3-trimethylammoniumpropane (DOTAP) or dioleoylphosphatidylethanolamine (DOPE) lipids); mRNA complexed with cationic lipids and cholesterol; or mRNA complexed with cationic lipids, cholesterol and PEG-lipid. In some embodiments, the RNA vaccine is administered by inhalation or ingestion. In some embodiments, the RNA is introduced into the blood, the thymus, the pancreas, the skin, the muscle, a tumor, or other sites, and/or by an intradermal, intramuscular, subcutaneous, intranasal, intranodal, intravenous, intrasplenic, intratumoral or other delivery route.

Polynucleotide or oligonucleotide components may be naked nucleotide sequences or be in combination with cationic lipids, polymers or targeting systems. They may be delivered by any available technique. For example, the polynucleotide or oligonucleotide may be introduced by needle injection, preferably intradermally, subcutaneously or intramuscularly. Alternatively, the polynucleotide or oligonucleotide may be delivered directly across the skin using a delivery device such as particle-mediated gene delivery. The polynucleotide or oligonucleotide may be administered topically to the skin, or to mucosal surfaces for example by intranasal, oral, or intrarectal administration.

Uptake of polynucleotide or oligonucleotide constructs may be enhanced by several known transfection techniques, for example those including the use of transfection agents. Examples of these agents include cationic agents, for example, calcium phosphate and DEAE-Dextran and lipofectants, for example, lipofectam and transfectam. The dosage of the polynucleotide or oligonucleotide to be administered can be altered.

Administration is typically in a “prophylactically effective amount” or a “therapeutically effective amount” (as the case may be, although prophylaxis may be considered therapy), this being sufficient to result in a clinical response or to show clinical benefit to the individual, e.g. an effective amount to prevent or delay onset of the disease or condition, to ameliorate one or more symptoms, to induce or prolong remission, or to delay relapse or recurrence.

The dose may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the individual to be treated; the route of administration; and the required regimen. The amount of antigen in each dose is selected as an amount which induces an immune response. A physician will be able to determine the required route of administration and dosage for any particular individual. The dose may be provided as a single dose or may be provided as multiple doses, for example taken at regular intervals, for example 2, 3 or 4 doses administered hourly. Typically peptides, polynucleotides or oligonucleotides are typically administered in the range of 1 μg to 1 mg, more typically 1 pg to 10 μg for particle mediated delivery and 1 μg to 1 mg, more typically 1-100 μg, more typically 5-50 μg for other routes. Generally, it is expected that each dose will comprise 0.01-3 mg of antigen. An optimal amount for a particular vaccine can be ascertained by studies involving observation of immune responses in subjects.

Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins.

In some cases in accordance with the disclosure, more than one peptide or composition of peptides is administered. Two or more pharmaceutical compositions may be administered together/simultaneously and/or at different times or sequentially. Thus, the disclosure includes sets of pharmaceutical compositions and uses thereof. The use of combination of different peptides, optionally targeting different antigens, is important to overcome the challenges of genetic heterogeneity of tumors and HLA heterogeneity of individuals. The use of peptides of the disclosure in combination expands the group of individuals who can experience clinical benefit from vaccination. Multiple pharmaceutical compositions of peptides of the disclosure, manufactured for use in one regimen, may define a drug product.

Routes of administration include but are not limited to intranasal, oral, subcutaneous, intradermal, and intramuscular. The subcutaneous administration is particularly preferred. Subcutaneous administration may for example be by injection into the abdomen, lateral and anterior aspects of upper arm or thigh, scapular area of back, or upper ventrodorsal gluteal area.

The compositions of the disclosure may also be administered in one, or more doses, as well as, by other routes of administration. For example, such other routes include, intracutaneously, intravenously, intravascularly, intraarterially, intraperitnoeally, intrathecally, intratracheally, intracardially, intralobally, intramedullarly, intrapulmonarily, and intravaginally. Depending on the desired duration of the treatment, the compositions according to the disclosure may be administered once or several times, also intermittently, for instance on a monthly basis for several months or years and in different dosages.

Solid dosage forms for oral administration include capsules, tablets, caplets, pills, powders, pellets, and granules. In such solid dosage forms, the active ingredient is ordinarily combined with one or more pharmaceutically acceptable excipients, examples of which are detailed above. Oral preparations may also be administered as aqueous suspensions, elixirs, or syrups. For these, the active ingredient may be combined with various sweetening or flavoring agents, coloring agents, and, if so desired, emulsifying and/or suspending agents, as well as diluents such as water, ethanol, glycerin, and combinations thereof.

One or more compositions of the disclosure may be administered, or the methods and uses for treatment according to the disclosure may be performed, alone or in combination with other pharmacological compositions or treatments, for example chemotherapy and/or immunotherapy and/or vaccine. The other therapeutic compositions or treatments may for example be one or more of those discussed herein, and may be administered either simultaneously or sequentially with (before or after) the composition or treatment of the disclosure.

In some cases the treatment may be administered in combination with checkpoint blockade therapy, co-stimulatory antibodies, chemotherapy and/or radiotherapy, targeted therapy or monoclonal antibody therapy. It has been demonstrated that chemotherapy sensitizes tumors to be killed by tumor specific cytotoxic T cells induced by vaccination (Ramakrishnan et al. J Clin Invest. 2010; 120(4): 1111-1124). Examples for checkpoint inhibitors are CTLA-4 inhibitor, Ipilimumab and programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) signaling inhibitors, Nibolumab, Pembrolizumab, Atezolizumab and Durvalumab. Examples of chemotherapy agents include alkylating agents including nitrogen mustards such as mechlorethamine (HN2), cyclophosphamide, ifosfamide, melphalan (L-sarcolysin) and chlorambucil; anthracyclines; epothilones; nitrosoureas such as carmustine (BCNU), lomustine (CCNU), semustine (methyl-CCNU) and streptozocin (streptozotocin); triazenes such as decarbazine (DTIC; dimethyltriazenoimidazole-carboxamide; ethylenimines/methylmelamines such as hexamethylmelamine, thiotepa; alkyl sulfonates such as busulfan; Antimetabolites including folic acid analogues such as methotrexate (amethopterin); alkylating agents, antimetabolites, pyrimidine analogs such as fluorouracil (5-fluorouracil; 5-FU), floxuridine (fluorodeoxyuridine; FUdR) and cytarabine (cytosine arabinoside); purine analogues and related inhibitors such as mercaptopurine (6-mercaptopurine; 6-MP), thioguanine (6-thioguanine; TG) and pentostatin (2′-deoxycoformycin); epipodophylotoxins; enzymes such as L-asparaginase; biological response modifiers such as IFNα, IL-2, G-CSF and GM-CSF; platinum coordination complexes such as cisplatin (cis-DDP), oxaliplatin and carboplatin; anthracenediones such as mitoxantrone and anthracycline; substituted urea such as hydroxyurea; methylhydrazine derivatives including procarbazine (N-methylhydrazine, MIH) and procarbazine; adrenocortical suppressants such as mitotane (o,p′-DDD) and aminoglutethimide; taxol and analogues/derivatives; hormones and agonists/antagonists including adrenocorticosteroid antagonists such as prednisone and equivalents, dexamethasone and aminoglutethimide, progestin such as hydroxyprogesterone caproate, medroxyprogesterone acetate and megestrol acetate, estrogen such as diethylstilbestrol and ethinyl estradiol equivalents, antiestrogen such as tamoxifen, androgens including testosterone propionate and fluoxymesterone/equivalents, antiandrogens such as flutamide, gonadotropin-releasing hormone analogs and leuprolide and non-steroidal antiandrogens such as flutamide; natural products including vinca alkaloids such as vinblastine (VLB) and vincristine, epipodophyllotoxins such as etoposide and teniposide, antibiotics such as dactinomycin (actinomycin D), daunorubicin (daunomycin; rubidomycin), doxorubicin, bleomycin, plicamycin (mithramycin) and mitomycin (mitomycin C), enzymes such as L-asparaginase, and biological response modifiers such as interferon alphenomes.

In some cases the method of treatment is a method of vaccination or a method of providing immunotherapy. As used herein, “immunotherapy” is the prevention or treatment of a disease or condition by inducing or enhancing an immune response in an individual. In certain embodiments, immunotherapy refers to a therapy that comprises the administration of one or more drugs to an individual to elicit T cell responses. In a specific embodiment, immunotherapy refers to a therapy that comprises the administration or expression of polypeptides that contain one or more PEPIs to an individual to elicit a T cell response to recognize and kill cells that display the one or more PEPIs on their cell surface in conjunction with a class I HLAs. In another specific embodiment, immunotherapy comprises the administration of one or more PEPIs to an individual to elicit a cytotoxic T cell response against cells that display tumor associated antigens (TAAs) or cancer testis antigens (CTAs) comprising the one or more PEPIs on their cell surface. In another embodiment, immunotherapy refers to a therapy that comprises the administration or expression of polypeptides that contain one or more PEPIs presented by class II HLAs to an individual to elicit a T helper response to provide co-stimulation to cytotoxic T cells that recognize and kill diseased cells that display the one or more PEPIs on their cell surface in conjunction with a class I HLAs. In still another specific embodiment, immunotherapy refers to a therapy that comprises administration of one or more drugs to an individual that re-activate existing T cells to kill target cells. The theory is that the cytotoxic T cell response will eliminate the cells displaying the one or more PEPIs, thereby improving the clinical condition of the individual. In some instances, immunotherapy may be used to treat tumors. In other instances, immunotherapy may be used to treat intracellular pathogen-based diseases or disorders.

In some cases the disclosure relates to the treatment of cancer or the treatment of solid tumors. In some cases the treatment is of breast cancer, ovarian cancer or colorectal cancer. In other cases the treatment may be of any other cancer or solid tumor that expresses a target tumor associated antigen of the present peptides as described herein, or any cancer in which such target polypeptide antigens are expressed in some or a high percentage of subjects. The treatment may be of cancers or malignant or benign tumors of any cell, tissue, or organ type. The cancer may or may not be metastatic. Exemplary cancers include carcinomas, sarcomas, lymphomas, leukemias, germ cell tumors, or blastomas. The cancer may or may not be a hormone related or dependent cancer (e.g., an estrogen or androgen related cancer).

Selection of Polypeptides and Patients

Specific polypeptide antigens, and particularly short peptides derived from such antigens that are commonly used in vaccination and immunotherapy, induce immune responses in only a fraction of human subjects. The polypeptides of the present disclosure are specifically selected to induce immune responses in a high proportion of the general population, but they may not be effective in all individuals due to HLA genotype heterogeneity. HLA genotype population heterogeneity means that the immune or clinical response rate to the vaccines described herein will differ between different human subpopulations. In some cases the vaccines described herein are for use to treat a specific or target subpopulation, for example an Asian population, or a Vietnamese, Chinese, and/or Japanese population.

The disclosure also provides a method of identifying a human subject who will likely have a cytotoxic T cell response to administration of a pharmaceutical composition comprising a peptide of the disclosure (likely responders), or of predicting the likelihood that a subject will have a cytotoxic T cell response.

As provided herein T cell epitope presentation by multiple HLAs of an individual is generally needed to trigger a T cell response. The best predictor of a cytotoxic T cell response to a given polypeptide, as determined by the inventors, is the presence of at least one T cell epitope that is presented by three or more HLA class I of an individual (≥1 PEPI3+). Accordingly the presence within the active ingredient peptides of a pharmaceutical composition of one or more T cell epitopes that is capable of binding to at least three HLA of a subject is predictive for the subject having a cytotoxic T cell response to administration of the pharmaceutical composition. The subject is a likely immune responder.

In some cases the T cell epitope that is capable of binding to at least three HLA class I of the subject has the amino acid sequence of any one of SEQ ID NOs: 1 to 40, or SEQ ID NOs: 1 to 40, 172-194, 234-250 and 272-301. In other cases the T cell epitope may have a different amino acid sequence within the one or more peptides of the pharmaceutical composition.

The inventors have further discovered that the presence in a vaccine or immunotherapy composition of at least two epitopes that can bind to at least three HLA of an individual is predictive for a clinical response. In other words, if an individual has a total of ≥2 PEPI3+ within the active ingredient polypeptide(s) of a vaccine or immunotherapy composition, and these PEPI3+s are derived from antigen sequences that are in fact expressed in the individual (for example, target tumor cells of the individual express the target tumor-associated antigens), then the individual is a likely clinical responder (i.e. a clinically relevant immune responder).

Accordingly some aspects of the disclosure relate to a method of identifying a subject who will likely have a clinical response to a method of treatment according to the disclosure, or of predicting the likelihood that a subject will have a clinical response. A “clinical response” or “clinical benefit” as used herein may be the prevention or a delay in the onset of a disease or condition, the amelioration of one or more symptoms, the induction or prolonging of remission, or the delay of a relapse or recurrence or deterioration, or any other improvement or stabilisation in the disease status of a subject. Where appropriate, a “clinical response” may correlate to “disease control” or an “objective response” as defined by the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines.

In some embodiments the method comprises determining that one or more cancer-associated antigens selected from SPAG9, AKAP-4, BORIS, NY-SAR-35, NY-BR-1, SURVIVIN, MAGE-A11, PRAME, MAGE-A9, HOM-TES-85, TSP50, EpCAM, CAGE1, FBXO39, MAGE-A8 and MAGE-A6 is expressed by a cancer. For example expression of the cancer associated antigen may be detected in a sample obtained from the subject, for example a tumor biopsy, using methods that are known in the art.

The inventors have discovered that it is not sufficient that a vaccine or immunotherapy composition targets an antigen that is expressed by cancer or tumor cells of a patient, nor that the target sequences of that antigen can bind to HLA class I of the patient (HLA restricted epitopes). The composition is likely effective only in patients that both express the target antigen and have three or more HLA class I that bind to a single T cell epitope of the target antigen. Moreover, as described above, at least two epitopes that binds to at least 3 HLAs of the patient are generally needed to induce a clinically relevant immune response.

Therefore the method further comprises determining that the active ingredient peptide(s) of the pharmaceutical composition comprise two or more different amino acid sequences each of which is a) a fragment of a cancer-associated antigen expressed by cancer cells of the subject, determined as described above; and b) a T cell epitope capable of binding to at least three HLA class I of the subject.

In some cases the T cell epitope that is capable of binding to at least three HLA class I of the subject has the amino acid sequence of any one of SEQ ID NOs: 1 to 40, or SEQ ID NOs: 1 to 40, 172-194, 234-250 and 272-301. In other cases the T cell epitope may have a different amino acid sequence within the one or more peptides of the pharmaceutical composition.

In some cases the likelihood that a subject will have a clinical response to a peptide vaccine or immunotherapy composition, such as those described herein, can be determined without knowing whether the target antigens are expressed in cancer or tumor cells of the subject and/or without determining the HLA class I genotype of the subject. Known antigen expression frequencies in the disease (e.g. MAGE-A3 in a tumor type like breast or colorectal cancer) and/or known frequencies for HLA class I and class II genotype of subjects in the target population (e.g ethnic population, general population, diseased population) may be used instead. Moreover by combining peptides that target the most frequently presented PEPIs across the population (BestEPIs) in multiple frequently expressed target antigens in the disease, as identified and described herein, it is possible to design a cancer vaccine regime that is effective for a high proportion of patients. However, using the companion diagnostic methods described herein to pre-select patients who are most likely to have a clinical response will increase clinical response rates amongst treated patients.

The likelihood that a subject will respond to treatment is increased by (i) the presence of more multiple HLA-binding PEPIs in the active ingredient polypeptides; (ii) the presence of PEPIs in more target polypeptide antigens; and (iii) expression of the target polypeptide antigens in the subject or in diseased cells of the subject. In some cases expression of the target polypeptide antigens in the subject may be known, for example if target polypeptide antigens are in a sample obtained from the subject. In other cases, the probability that a specific subject, or diseased cells of a specific subject, (over-)express a specific or any combination of target polypeptide antigens may be determined using population expression frequency data, e.g. probability of expression of an antigen in breast cancer, colorectal cancer or ovarian cancer. The population expression frequency data may relate to a subject- and/or disease-matched population or the intent-to-treat population. For example, the frequency or probability of expression of a particular cancer-associated antigen in a particular cancer or subject having a particular cancer, for example breast cancer, can be determined by detecting the antigen in tumor, e.g. breast cancer tumor samples. In some cases such expression frequencies may be determined from published figures and scientific publications. In some cases a method of the disclosure comprises a step of determining the expression frequency of a relevant target polypeptide antigen in a relevant population.

Disclosed is a range of pharmacodynamic biomarkers to predict the activity/effect of vaccines in individual human subjects as well as in populations of human subjects. These biomarkers expedite more effective vaccine development and also decrease the development cost and may be used to assess and compare different compositions. Exemplary biomarkers are as follows.

-   -   AG95—potency of a vaccine: The number of antigens in a cancer         vaccine that a specific tumor type expresses with 95%         probability. AG95 is an indicator of the vaccine's potency, and         is independent of the immunogenicity of the vaccine antigens.         AG95 is calculated from the tumor antigen expression rate data.         Such data may be obtained from experiments published in peer         reviewed scientific journals. Technically, AG95 is determined         from the binomial distribution of antigens in the vaccine, and         takes into account all possible variations and expression rates.     -   PEPI3+ count—immunogenicity of a vaccine in a subject:         Vaccine-derived PEPI3+ are personal epitopes that bind to et         least 3 HLAs of a subject and induce T cell responses. PEPI3+         can be determined using the PEPI3+ Test in subjects who's         complete 4-digit ELLA genotype is known.     -   AP count—antigenicity of a vaccine in a subject: Number of         vaccine antigens with PEPI3+. Vaccines contain sequences from         target polypeptide antigens expressed by diseased cells. AP         count is the number of antigens in the vaccine that contain         PEPI3+, and the AP count represents the number of antigens in         the vaccine that can induce T cell responses in a subject. AP         count characterizes the vaccine-antigen specific T cell         responses of the subject since it depends only on the ELLA         genotype of the subject and is independent of the subject's         disease, age, and medication. The correct value is between 0 (no         PEPI presented by the antigen) and maximum number of antigens         (all antigens present PEPIs).     -   AP50—antigenicity of a vaccine in a population: The mean number         of vaccine antigens with a PEPI in a population. The AP50 is         suitable for the characterization of vaccine-antigen specific T         cell responses in a given population since it depends on the HLA         genotype of subjects in a population.     -   AGP count—effectiveness of a vaccine in a subject: Number of         vaccine antigens expressed in the tumor with PEPI. The AGP count         indicates the number of tumor antigens that vaccine recognizes         and induces a T cell response against (hit the target). The AGP         count depends on the vaccine-antigen expression rate in the         subject's tumor and the HLA genotype of the subject. The correct         value is between 0 (no PEPI presented by expressed antigen) and         maximum number of antigens (all antigens are expressed and         present a PEPI).     -   AGP50—effectiveness of a cancer vaccine in a population: The         mean number of vaccine antigens expressed in the indicated tumor         with PEPI (i.e., AGP) in a population. The AGP50 indicates the         mean number of tumor antigens that the T cell responses induced         by the vaccine can recognize. AGP50 is dependent on the         expression rate of the antigens in the indicated tumor type and         the immunogenicity of the antigens in the target population.         AGP50 can estimate a vaccine's effectiveness in different         populations and can be used to compare different vaccines in the         same population. The computation of AGP50 is similar to that         used for AG50, except the expression is weighted by the         occurrence of the PEPI3+ in the subject on the expressed vaccine         antigens. In a theoretical population, where each subject has a         PEPI from each vaccine antigen, the AGP50 will be equal to AG50.         In another theoretical population, where no subject has a PEPI         from any vaccine antigen, the AGP50 will be 0. In general, the         following statement is valid: 0≤AGP50≤AG50.     -   mAGP—a candidate biomarker for the selection of likely         responders: Likelihood that a cancer vaccine induces T cell         responses against multiple antigens expressed in the indicated         tumor. mAGP is calculated from the expression rates of         vaccine-antigens in the tumor and the presence of vaccine         derived PEPIs in the subject. Technically, based on the AGP         distribution, the mAGP is the sum of probabilities of the         multiple AGP (≥2 AGPs).

The results of a prediction as set out above may be used to inform a physician's decisions concerning treatment of the subject. Accordingly, in some cases the method of the disclosure predicts that a subject will have or is likely to have a T cell response and/or a clinical response to a treatment as described herein, and the method further comprises selecting the treatment for the human subject. In some cases a subject is selected for treatment if their likelihood of a response targeted at a predefined number of target polypeptide antigens, optionally wherein the target polypeptide antigens are (predicted to be) expressed, is above a predetermined threshold. In some cases the number of target polypeptide antigens or epitopes is two. In some cases the number of target polypeptide antigens or epitopes is three, or four, or five, or six, or seven, or eight, or nine, or ten. The method may further comprise administering the treatment to the human subject. Alternatively, the method may predict that the subject will not have an immune response and/or a clinical response and further comprise selecting a different treatment for the subject.

Further Embodiments of the Disclosure

1. A polypeptide that comprises a fragment of up to 50 consecutive amino acids of

(a) a colorectal cancer-associated antigen selected from TSP50, EpCAM, SPAG9, CAGE1, FBXO39, SURVIVIN, LEMD1, MAGE-A8, MAGE-A6 and MAGE-A3, wherein the fragment comprises an amino acid sequence selected from any one of SEQ ID NOs: 21 to 40 and 234 to 250;

(b) an ovarian cancer-associated antigen selected from PIWIL-4, WT1, EpCAM, BORIS, AKAP-4, OY-TES-1, SP17, PIWIL-2, PIWIL-3, SPAG9, PRAME, HIWI, SURVIVIN, and AKAP-3 wherein the fragment comprises the amino acid sequence of any one of SEQ ID NOs: 272 to 301; and/or

(c) a breast cancer associated antigen selected from PIWIL-2, AKAP-4, EpCAM, BORIS, HIWI, SPAG9, PLU-1, TSGA10, ODF-4, SP17, RHOXF-2, PRAME, NY-SAR-35, MAGE-A9, NY-BR-1, SURVIVIN, MAGE-A11, HOM-TES-85 and NY-ESO-1 wherein the fragment comprises an amino acid sequence selected from any one of SEQ ID NOs: 1 to 20, 24 and 172 to 194;

optionally wherein the fragment is flanked at the N and/or C terminus by additional amino acids that are not part of the sequence of the breast, ovarian or colorectal cancer-associated antigen.

2. The polypeptide of item 1, wherein the polypeptide

-   -   a. is a fragment of a colorectal cancer-associated antigen         selected from TSP50, EpCAM, SPAG9, CAGE1, FBXO39, SURVIVIN,         MAGE-A8, MAGE-A6, MAGE-A3 and LEMD1, wherein the fragment         comprises an amino acid sequence selected from any one of SEQ ID         NOs: 21 to 40 and 234 to 250; or     -   b. comprises or consists of two or more fragments of one or more         colorectal cancer associated antigens selected from TSP50,         EpCAM, SPAG9, CAGE1, FBXO39, SURVIVIN, MAGE-A8, MAGE-A6, MAGE-A3         and LEMD1, wherein each fragment comprises a different amino         acid sequence selected from any one of SEQ ID NOs: 21 to 40 and         234 to 250, optionally wherein the fragments overlap or are         arranged end to end in the polypeptide; or     -   c. is a fragment of a ovarian cancer-associated antigen selected         from PIWIL-4, WT1, EpCAM, BORIS, AKAP-4, OY-TES-1, SP17,         PIWIL-2, PIWIL-3, SPAG9, PRAME, HIWI, SURVIVIN and AKAP-3,         wherein the fragment comprises an amino acid sequence selected         from any one of SEQ ID NOs: 272 to 301; or     -   d. comprises or consists of two or more fragments of one or more         ovarian cancer associated antigens selected from PIWIL-4, WT1,         EpCAM, BORIS, AKAP-4, OY-TES-1, SP17, PIWIL-2, PIWIL-3, SPAG9,         PRAME, HIWI, SURVIVIN and AKAP-3, wherein each fragment         comprises a different amino acid sequence selected from any one         of SEQ ID NOs: 272 to 301, optionally wherein the fragments         overlap or are arranged end to end in the polypeptide; or     -   e. is a fragment of a breast cancer associated antigen selected         from SPAG9, AKAP-4, BORIS, NY-SAR-35, NY-BR-1, SURVIVIN,         MAGE-A11, PRAME, MAGE-A9, HOM-TES-85, PIWIL-2, EpCAM, HIWI,         PLU-1, TSGA10, ODF-4, SP17, RHOXF-2, wherein the fragment         comprises the amino acid sequence from any one of SEQ ID NOs: 1         to 20, 24 and 172 to 194; or     -   f. comprises or consists of two or more fragments of one or more         breast cancer associated antigens selected from SPAG9, AKAP-4,         BORIS, NY-SAR-35, NY-BR-1, SURVIVIN, MAGE-A11, PRAME, MAGE-A9,         HOM-TES-8, PIWIL-2, EpCAM, HIWI, PLU-1, TSGA10, ODF-4, SP17,         RHOXF-2, wherein each fragment comprises a different amino acid         sequence selected from any one of SEQ ID NOs: 1 to 20, 24 and         172 to 194; optionally wherein the fragments overlap or are         arranged end to end in the polypeptide and.

3. The polypeptide according to item 1 or item 2, wherein the polypeptide comprises or consists of fragments of at least two different cancer-associated antigens, wherein the cancer-associated antigens are selected from

-   -   (a) TSP50, EpCAM, SPAG9, CAGE1, FBXO39, SURVIVIN, MAGE-A8,         MAGE-A6, MAGE-A3 and LEMD1;     -   (b) PIWIL-4, WT1, EpCAM, BORIS, AKAP-4, OY-TES-1, SP17, PIWIL-2,         PIWIL-3, SPAG9, PRAME, HIWI, SURVIVIN and AKAP-3; and/or     -   (c) SPAG9, AKAP-4, BORIS, NY-SAR-35, NY-BR-1, SURVIVIN,         MAGE-A11, PRAME, MAGE-A9, HOM-TES-8, PIWIL-2, EpCAM, HIWI,         PLU-1, TSGA10, ODF-4, SP17, RHOXF-2;         wherein each fragment comprises a different amino acid sequence         selected from SEQ ID NOs: 21 to 40 and 234 to 250; SEQ ID NOs:         272 to 301; and/or SEQ ID NOs: 1 to 20, 24 and 172 to 194.

4. The polypeptide according to any one of items 1 to 3, comprising or consisting of one or more amino acid sequences selected from SEQ ID NOs: 41-80, 251 to 271, 302 to 331 and 196 to 233.

5. The polypeptide according to any one of items 1 to 4 comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 81 to 142, 332 to 346 and 435-449.

6. A panel of two or more polypeptides according to any one of items 1 to 5, wherein

-   -   (a) each polypeptide comprises a different amino acid sequence         selected from SEQ ID NOs: 21 to 40 and 234 to 250; or     -   (b) each polypeptide comprises a different amino acid sequence         selected from SEQ ID NOs: 272 to 301; or     -   (c) each peptide comprises a different amino acid sequence         selected from SEQ ID NOs: 1 to 20, 24 and 172 to 194; or (c)         each peptide comprises a different amino acid sequence selected         from SEQ ID NOs: 1 to 40, 234 to 250, 272 to 301 and 172 to 194.

7. The panel of polypeptides according to item 6 comprising six peptides having the amino acid sequences of SEQ ID NOs: 130, 121, 131, 124, 134, 126.

8. A pharmaceutical composition or kit having one or more polypeptides according to any one of items 1 to 5, or a panel of polypeptides according to item 6 or item 7, or a polypeptide comprising at least two amino acid sequences selected SEQ ID NOs: 21 to 40 and 234 to 250; SEQ ID NOs: 272 to 301; and/or SEQ ID NOs: 1 to 20, 24 and 172 to 194 as an active ingredient.

9. A method of vaccination, providing immunotherapy or inducing a cytotoxic T cell response in a subject, the method comprising administering to the subject a pharmaceutical composition according to item 8.

10. The method of item 9 that is a method of treating cancer, optionally colorectal cancer, ovarian cancer or breast cancer.

11. A method of identifying a human subject who will likely have a cytotoxic T cell response to administration of a pharmaceutical composition according to item 8, the method comprising

-   -   (i) determining that the active ingredient polypeptide(s) of the         pharmaceutical composition comprise a sequence that is a T cell         epitope capable of binding to at least three HLA class I         molecules of the subject; and     -   (ii) identifying the subject as likely to have a cytotoxic T         cell response to administration of the pharmaceutical         composition.

12. The method of item 11 further comprising using population expression data for each antigen that

-   -   (a) is selected from TSP50, EpCAM, SPAG9, CAGE1, FBXO39,         SURVIVIN, LEMD1, MAGE-A8, MAGE-A6, MAGE-A3, PIWIL-4, WT1, BORIS,         AKAP-4, OY-TES-1, SP17, PIWIL-2, PIWIL-3, PRAME, HIWI, PLU-1,         TSGA10, ODF-4, RHOXF-2, NY-SAR-35, MAGE-A9, NY-BR-1, MAGE-A11,         HOM-TES-85, NY-ESO-1 and AKAP-3; and     -   (b) comprises an amino acid sequence that is         -   i. a fragment of an active ingredient peptide of the             pharmaceutical composition; and         -   ii. a T cell epitope capable of binding to at least three             ELLA class I molecules of the subject;     -   to determine the likelihood that the subject will have a         cytotoxic T cell response that targets one or more polypeptide         antigens that are expressed by cancer cells of the subject.

13. A method of identifying a subject who will likely have a clinical response to a method of treatment according to item 10, the method comprising

-   -   (i) determining that the active ingredient polypeptide(s) of the         pharmaceutical composition comprise two or more different amino         acid sequences each of which is         -   a. a T cell epitope capable of binding to at least three             ELLA class I molecules of the subject; and         -   b. a fragment of a cancer-associated antigen expressed by             cancer cells of the subject, optionally wherein the             cancer-associated antigen is present in a sample obtained             from the subject; and     -   (ii) identifying the subject as likely to have a clinical         response to the method of treatment.

14. A method of determining the likelihood that a specific human subject will have a clinical response to a method of treatment according to item 10, wherein one or more of the following factors corresponds to a higher likelihood of a clinical response:

-   -   (a) presence in the active ingredient polypeptide(s) of a higher         number of amino acid sequences and/or different amino acid         sequences that are each a T cell epitope capable of binding to         at least three ELLA class I of the subject;     -   (b) a higher number of target polypeptide antigens, comprising         at least one amino acid sequence that is both         -   A. comprised in an active ingredient polypeptide; and         -   B. a T cell epitope capable of binding to at least three             ELLA class I of the subject; optionally wherein the target             polypeptide antigens are expressed in the subject, further             optionally wherein the target polypeptides antigens are in             one or more samples obtained from the subject;     -   (c) a higher probability that the subject expresses target         polypeptide antigens, optionally a threshold number of the         target polypeptide antigens and/or optionally target polypeptide         antigens that have been determined to comprise at least one         amino acid sequence that is both         -   A. comprised in in an active ingredient polypeptide; and         -   B. a T cell epitope capable of binding to at least three HLA             class I of the subject; and/or     -   (d) a higher number of target polypeptide antigens that the         subject is predicted to express, optionally a higher number of         target polypeptide antigens that the subject expresses with a         threshold probability, and/or optionally the target polypeptide         antigens that have been determined to comprise at least one         amino acid sequence that is both         -   A. comprised in in an active ingredient polypeptide; and         -   B. a T cell epitope capable of binding to at least three HLA             class I of the subject.

15. The method of item 14, wherein the method comprises

-   -   (i) identifying which polypeptide antigens targeted by the         active ingredient polypeptide(s) comprise an amino acid sequence         that is both         -   A. comprised in an active ingredient polypeptide; and         -   B. a T cell epitope capable of binding to at least three HLA             class I of the subject;     -   (ii) using population expression data for each antigen         identified in step (i) to determine the probability that the         subject expresses one or more of the antigens identified in         step (i) that together comprise at least two different amino         acid sequences of step (i); and     -   (iii) determining the likelihood that the subject will have a         clinical response to administration of the pharmaceutical         composition, kit or panel of polypeptides, wherein a higher         probability determined in step (ii) corresponds to a more likely         clinical response.

16. The method of item 15, wherein the at least two different amino acid sequences are comprised in the amino acid sequence of two different polypeptide antigens targeted by the active ingredient polypeptide(s).

The method of any one of items 13 to 16 further comprising selecting or recommending administration of the pharmaceutical composition as a method of treatment for the subject, and optionally further treating the subject by administering the pharmaceutical composition.

A method of treatment according to item 10, wherein the subject has been identified as likely to have a clinical response or as having above a threshold minimum likelihood of having a clinical response to the treatment by a method according to any one of items 13 to 16.

The method of any one of items 9, 10, 17 and 18 wherein the treatment is administered in combination with chemotherapy, targeted therapy or a checkpoint inhibitor.

A method of identifying a human subject who will likely not have a clinical response to a method of treatment according to item 10, the method comprising

-   -   (i) determining that the active ingredient peptide(s) of the         pharmaceutical composition do not comprise two or more different         amino acid sequences each of which is a T cell epitope capable         of binding to at least three HLA class I molecules of the         subject; and     -   (iii) identifying the subject as likely not to have a clinical         response to the method of treatment.

EXAMPLES Example 1—HLA-Epitope Binding Prediction Process and Validation

Predicted binding between particular HLA and epitopes (9 mer peptides) was based on the Immune Epitope Database tool for epitope prediction (www.iedb.org).

The HLA I-epitope binding prediction process was validated by comparison with HLA I-epitope pairs determined by laboratory experiments. A dataset was compiled of HLA I-epitope pairs reported in peer reviewed publications or public immunological databases.

The rate of agreement with the experimentally determined dataset was determined (Table 2). The binding HLA I-epitope pairs of the dataset were correctly predicted with a 93% probability. Coincidentally the non-binding HLA I-epitope pairs were also correctly predicted with a 93% probability.

TABLE 2 Analytical specificity and sensitivity of the HLA-epitope binding prediction process. HLA-epitope True epitopes (n = 327) False epitopes (n = 100) pairs (Binder match) (Non-binder match) HIV 91% (32) 82% (14) Viral 100% (35) 100% (11) Tumor 90% (172) 94% (32) Other (fungi, 100% (65) 95% (36) bacteria, etc.) All 93% (304) 93% (93)

The accuracy of the prediction of multiple HLA binding epitopes was determined. Based on the analytical specificity and sensitivity using the 93% probability for both true positive and true negative prediction and 7% (=100%−93%) probability for false positive and false negative prediction, the probability of the existence of a multiple HLA binding epitope in a person can be calculated. The probability of multiple HLA binding to an epitope shows the relationship between the number of HLAs binding an epitope and the expected minimum number of real binding. Per PEPI definition three is the expected minimum number of HLA to bind an epitope (bold).

TABLE 3 Accuracy of multiple HLA binding epitopes predictions. Expected minimum number of real Predicted number of HLAs binding to an epitope HLA binding 0 1 2 3 4 5 6 1 35%  95%  100%  100%  100%  100%  100%  2 6% 29%  90%  99%  100%  100%  100%  3 1% 4% 22%  84%  98% 100%  100%  4 0% 0% 2% 16%  78% 96% 99% 5 0% 0% 0% 1% 10% 71% 94% 6 0% 0% 0% 0%  0%  5% 65%

The validated HLA-epitope binding prediction process was used to determine all HLA-epitope binding pairs described in the Examples below.

Example 2—Epitope Presentation by Multiple HLA Predicts Cytotoxic T Lymphocyte (CTL) Response

The presentation of one or more epitopes of a polypeptide antigen by one or more HLA I of an individual is predictive for a CTL response was determined.

The study was carried out by retrospective analysis of six clinical trials, conducted on 71 cancer and 9 HIV-infected patients (Table 4)¹⁻⁷. Patients from these studies were treated with an HPV vaccine, three different NY-ESO-1 specific cancer vaccines, one HIV-1 vaccine and a CTLA-4 specific monoclonal antibody (Ipilimumab) that was shown to reactivate CTLs against NY-ESO-1 antigen in melanoma patients. All of these clinical trials measured antigen specific CD8+ CTL responses (immunogenicity) in the study subjects after vaccination. In some cases, correlation between CTL responses and clinical responses were reported.

No patient was excluded from the retroactive study for any reason other than data availability. The 157 patient datasets (Table 4) were randomized with a standard random number generator to create two independent cohorts for training and evaluation studies. In some cases the cohorts contained multiple datasets from the same patient, resulting in a training cohort of 76 datasets from 48 patients and a test/validation cohort of 81 datasets from 51 patients.

TABLE 4 Summary of patient datasets Immunoassay # Datasets performed in HLA Clinical Target # (#antigen × the clinical genotyping trial Immunotherapy Antigen Disease Patients* #patient) trials** method Ref 1 VGX-3100 HPV16-E6 Cervical 17/18 5 × 17 IFN-γ High 1 HPV16-E7 cancer ELISPOT Resolution HPV18-E6 SBT HPV18-E7 HPV16/18 2 HIVIS vaccine HIV-1 AIDS 9/12 2 × 9  IFN-γ Low-Medium 2 Gag HIV- ELISPOT Resolution 1 RT SSO 3 rNY-ESO-1 NY-ESO-1 Breast-and 18/18 1 × 18 In vitro and High 3 ovarian Ex vivo IFN- Resolution 4 cancers, γ ELISPOT SBT melanoma and sarcoma 4 Ipilimumab NY-ESO-1 Metastatic 19/20 1 × 19 ICS after T- Low to 5 melanoma cell medium stimulation resolution typing, SSP of genomic DNA, high resolution sequencing 5 NY-ESO-1f NY-ESO-1 Esophageal-, 10/10 1 × 10 ICS after T- SSO probing 6 (91-110) non-small- cell and SSP of cell lung- stimulation genomic DNA and gastric cancer 6 NY-ESO-1 NY-ESO-1 Esophageal- 7/9 1 × 7  ICS after T- SSO probing 7 overlapping (79-173) and lung cell and SSP of peptides cancer, stimulation genomic DNA malignant melanoma Total 6 7 80 157 N/A *Number of patients used in the retrospective analysis from the original number of patient of the clinical trials. **Immunoassays are based on T cell stimulation with antigen-specific peptide pools and quantify the released cytokines by different techniques. CT: Clinical trial; SBT: Sequence Based Typing; SSO: Sequence-Specific Oligonucleotide; ICS: Intracellular cytokine staining; SSP: Sequence-specific priming

The reported CTL responses of the training dataset were compared with the HLA I restriction profile of epitopes (9 mers) of the vaccine antigens. The antigen sequences and the HLA I genotype of each patient were obtained from publicly available protein sequence databases or peer reviewed publications and the HLA I-epitope binding prediction process was blinded to patients' clinical CTL response data. The number of epitopes from each antigen predicted to bind to at least 1 (PEPI1+), or at least 2 (PEPI2+), or at least 3 (PEPI3+), or at least 4 (PEPI4+), or at least 5 (PEPI5+), or all 6 (PEPI6) HLA class I molecules of each patient was determined and the number of HLA bound were used as classifiers for the reported CTL responses. The true positive rate (sensitivity) and true negative rate (specificity) were determined from the training dataset for each classifier (number of HLA bound) separately.

ROC analysis was performed for each classifier. In a ROC curve, the true positive rate (Sensitivity) was plotted in function of the false positive rate (1-Specificity) for different cut-off points (FIG. 1). Each point on the ROC curve represents a sensitivity/specificity pair corresponding to a particular decision threshold (epitope (PEPI) count). The area under the ROC curve (AUC) is a measure of how well the classifier can distinguish between two diagnostic groups (CTL responder or non-responder).

The analysis unexpectedly revealed that predicted epitope presentation by multiple class I HLAs of a subject (PEPI2+, PEPI3+, PEPI4+, PEPI5+, or PEPI6), was in every case a better predictor of CTL response than epitope presentation by merely one or more ELLA class I (PEPI1+, AUC=0.48, Table 5).

TABLE 5 Determination of diagnostic value of the PEPI biomarker by ROC analysis Classifiers AUC PEPI1+ 0.48 PEPI2+ 0.51 PEPI3+ 0.65 PEPI4+ 0.52 PEPI5+ 0.5 PEPI6+ 0.5

The CTL response of an individual was best predicted by considering the epitopes of an antigen that could be presented by at least 3 ELLA class I of an individual (PEPI3+, AUC=0.65, Table 5). The threshold count of PEPI3+(number of antigen-specific epitopes presented by 3 or more ELLA of an individual) that best predicted a positive CTL response was 1 (Table 6). In other words, at least one antigen-derived epitope is presented by at least 3 HLA class I of a subject (≥1 PEPI3+), then the antigen can trigger at least one CTL clone, and the subject is a likely CTL responder. Using the ≥1 PEPI3+ threshold to predict likely CTL responders (“≥1 PEPI3+ Test”) provided 76% diagnostic sensitivity (Table 12).

TABLE 6 Determination of the ≥1 PEPI3+ threshold to predict likely CTL responders in the training dataset. PEPI3+ Count 1 2 3 4 5 6 7 8 9 10 11 12 Sensitivity: 0.76 0.60 0.31 0.26 0.14 0.02 0 0 0 0 0 0 1− 0.59 0.24 0.21 0.15 0.09 0.06 0.06 0.03 0.03 0.03 0.03 0.03

Example 3—Validation of the ≥1 PEPI3+ Test

The test cohort of 81 datasets from 51 patients was used to validate the ≥1 PEPI3+ threshold to predict an antigen-specific CTL response. For each dataset in the test cohort it was determined whether the ≥1 PEPI3+ threshold was met (at least one antigen-derived epitope presented by at least three class I ELLA of the individual). This was compared with the experimentally determined CTL responses reported from the clinical trials (Table 7).

The clinical validation demonstrated that a PEPI3+ peptide induce CTL response in an individual with 84% probability. 84% is the same value that was determined in the analytical validation of the PEPI3+ prediction, epitopes that binds to at least 3 HLAs of an individual (Table 3). These data provide strong evidences that immune responses are induced by PEPIs in individuals.

TABLE 7 Diagnostic performance characteristics of the ≥ 1 PEPI3 + Test (n = 81). Performance characteristic Description Result Positive 100%[A/(A + B)] The likelihood that an individual that meets the ≥ 1 84% predictive PEPI3 + threshold has antigen-specific CTL value (PPV) responses after treatment with immunotherapy. Sensitivity 100%[A/(A + C)] The proportion of subjects with antigen-specific 75% CTL responses after treatment with immunotherapy who meet the ≥ 1 PEPI3 + threshold. Specificity 100%[D/(B + D)] The proportion of subjects without antigen- 55% specific CTL responses after treatment with immunotherapy who do not meet the ≥ 1 PEPI3 + threshold. Negative 100%[D/(C + D)] The likelihood that an individual who does not 42% predictive meet the ≥ 1 PEPI3 + threshold does not have value antigen-specific CTL responses after treatment (NPV) with immunotherapy. Overall 100%[(A + D)/N The percentage of predictions based on the ≥ 1 70% percent PEPI3 + threshold that match the experimentally agreement determined result, whether positive or negative. (OPA) Fisher's exact (p) 0.01

ROC analysis determined the diagnostic accuracy, using the PEPI3+ count as cut-off values (FIG. 2). The AUC value=0.73. For ROC analysis an AUC of 0.7 to 0.8 is generally considered as fair diagnostic.

A PEPI3+ count of at least 1 (≥1 PEPI3+) best predicted a CTL response in the test dataset (Table 8). This result confirmed the threshold determined during the training (Table 5).

TABLE 8 Confirmation of the ≥1 PEPI3+ threshold to predict likely CTL responders in the test/validation dataset. PEPI3+ Count 1 2 3 4 5 6 7 8 9 10 11 12 Sensitivity: 0.75 0.52 0.26 0.23 0.15 0.13 0.08 0.05 0 0 0 0 1-Specificity: 0.45 0.15 0.05 0 0 0 0 0 0 0 0 0

Example 4—the ≥1 PEPI3+ Test Predicts CD8+ CTL Reactivities

The ≥1 PEPI3+ Test was compared with a previously reported method for predicting a specific human subject's CTL response to peptide antigens.

The HLA genotypes of 28 cervical cancer and VIN-3 patients that received the HPV-16 synthetic long peptide vaccine (LPV) in two different clinical trials were determined from DNA samples⁸ ⁸ ⁹ ¹⁰. The LPV consists of long peptides covering the HPV-16 viral oncoproteins E6 and E7. The amino acid sequence of the LPV was obtained from these publications. The publications also report the T cell responses of each vaccinated patient to pools of overlapping peptides of the vaccine.

For each patient epitopes (9 mers) of the LPV that are presented by at least three patient class I HLA (PEPI3+s) were identified and their distribution among the peptide pools was determined. Peptides that comprised at least one PEPI3+(≥1 PEPI3+) were predicted to induce a CTL response. Peptides that comprised no PEPI3+ were predicted not to induce a CTL response.

The ≥1 PEPI3+ Test correctly predicted 489 out of 512 negative CTL responses and 8 out of 40 positive CTL responses measured after vaccination (FIG. 3A). Overall, the agreement between the ≥1 PEPI3+ Test and experimentally determined CD8+ T cell reactivity was 90% (p<0.001).

For each patient the distribution among the peptide pools of epitopes that are presented by at least one patient class I HLA (≥1 PEPI1+, ELLA restricted epitope prediction, prior art method) was also determined. ≥1 PEPI1+ correctly predicted 116 out of 512 negative CTL responses and 37 out of 40 positive CTL responses measured after vaccination (FIG. 3B). Overall, the agreement between the HLA restricted epitope prediction (≥1 PEPI1+) and CD8+ T cell reactivity was 28% (not significant).

Example 5—Prediction of HLA Class II Restricted CD4+ Helper T Cell Epitopes

The 28 cervical cancer and VIN-3 patients that received the HPV-16 synthetic long peptide vaccine (LPV) in two different clinical trials (as detailed in Example 4) were investigated for CD4+ T helper responses following LPV vaccination (FIGS. 4A-B). The sensitivity of the prediction of HLA class II restricted epitopes was 78%, since the State of Art tool predicted 84 positive responses (positive CD4+ T cell reactivity to a peptide pool for a person's DP alleles) out of 107 (sensitivity=78%). The specificity was 22% since it could rule out 7 negative responses out of 31. Overall, the agreement between HLA-restricted class II epitope prediction and CD4+ T cell reactivity was 66%, which was statistically not significant.

Example 6—the ≥1 PEPI3+ Test Predicts T Cell Responses to Full Length LPV Polypeptides

Using the same reported studies as Examples 4 and 5, the ≥1 PEPI3+ Test was used to predict patient CD8+ and CD4+ T cell responses to the full length E6 and E7 polypeptide antigens of the LPV vaccine. Results were compared to the experimentally determined responses were reported. The Test correctly predicted the CD8+ T cell reactivity (PEPI3+) of 11 out of 15 VIN-3 patients with positive CD8+ T cell reactivity test results (sensitivity 73%, PPV 85%) and of 2 out of 5 cervical cancer patients (sensitivity 40%, PPV 100%). The CD4+ T cell reactivities (PEPI4+) were correctly predicted 100% both of VIN-3 and cervical cancer patients (FIG. 5).

Class I and class II HLA restricted PEPI3+ count was also observed to correlate with the reported clinical benefit to LPV vaccinated patients. Patients with higher PEPI3+ counts had either complete or partial response already after 3 months.

Example 7—Case Study

pGX3001 is an HPV16 based DNA vaccine containing full length E6 and E7 antigens with a linker in between. pGX3002 is an HPV18 based DNA vaccine containing full length E6 and E7 antigens with a linker in between. A Phase II clinical trial investigated the T cell responses of 17 HPV-infected patients with cervical cancer who were vaccinated with both pGX3001 and pGX3002 (VGX-3100 vaccination)¹.

FIGS. 5A-D and FIG. 6 shows for two illustrative patients (patient 12-11 and patient 14-5) the position of each epitope (9 mer) presented by at least 1 (PEPI1+), at least 2 (PEPI2+), at least 3 (PEPI3+), at least 4 (PEPI4+), at least 5 (PEPI5+), or all 6 (PEPI6) class I HLA of these patients within the full length sequence of the two HPV-16 and two HPV-18 antigens.

Patient 12-11 had an overall PEPI1+ count of 54 for the combined vaccines (54 epitopes presented by one or more class I HLA). Patient 14-5 had a PEPI1+ count of 91. Therefore patient 14-5 has a higher PEPI1+ count than patient 12-11 with respect to the four HPV antigens. The PEPI1+s represent the distinct vaccine antigen specific HLA restricted epitope sets of patients 12-11 and 14-5. Only 27 PEPI1+s were common between these two patients.

For the PEPI3+ counts (number of epitopes presented by three or more patient class I HLA), the results for patients 12-11 and 14-5 were reversed. Patient 12-11 had a PEPI3+ count of 8, including at least one PEPI3+ in each of the four HPV16/18 antigens. Patient 14-5 had a PEPI3+ count of 0.

The reported immune responses of these two patients matched the PEPI3+ counts, not the PEPI1+ counts. Patient 12-11 developed immune responses to each of the four antigens post-vaccination as measured by ELISpot, whilst patient 14-5 did not develop immune responses to any of the four antigens of the vaccines. A similar pattern was observed when the PEPI1+ and PEPI3+ sets of all 17 patients in the trial were compared. There was no correlation between the PEPI1+ count and the experimentally determined T cell responses reported from the clinical trial. However, correlation between the T cell immunity predicted by the ≥1 PEPI3+ Test and the reported T cell immunity was observed. The ≥1 PEPI3+ Test predicted the immune responders to HPV DNA vaccine.

Moreover, the diversity of the patient's PEPI3+ set resembled the diversity of T cell responses generally found in cancer vaccine trials. Patients 12-3 and 12-6, similar to patient 14-5, did not have PEPI3+s predicting that the HPV vaccine could not trigger T cell immunity. All other patients had at least one PEPI3 predicting the likelihood that the HPV vaccine can trigger T cell immunity. 11 patients had multiple PEPI3+ predicting that the HPV vaccine likely triggers polyclonal T cell responses. Patients 15-2 and 15-3 could mount high magnitude T cell immunity to E6 of both HPV, but poor immunity to E7. Other patients 15-1 and 12-11 had the same magnitude response to E7 of HPV18 and HPV16, respectively.

Example 8—Design of a Model Population for Conducting in Silico Trials and Identifying Candidate Precision Vaccine Targets for Large Population

An in silico human trial cohort of 433 subjects with complete 4-digit HLA class I genotype (2×HLA-A*xx:xx; 2×HLA-B*xx:xx; 2×HLA-C*xx:xx) and demographic information was compiled. This Model Population has subjects with mixed ethnicity having a total of 152 different HLA alleles that are representative for >85% of presently known allele G-groups.

A database of a “Big Population” containing 7,189 subjects characterized with 4-digit HLA genotype and demographic information was also established. The Big Population has 328 different HLA class I alleles. The HLA allele distribution of the Model Population significantly correlated with the Big Population (Table 9) (Pearson p<001). Therefore the 433 patient Model Population is representative for a 16 times larger population.

The Model Population is representative for 85% of the human race as given by HLA diversity as well as HLA frequency.

TABLE 9 Statistical analysis of HLA distributions in “Model Population” vs. “Big Population”. Group Group Pearson R name 1 name 2 value Correlation P Value 433 Model 7,189 Big 0.89 Strong P < 0.001 Population Population

Example 9—In Silico Trials Based on the Identification of Multiple HLA Binding Epitopes Predict the Reported T Cell Response Rates of Clinical Trials

The objective of this study was to determine whether a model population, such as the one described in Example 8, may be used to predict CTL reactivity rates of vaccines, i.e. used in an in silico efficacy trials.

Twelve peptide vaccines derived from cancer antigens that induced T cell responses in a subpopulation of subjects were identified from peer reviewed publications. These peptides have been investigated in clinical trials enrolling a total of 172 patients (4 ethnicities). T cell responses induced by the vaccine peptides have been determined from blood specimens and reported. The immune response rate as the percentage of study subjects with positive T cell responses measured in the clinical trials was determined (FIG. 7).

TABLE 10 Clinical trials conducted with peptide vaccines. Source Peptide Pop. Peptide vaccines antigen length T cell assay (n) Ethnicity Ref MMNLMQPKTQQTYTYD JUP 16 mer Multimer 18 Canadian 12 staining GRGSTTTNYLLDRDDYRNTSD ADA17 21 mer Multimer 18 Canadian 12 staining LKKGAADGGKLDGNAKLNRSLK BAP31 22 mer Multimer 18 Canadian 12 staining FPPKDDHTLKFLYDDNQRPYPP TOP2A 22 mer Multimer 18 Canadian 12 staining RYRKPDYTLDDGHGLLRFKST Ab1-2 21 mer Multimer 18 Canadian 12 staining QRPPFSQLHRFLADALNT DDR1 18 mer Multimer 18 Canadian 12 staining ALDQCKTSCALMQQHYDQTSCFSSP ITGB8 25 mer Multimer 18 Canadian 12 staining STAPPAHGVTSAPDTRPAPGSTAPP MUC-1 25 mer Proliferation 80 Canadian 13 YLEPGPVTA gp 100  9 mer Tetramer 18 U.S. 14 MTPGTQSPFFLLLLLTVLTVV MUC-1 21 mer Cytotoxicity 10 Israeli 15 SSKALQRPV Bcr-  9 mer ELISPOT 4 U.S. 16 Abl RMFPNAPYL WT-1  9 mer Multimer 24 U.S. 17 staining RMFPNAPYL (HLA-A*0201) WT-1  9 mer Cytokine 18 CEU 18 staining

The 12 peptides were investigated with the ≥1 PEPI3+ Test in each of the 433 subjects of the Model Population described in Example 8. The “≥1 PEPI3+ Score” for each peptide was calculated as the proportion of subjects in the Model Population having at least one vaccine derived epitope that could bind to at least three subject-specific HLA class I (≥1 PEPI3+). If the corresponding clinical trial stratified patients for HLA allele selected population, the Model Population was also filtered for subjects with the respective allele(s) (Example: WT1, HLA-A*0201).

The experimentally determined response rates reported from the trials were compared with the ≥1 PEPI3+ Scores. The Overall Percentage of Agreements (OPA) were calculated on the paired data (Table 11). A linear correlation between ≥1 PEPI3+ Score and response rate (R²=0.77) was observed (FIG. 7). This result shows that the identification of peptides predicted to bind to multiple HLAs of an individual is useful to predict in silico the outcome of clinical trials.

TABLE 11 Comparison of ≥1 PEPI3+ Scores and CTL response rates of 12 peptide vaccines. ≥1 PEPI3+ Score* Source Response rate (Model Peptide vaccine antigen (Clinical Trials) Population) OPA MMNLMQPKTQQTYTYD JUP   0% 22% NA GRGSTTTNYLLDRDDYRNTSD ADA17  11% 18%  61% LKKGAADGGKLDGNAKLNRSLK BAP31  11%  7%  64% FPPKDDHTLKFLYDDNQRPYPP TOP2A  11% 39%  28% RYRKPDYTLDDGHGLLRFKST Ab1-2  17% 12%  71% QRPPFSQLHRFLADALNT DDR1  17%  5%  29% ALDQCKTSCALMQQHYDQTSCFSSP ITGB8  28% 31%  90% STAPPAHGVTSAPDTRPAPGSTAPP MUC-1  20%  2%  10% YLEPGPVTA gp100  28%  4%  14% MTPGTQSPFFLLLLLTVLTVV MUC-1  90% 95%  95% SSKALQRPV Bcr-   0%  0% 100% Abl RMFPNAPYL WT-1 100% 78%  78% RMFPNAPYL (HLA-A*0201) WT-1  81% 61%  75% *% subjects in the Model Population with ≥1 vaccine derived PEPI3+ 

Example 10. In Silico Trials Based on the Identification of Multiple HLA Binding Epitopes Predict the Reported T Cell Response Rates of Clinical Trials II

Nineteen clinical trials with published immune response rates (IRR) conducted with peptide or DNA based vaccines were identified (Table 19). These trials involved 604 patients (9 ethnicities) and covered 38 vaccines derived from tumor and viral antigens. Vaccine antigen specific CTL responses were measured in each study patient and the response rate in the clinical study populations was calculated and reported.

Each vaccine peptide of the 19 clinical trials was investigated with the ≥1 PEPI3+ Test in each subject of the Model Population. The ≥1 PEPI3+ Score for each peptide was calculated as the proportion of subjects in the Model Population having at least one vaccine derived PEPI3+. The experimentally determined response rates reported from the trials were compared with the PEPI Scores, as in Example 9 (Table 20). A linear correlation between the response rate and ≥1 PEPI3+ Score (R²=0.70) was observed (FIG. 8). This result confirms that the identification of peptides predicted to bind to multiple HLAs of an individual can predict T cell responses of subjects, and in silico trials can predict the outcome of clinical trials.

TABLE 12 Response rates published in clinical trials. Immuno- Pop. Race/ therapy Type CTL assay (n) Ethnicity Ref. StimuVax peptide Proliferation 80 Canadian 13 gp100 vaccine DNA Tetramer 18 US 14 IMA901 peptide ELISPOT 64 CEU 19 phase I IMA901 peptide Multimer 27 CEU phase II staining ICT107 peptide ICC 15 US 20 ProstVac DNA ELISPOT 32 CEU87%, ²1 Afr. Am.12%, Hisp.1% Synchrotope DNA Tetramer 26 US 22 TA2M MELITAC peptide ELISPOT 167 US 23 12.1 WT1 vaccine peptide Tetramer 22 Japanese 24 Ipilimumab check- (NY-ESO-1) point ICC 19 US 5 inhibitor ** VGX-3100 DNA ELISPOT 17 US 1 HIVIS-1 DNA ELISPOT 12 CEU98%, Asian1%, 2 Hisp.1% ImMucin peptide Cytotoxicity 10 Israeli 15 NY-ESO-1 peptide IFN-gamma 7 Japanese 7 OLP GVX301 peptide Proliferation 14 CEU 25 WT1 vaccine peptide ELISPOT 12 US 26 WT1 vaccine peptide ICC 18 CEU 18 DPX-0907* peptide Multimer 18 Canadian 12 staining Melanoma peptide ELISPOT 26 White 27 peptide vaccine

TABLE 13 Linear correlation between PEPI Score and response rate (R² = 0.7). Clinical Trial ≥1PEPI3 + Immunotherapy Response Rate Score* OPA StimuVax (failed to show 20%  2% 10% efficacy in Phase III) gp100 vaccine 28%  4% 14% IMA901 phase I 74% 48% 65% IMA901 phase II 64% 48% 75% ICT107 33% 52% 63% ProstVac 45% 56% 80% Synchrotope TA2M 46% 24% 52% MELITAC 12.1 49% 47% 96% WT1 vaccine 59% 78% 76% Ipilimumab (NY-ESO-1*) 72% 84% 86% VGX-3100 78% 87% 90% HIVIS-1 80% 93% 86% ImMucin 90% 95% 95% NY-ESO-1 OLP 100%  84% 84% GVX301 64% 65% 98% WT1 vaccine 83% 80% 96% WT1 vaccine 81% 61% 75% DPX-0907 61% 58% 95% Melanoma peptide vaccine 52% 42% 81% *% subjects in the Model Population with ≥ 1 vaccine derived PEPI3+

Example 11—in Silico Trial Based on the Identification of Multiple HLA Binding Epitopes in a Multi-Peptide Vaccine Predict the Repotted Clinical Trial Immune Response Rate

IMA901 is a therapeutic vaccine for renal cell cancer (RCC) comprising 9 peptides derived from tumor-associated peptides (TUMAPs) that are naturally presented in human cancer tissue. A total of 96 HLA-A*02+ subjects with advanced RCC were treated with IMA901 in two independent clinical studies (phase I and phase II). Each of the 9 peptides of IMA901 have been identified in the prior art as HLA-A2-restricted epitopes. Based on currently accepted standards, they are all strong candidate peptides to boost T cell responses against renal cancer in the trial subjects, because their presence has been detected in renal cancer patients, and because the trial patients were specifically selected to have at least one HLA molecule capable of presenting each of the peptides.

For each subject in the Model population how many of the nine peptides of the IMA901 vaccine were capable of binding to three or more HLA was determined. Since each peptide in the IMA901 vaccine is a 9 mer this corresponds to the PEPI3+ count. The results were compared with the immune response rates reported for the Phase I and Phase II clinical trials (Table 14).

TABLE 14 Immune Response Rates in the Model Population and in two clinical trials to IMA901 Immune Model Population responses (HLA-A2+) Phase I Phase II to TUMAPs (n = 180) (n = 27)* (n = 64)* No peptide 39% 25% 36%  1 peptide 34% 44% 38% ≥2 peptides 27% 29% 26% (MultiPEPI Score) ≥3 peptides  3% ND  3% *No of patients evaluated for immune responses

The phase I and phase II study results show the variability of the immune responses to the same vaccine in different trial cohorts. Overall, however, there was a good agreement between response rates predicted by the ≥2 PEPI3+ Test and the reported clinical response rates.

In a retrospective analysis, the clinical investigators of the trials discussed above found that subjects who responded to multiple peptides of the IMA901 vaccine were significantly (p=0.019) more likely to experience disease control (stable disease, partial response) than subjects who responded only to one peptide or had no response. 6 of 8 subjects (75%) who responded to multiple peptides experienced clinical benefit in the trial, in contrast to 14% and 33% of 0 and 1 peptide responders, respectively. The randomized phase II trial confirmed that immune responses to multiple TUMAPs were associated with a longer overall survival.

Since the presence of PEPIs accurately predicted responders to TUMAPs, clinical responders to IMA901 are likely patients who can present ≥2 PEPIs from TUMAPs. This subpopulation is only 27% of HLA-A*02 selected patients, and according to the clinical trial result, 75% of this subpopulation is expected to experience clinical benefit. The same clinical results suggest that 100% of patients would experience clinical benefit if patient selection is based on ≥3 PEPIs from TUMAPs, albeit this population would represent only 3% of the HLA-A*02 selected patient population. These results suggest that the disease control rate (stable disease or partial response) is between 3% and 27% in the patient population which was investigated in the IMA901 clinical trials. In the absence of complete response, only a portion of these patients can experience survival benefit.

These findings explain the absence of improved survival in the Phase III IMA901 clinical trial. These results also demonstrated that HLA-A*02 enrichment of the study population was not sufficient to reach the primary overall survival endpoint in the Phase III IMA901 trial. As the IMA901 trial investigators noted, there is a need for the development of a companion diagnostic (CDx) to select likely responders to peptide vaccines. These findings also suggest that selection of patients with ≥2 TUMAP specific PEPIs may provide sufficient enrichment to demonstrate significant clinical benefit of IMA901.

Example 12—in Silico Trial Based on the Identification of Vaccine-Derived Multiple HLA Binding Epitopes Predict Reported Experimental Clinical Response Rates

A correlation between the ≥2 PEPI3+ Score of immunotherapy vaccines determined in the Model Population described in Example 8 and the reported Disease Control Rate (DCR, proportion of patients with complete responses and partial responses and stable disease) determined in clinical trials was determined.

Seventeen clinical trials conducted with peptide- and DNA-based cancer immunotherapy vaccines that have published Disease Control Rates (DCRs) or objective response rate (ORR) were identified from peer reviewed scientific journals (Table 15). These trials involved 594 patients (5 ethnicities) and covered 29 tumor and viral antigens. DCRs were determined according to the Response Evaluation Criteria in Solid Tumors (RECIST), which is the current standard for clinical trials, in which clinical responses are based on changes in maximum cross-sectional dimensions^(42, 43, 44). In case there was no available DCR data, objective response rate (ORR) data was used, which is also defined according to the RECIST guidelines.

Table 16 compares the ≥2 PEPI3+ Score for each vaccine in the Model Population and the published DCR or ORR. A correlation between the predicted and measured DCR was observed providing further evidence that not only the immunogenicity but also the potency of cancer vaccines depends on the multiple HLA sequences of individuals (R2=0.76) (FIG. 9).

TABLE 15 Clinical trials selected for Disease Control Rate (DCR) prediction. Study HLA Assessment Immuno- Pop. pop./ restric- Adm. Dose time therapy Antigen Sponsor Disease (n) Ethnicity tion form (mg) Dosing schedule (weeks) Ref. IMA901 9 TAAs Immatics Renal cell 28 CEU A02 i.d. 0.4 8× in 10 wks 12 19 phase I cancer IMA901 9 TAAs Immatics Renal cell 68 CEU A02 i.d 0.4 7× in 5 wks 24 19 phase II cancer then 10× 3 wks Ipilimumab NY-ESO-1 MSKCC Melanoma 19 US no i.v. 0.3 4× every 3 wks 24 5 3 10 HPV-SLP* HPV-16 Leiden VIN 20 CEU no s.c. 0.3 3× every 3 wks 12 9 E6, E7 University HPV-SLP* Leiden HPV-related 5 CEU no s.c. 0.3 3× every 3 wks 12 (OR) 10 University cervical cancer gP100-2 gp100 BMS Melanoma 136 US A*0201 s.c. 1 4× every 3 wks 12 ²8 peptides* Immucin Muc-1 VaxilBio Myeloma 15 Israeli no s.c. 0.1 6× every 2 wks  12** ²⁹ StimuVax Muc-1 Merck NSCLC 80 Canadian no s.c. 1 8× wkly then 12 13, 30 every 6 wks VGX-3100 HPV-16&18 Inovio HPV-related 125 US no i.m. 6 0, 4, 12 wks 36 ³1 cervical cancer TSPP peptide Thymidylate Siena CRC, NSCLC, 21 CEU no s.c. 0.1 3 × 3 wks 12 32 vaccine synthase University Gallbladder 0.2 carc., Breast-, 0.3 Gastric cancer KIF20A-66 KIF20A Chiba Metastatic 29 Japanese A*2402 s.c. 1 2 cycles 1, 8, 12 (OR) 33 peptide Tokushukai pancreatic 3 15, 22 days vaccine* Hospital cancer then every 2 wks Peptide 3 TAAs Kumamoto HNSCC 37 Japanese A*2402 s.c. 1 8× wkly then 12 ³4 vaccine* University every 4 wks 7-peptide 7 TAAs Kinki Metastatic 30 Japanese A*2402 s.c. 1 Cycles: 5× 10 (OR) ³5 cocktail University colorectal wkly then vaccine* cancer 1 wk rest GVX301* hTERT University Prostate and 14 Japanese A02 i.d. 0.5 1, 3, 5, 7, 14, 12 25 Genoa renal cancer 21, 35, 63 days MAGE-A3 MAGE-A3 Abramson Multiple 26 US no s.c. 0.3 14, 42, 90, 24 ³6 Trojan* Cancer myeloma 120, 150 days Center PepCan HPV-16 E6 University CIN2/3 23 US no i.m. 0.05 4 × 3 wks 24 ³7 of Arkansas 0.1 0.25 0.5 Melanoma Tyrosinase, University Melanoma 26 US A1, A2 s.c. 0.1 6 cycles: 0, 7, 6 27 peptide gp100 of Virginia or A3 14, 28, 35, vaccine* 42 days *Montanide ISA51 VG as adjuvant **Disease response was assessed according to the International Myeloma Working Group response criteria⁴⁵

TABLE 16 The Disease Control Rates (DCRs) and MultiPEPI Scores (predicted DCR) in 17 clinical trials. MultiPEPI Score Overall Percentage Immunotherapy DCR (Predicted DCR) of Agreement IMA901 phase I 43% 27% 61% IMA901 phase II 22% 27% 81% Ipilimumab 60% 65% 92% HPV-SLP 60% 70% 86% HPV-SLP 62% 70% 89% gp100 - 2 peptides 15% 11% 73% Immucin 73% 59% 81% StimuVax  0%  0% 100%  VGX-3100 50% 56% 89% TSPP peptide vaccine 48% 31% 65% KIF20A-66 peptide 26%  7% 27% vaccine Peptide vaccine 27% 10% 37% 7-peptide cocktail 10%  9% 90% vaccine GVX301 29%  7% 24% MAGE-A3 Trojan 35% 10% 29% PepCan 52% 26% 50% Melanoma peptide 12%  6% 50% vaccine

Example 13—Breast Cancer Vaccine Design for Large Population and Composition

We used the PEPI3+ Test described above to design peptides for use in breast cancer vaccines that are effective in a large percentage of patients, taking into account the heterogeneities of both tumour antigens and patients' HLAs.

Breast cancer CTAs were identified and ranked based on the overall expression frequencies of antigens found in breast cancer tumor samples as reported in peer reviewed publications (Chen et al. Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast Cancers. Plos One 2011; 6(3): e17876; Kanojia et al. Sperm-Associated Antigen 9, a Novel Biomarker for Early Detection of Breast Cancer. Cancer Epidemiol Biomarkers Prev 2009; 18(2):630-639; Saini et al. A Novel Cancer Testis Antigen, A-Kinase Anchor Protein 4 (AKAP4) Is a Potential Biomarker for Breast Cancer. Plos One 2013; 8(2): e57095).

Based on the ranked expression rate we have selected the most frequently expressed CTA as target antigens for breast cancer vaccine. The expression rates of the selected breast cancer specific CTAs are illustrated in FIG. 11.

To select immunogenic peptides from the target CTAs we used the PEPI3+ Test and the Model Population described in Example 8 to identify the 9 mer epitopes (PEPI3+s) that are most frequently presented by at least 3HLAs of the individuals in the Model Population. We refer to these epitopes herein as “bestEPIs”. An illustrative example of the “PEPI3+ hotspot” analysis and bestEPI identification is shown in FIG. 10 for the PRAME antigen.

We multiplied the reported expression frequency for each CTA by the frequency of the PEPI3+ hotspots in the Model Population to identify the T cell epitopes (9 mers) that will induce a cytotoxic T cell response against breast cancer antigens in the highest proportion of individuals (Table 17). We then selected 15 mers encompassing each of the selected 9 mers (Table 17). The 15 mers were selected to bind to most ELLA class II alleles of most subjects, using the process described in Example 19 below. These 15 mers can induce both CTL and T helper responses in the highest proportion of subjects.

TABLE 17 BestEPI list (9-mers underlined) for selecting breast cancer peptides for vaccine composition. N%: Antigen expression frequency in colorectal cancers; B%: bestEPI frequency, ie. the percentage of individuals with epitopes binding to at least 3 HLA class I of subjects in the model population (433 subjects); HLAII**: Percentage of individuals having CD4+ T cell specific PEPI4+ within normal donors (n = 400); N% * B%: N% multiplied by B%. SEQ SEQ ID ID BestEPIs and Optimized 15 mer NO. NO. Antigen Opt. HLAII** 9 mer 15 mer Antigen N% Opt. 15 mer Position B% (CD4) B% * N% 172 195 PIWIL-2  94% FVASINLTLTKWYSR 760 67%  93% 64% 173 196 PIWIL-2  94% RNFYDPTSAMVLQQH 341 60%  49% 57% 1 41 AKAP4  85% DQVNIDYLMNRPQNL 161 52%  46% 44% 1 197 AKAP4  85% VNIDYLMNRPQNLRL 163 52%  57% 44% 174 198 EpCam  84% RTYWIIIELKHKARE 140 51% 100% 43% 2 42 AKAP4  85% MMAYSDTTMMSDDID 1 49%   0% 41% 3 43 BORIS  71% MFTSSRMSSFNRHMK 263 57%  66% 40% 3 199 BORIS  71% VCMFTSSRMSSFNRH 261 57%  96% 40% 175 200 HIWI 100% HAFDGTILFLPKRLQ 161 39%  83% 39% 4 201 AKAP4  85% SDLQKYALGFQHALS 116 46%  81% 39% 4 44 AKAP4  85% LQKYALGFQHALSPS 118 46%  88% 39% 24 64 SPAG9  88% GTGKLGFSFVRITAL 1137 44%  94% 39% 24 202 SPAG9  88% KLGFSFVRITALMVS 1140 44% 100% 39% 5 45 SPAG9  88% AQKMSSLLPTMWLGA 962 43%  69% 38% 176 203 PIWIL-2  94% YSRVVFQMPHQEIVD 772 40%  77% 38% 177 204 HIWI 100% GFTTSILQYENSIML 251 37%  86% 37% 178 205 PLU-1  82% LRYRYTLDDLYPMMN 732 45%  84% 37% 179 206 TSGA10  70% YSSNAYHMSSTMKPN 653 48%  33% 34% 180 207 TSGA10  70% LQKVQFEKVSALADL 494 46%  97% 32% 181 208 PLU-1  82% NRTSYLHSPFSTGRS 1321 38%  37% 31% 6 46 SPAG9  88% GNILDSFTVCNSHVL 779 36%   4% 31% 6 209 SPAG9  88% LDSFTVCNSHVLCIA 782 36%   6% 31% 7 47 BORIS  71% NMAFVTSGELVRHRR 319 44%  75% 31% 182 210 ODF-4  63% NSPLPFQWRITHSFR 63 49%  35% 30% 183 211 SP17  47% AFAAAYFESLLEKRE 37 65% 100% 30% 184 212 AKAP4  85% DLSFYVNRLSSLVIQ 216 36% 100% 30% 185 213 ODF-4  63% QDGRLLSSTLSLSSN 41 47%  75% 29% 186 214 RHOXF-2  60% WEEAYTFEGARYYIN 62 48%  79% 29% 187 215 PLU-1  82% EKAMARLQELLTVSE 955 34%  69% 28% 188 216 HIWI 100% RSIAGFVASINEGMT 642 28%  57% 28% 8 48 PRAME  53% LERLAYLHARLRELL 457 52% 100% 28% 189 217 RHOXF-2  60% SDYAVHPMSPVGRTS 132 43%   5% 26% 190 218 NY-SAR-35  55% MMQMFGLGAISLILV 184 46%  69% 25% 11 51 NY-SAR-35  55% FSSSGTTSFKCFAPF 163 45%   0% 25% 11 219 NY-SAR-35  55% LRHKCCFSSSGTTSF 157 45%   1% 25% 9 49 SPAG9  88% SGAVMSERVSGLAGS 16 28%   9% 25% 10 220 BORIS  71% RFTQSGTMKIHILQK 406 35%  69% 25% 10 50 BORIS  71% HTRFTQSGTMKIHIL 404 35%  80% 25% 191 221 EpCam  84% QTLIYYVDEKAPEFS 246 28%  34% 24% 13 222 NY-SAR-35  55% FVLANGHILPNSENA 97 42%   6% 23% 13 53 NY-SAR-35  55% CSGSSYFVLANGHIL 91 42%  78% 23% 13 223 NY-SAR-35  55% SSYFVLANGHILPNS 94 42%  85% 23% 12 224 MAGE-A9  44% FMFQEALKLKVAELV 102 49% 100% 22% 12 52 MAGE-A9  44% QLEFMFQEALKLKVA 99 49% 100% 22% 14 54 PRAME  53% RHSQTLKAMVQAWPF 64 37%  38% 20% 14 225 PRAME  53% HSQTLKAMVQAWPFT 65 37%  37% 20% 14 226 PRAME  53% QTLKAMVQAWPFTCL 67 37%  85% 20% 15 55 NY-BR-1  47% YSCDSRSLFESSAKI 424 39%   0% 18% 16 56 Survivin  66% TAKKVRRAIEQLAAM 127 26%  26% 17% 192 227 MAGE-A11  59% SHSYVLVTSLNLSYD 286 26% 100% 15% 192 228 MAGE-A11  59% TSHSYVLVTSLNLSY 285 26% 100% 15% 17 229 MAGE-A11  59% AMDAIFGSLSDEGSG 184 23%   0% 14% 17 230 MAGE-A11  59% ESFSPTAMDAIFGSL 178 23%   0% 14% 17 57 MAGE-A11  59% SPTAMDAIFGSLSDE 181 23%   0% 14% 18 58 HOM-TES-85  47% MASFRKLTLSEKVPP 1 29%  51% 13% 19 59 MAGE-A9  44% SSISVYYTLWSQFDE 67 30%  97% 13% 20 231 NY-BR-1  47% KPSAFEPATEMQKSV 582 27%   0% 12% 20 60 NY-BR-1  47% PGKPSAFEPATEMQK 580 27%   0% 12% 193 232 NY-ESO-1   9% SRLLEFYLAMPFATP 85 52%  98%  5% 194 233 NY-ESO-1   9% FYLAMPFATPMEAEL 90 51%  96%  5%

Then we designed thirty-one 30 mer peptides (Table 18a). The 30 mers may each consist of two optimized 15 mer fragments, generally from different frequent CTAs, arranged end to end, each fragment comprising one of the 9 mers (BestEPIs) from Table 17. Nine of these 30 mer peptides were selected for a panel of peptides, referred to as PolyPEPI915 (Table 18b). Expression frequencies for the 10 CTAs targeted by PolyPEPI915, singly and in combination, are shown in FIG. 11.

TABLE 18a 30 mer breast cancer vaccine peptides HLAI* HLAII** SEQID TREOSID Source Antigen Peptide (30 mer) (CD8) (CD4) 81 BCV900-2-1 AKAP4 LQKYALGFQHALSPSMMAYSDTTMMSDDID 69%  88% 82 BCV900-2-2 BORIS/AKAP4 VCMFTSSRMSSFNRHVNIDYLMNRPQNLRL 76%  97% 83 BCV900-2-3 BORIS NMAFVTSGELVRHRRHTRFTQSGTMKIHIL 57%  92% 84 BCV900-2-4 SPAG9 LDSFTVCNSHVLCIAKLGFSFVRITALMVS 58% 100% 85 BCV900-2-5 SPAG9/NY-SAR-35 AQKMSSLLPTMWLGAMMQMFGLGAISLILV 66%  83% 86 BCV900-2-6 PRAME LERLAYLHARLRELLQTLKAMVQAWPFTCL 71% 100% 87 BCV900-2-7 NY-SAR-35 SSYFVLANGHILPNSLRHKCCFSSSGTTSF 64%  85% 88 BCV900-2-8 Survivin/MAGE-A9 TAKKVRRAIEQLAAMQLEFMFQEALKLKVA 58% 100% 89 BCV900-2-9 MAGE-A11/NY-BR-1 TSHSYVLVTSLNLSYYSCDSRSLFESSAKI 65% 100% 90 BCV900-3-1 SPAG9/BORIS LDSFTVCNSHVLCIAVCMFTSSRMSSFNRH 65%  96% 91 BCV900-3-2 NY-SAR-35/PRAME LRHKCCFSSSGTTSFQTLKAMVQAWPFTCL 59%  85% 92 BCV900-3-3 NY-BR-1/SURVIVIN YSCDSRSLFESSAKITAKKVRRAIEQLAAM 55%  26% 93 BCV900-3-4 AKAP-4/BORIS MMAYSDTTMMSDDIDHTRFTQSGTMKIHIL 72%  80% 94 BCV900-3-5 SPAG9/AKAP-4 AQKMSSLLPTMWLGALQKYALGFQHALSPS 64%  92% 95 BCV900-3-6 MAGE-A11/BORIS TSHSYVLVTSLNLSYNMAFVTSGELVRHRR 61% 100% 96 BCV900-3-7 NY-SAR-35/AKAP-4 MMQMFGLGAISLILVVNIDYLMNRPQNLRL 71%  84% 97 BCV900-3-8 NY-SAR-35/SPAG-9 SSYFVLANGHILPNSKLGFSFVRITALMVS 65% 100% 98 BCV900-3-9 PRAME/MAGE-A9 LERLAYLHARLRELLQLEFMFQEALKLKVA 73% 100% 99 BCV900-4-1 SPAG9/AKAP4 GNILDSFTVCNSHVLLQKYALGFQHALSPS 53%  88% 100 BCV900-4-2 BORIS/NY-SAR-35 NMAFVTSGELVRHRRFSSSGTTSFKCFAPF 65%  75% 101 BCV900-4-5 SPAG9/BORIS AQKMSSLLPTMWLGAMFTSSRMSSFNRHMK 72%  87% 102 BCV900-4-6 MAGE-A11/PRAME TSHSYVLVTSLNLSYHSQTLKAMVQAWPFT 60% 100% 103 BCV900-5-6 HomTes85/MageA11 MASFRKLTLSEKVPPSPTAMDAIFGSLSDE 45%  51% 104 BCV900-5-7 AKAP4/PRAME DQVNIDYLMNRPQNLRHSQTLKAMVQAWPF 64%  67% 105 BCV900-5-8 NYSAR/SPAG9 CSGSSYFVLANGHILSGAVMSERVSGLAGS 46%  78% 106 BCV900-S-2 AKAP-4/MAGE-A9 DLSFYVNRLSSLVIQSSISVYYTLWSQFDE 60% 100% 107 BCV900-S-4 SPAG9/NY-ESO-1 SGAVMSERVSGLAGSSRLLEFYLAMPFATP 59%  98% 108 BCV900-S-6 HOM-TES-85/MAGE- MASFRKLTLSEKVPPESFSPTAMDAIFGSL 46%  51% A11 109 BCV900-S-7 NY-ESO-1/NY-BR-1 FYLAMPFATPMEAELKPSAFEPATEMQKSV 60%  96% 110 BCV900-T-27 MAGE-A11/PRAME AMDAIFGSLSDEGSGHSQTLKAMVQAWPFT 54%  37% 111 BCV900-T-28 NY-SAR-35/SPAG9 FVLANGHILPNSENAGTGKLGFSFVRITAL 61%  94% 435 BCV900-6-1 TSGA10/PIWIL-2 YSSNAYHMSSTMKPNFVASINLTLTKWYSR 80%  95% 436 BCV900-6-2 PIWIL-2/AKAP4 RNFYDPTSAMVLQQHMMAYSDTTMMSDDID 88%  49% 437 BCV900-6-3 PLU-1/RHOXF-2 LRYRYTLDDLYPMMNSDYAVHPMSPVGRTS 67%  85% 438 BCV900-6-4 SPAG9/EpCam SGAVMSERVSGLAGSRTYWIIIELKHKARE 60% 100% 439 BCV900-6-5 AKAP4/PLU-1 DLSFYVNRLSSLVIQNRTSYLHSPFSTGRS 66% 100% 440 BCV900-6-6 AKAP4/HIWI VNIDYLMNRPQNLRLHAFDGTILFLPKRLQ 70%  94% 441 BCV900-6-7 AKAP4/PLU-1 SDLQKYALGFQHALSEKAMARLQELLTVSE 56%  92% 442 BCV900-6-8 HIWI/ODF-4 GFTTSILQYENSIMLQDGRLLSSTLSLSSN 61%  94% 443 BCV900-6-9 PIWIL-2/BORIS YSRVVFQMPHQEIVDNMAFVTSGELVRHRR 61%  85% 444 BCV900-6-10 SP17/BORIS AFAAAYFESLLEKREMFTSSRMSSFNRHMK 82% 100% 445 BCV900-6-11 ODF-4/HIWI NSPLPFQWRITHSFRRSIAGFVASINEGMT 60%  69% 446 BCV900-6-12 NY-SAR-35/RHOXF- SSYFVLANGHILPNSWEEAYTFEGARYYIN 74%  93% 2 447 BCV900-6-13 TSGA10/PRAME LQKVQFEKVSALADLLERLAYLHARLRELL 68% 100% 448 BCV900-6-14 MAGE-A11/MAGE- SHSYVLVTSLNLSYDFMFQEALKLKVAELV 65% 100% A9 449 BCV900-6-15 BORIS/EpCam RFTQSGTMKIHILQKQTLIYYVDEKAPEFS 53%  80%

TABLE 18b Selected Breast Cancer Vaccine peptides for PolyPEPI915 panel/composition HLAI* HLAII** SEQID TREOSID Source Antigen Peptide (30 mer) (CD8) (CD4) 99 BCV900-4-1 SPAG9/AKAP4 GNILDSFTVCNSHVLLQKYALGFQHALSPS 53% 75% 100 BCV900-4-2 BORIS/NY-SAR-35 NMAFVTSGELVRHRRFSSSGTTSFKCFAPF 65% 46% 92 BCV900-3-3 NY-BR-1/SURVIVIN YSCDSRSLFESSAKITAKKVRRAIEQLAAM 55% 11% 93 BCV900-3-4 AKAP-4/BORIS MMAYSDTTMMSDDIDHTRFTQSGTMKIHIL 72% 45% 101 BCV900-4-5 SPAG9/BORIS AQKMSSLLPTMWLGAMFTSSRMSSFNRHMK 72% 50% 103 BCV900-5-6 HonnTes85/MageA11 MASFRKLTLSEKVPPSPTAMDAIFGSLSDE 45% 16% 104 BCV900-5-7 AKAP4/PRAME DQVNIDYLMNRPQNLRHSQTLKAMVQAWPF 64% 33% 105 BCV900-5-8 NYSAR/SPAG9 CSGSSYFVLANGHILSGAVMSERVSGLAGS 46% 48% 98 BCV900-3-9 PRAM E/MAGE-A9 LERLAYLHARLRELLQLEFMFQEALKLKVA 73% 100% PolyPEPI915 (9 peptide 96% 100% together) *Percentage of individuals having CD8+ T cell specific PEPI3+ within the HLA class I Model Population (n = 433). **Percentage of individuals having CD4+ T cell specific PEPI4+ within the normal donors (n = 400).

Characterization of PolyPEPI915

Tumor heterogeneity can be addressed by including peptide sequences that target multiple CTAs in a vaccine or immunotherapy regime. The PolyPEPI915 composition targets 10 different CTAs. Based on the antigen expression rates for these 10 CTAs, we modelled the predicted average number of expressed antigens (AG50) and the minimum number of expressed antigens with 95% likelihood (AG95) in the cancer cells. 95% of individuals expressed minimum 4 of the 10 target antigens (AG95=4) as shown by the antigen expression curve in FIGS. 12A-B.

The AG values described above characterize a vaccine independently from the target patient population. They can be used to predict the likelihood that a specific cancer (e.g. breast cancer) expresses antigens targeted by a specific vaccine or immunotherapy composition. AG values are based on known tumor heterogeneity, but do not take HLA heterogeneity into account.

HLA heterogeneity of a certain population can be characterised from the viewpoint of an immunotherapy or vaccine composition by the number of antigens representing PEPI3+. These are the vaccine-specific CTA antigens for which ≥1 PEPI3+ is predicted, referred to herein as the “AP”. The average number of antigens with PEPI3+(AP50) shows how the vaccine can induce immune response against the antigens targeted by the composition (breast cancer vaccine specific immune response). The PolyPEPI915 composition can induce immune response against an average of 5.3 vaccine antigens (AP50=5.30) and 95% of the Model Population can induce immune response against at least one vaccine antigen (AP95=1)(FIGS. 13A-B).

Vaccines can be further characterized by AGP values that refers to antigens with PEPIs”. This parameter is the combination of the previous two parameters: (1) AG is depending on the antigen expression frequencies in the specific tumor type but not on the HLA genotype of individuals in the population, and (2) AP is depending on the HLA genotype of individuals in a population without taking account the expression frequencies of the antigen. The AGP is depending on both, the expression frequencies of vaccine antigens in the disease and the HLA genotype of individuals in a population.

Combining the data of AG of breast cancer and AP in the Model Population we determined the AGP value of PolyPEPI915 that represents the probability distribution of vaccine antigens that are induce immune responses against antigens expressed in breast tumors. For PolyPEPI915, the AGP50 value in the Model Population is 3.37. The AGP92=1, means that 92% of the subjects in the Model Population induce immune responses against at least one expressed vaccine antigen (FIGS. 14A-B).

Example 14—Patient Selection Using Companion Diagnostic for Breast Cancer Vaccine

The likelihood that a specific patient will have an immune response or a clinical response to treatment with one or more cancer vaccine peptides, for example as described above, can be determined based on (i) the identification of PEPI3+ within the vaccine peptide(s) (9 mer epitopes capable of binding at least three HLA of the patient); and/or (ii) a determination of target antigen expression in cancer cells of the patient, for example as measured in a tumour biopsy. Ideally both parameters are determined and the optimal combination of vaccine peptides is selected for use in treatment of the patient. However, PEPI3+ analysis alone may be used if a determination of the expressed tumour antigens, for example by biopsy, is not possible, not advised, or unreliable due to biopsy error (i.e. biopsy tissue samples taken from a small portion of the tumor or metastasised tumors do not represent the complete repertoire of CTAs expressed in the patient).

Example 15—Comparison of PolyPEPI915 with Competing Breast Cancer Vaccines

We used the in silico clinical trial model described in above to predict the immune response rates of competing breast cancer vaccines that investigated in clinical trials (Table 19). The immune response rate of these products were between 3% and 91%.

The single peptide vaccines were immunogenic in 3%-23% of individuals. In comparison, peptides having an amino acid sequence selected from SEQ ID NOs: 81-111 were immunogenic in from 44% to 73% of individuals in the same cohorts. This result represents substantial improvement in immunogenicity of each peptide in PolyPEPI915.

Competing combination peptide products immune response rates were between 10-62%. The invented PolyPEPI915 combination product were 96% in the Model Population and 93% in a breast cancer patient population representing improvement in immunogenicity.

TABLE 19 Predicted immune response rates of competing breast cancer vaccines Predicted immune response rates* 433 normal 90 patients Target donors (Model with breast Breast Cancer Vaccines Sponsors antigens Population) cancer DPX0907 Multipeptide Immuno Vaccine 7 58% 62% Tech. Multipeptide vaccine University of 5 22% 31% Virginia Ad-sig-hMUC-1/ecdCD40L Singapore CRI 1 91% 80% NY-ESO-1 IDC-G305 Immune Design 1 84% 84% Corp. 6 HER2 peptide pulsed DC University 1 29% 36% Pennsylvania HER-2 B Cell peptide Ohio State 1 18% 23% University HER-2/neu ID protein University 1 10% 11% Washington NeuVax peptide Galena Biopharma 1  6%  3% StimuVax ® L-BLP25) EMD Serono 1  6%  8% peptide PolyPEPI915 Treos Bio 10 96% 93% *Proportion of subjects with ≥ 1 PEPI3+

Another improvement of using the PolyPEPI915 vaccine is the lower chance of tumor escape. Each 30 mer peptide in PolyPEPI915 targets 2 tumor antigens. CTLs against more tumor antigens are more effective against heterologous tumor cells that CTLs against a single tumor antigen.

Another improvement is that PolyPEPI915 vaccine that individuals who likely respond to vaccination can be identified based on their HLA genotype (sequence) and optionally antigen expression in their tumor using the methods described here. Pharmaceutical compositions with PolyPEPI vaccines will not be administered to individuals whose HLA cannot present any PEPI3 from the vaccines. During clinical trials correlation will be made between the mAGP or number of AGP in the PolyPEPI915 regimen and the duration of individual's responses. A vaccine combination with >1 AGP is most likely required to destroy heterologous tumor cells. Pharmaceutical compositions with PolyPEPI vaccines will not be administered to individuals whose HLA cannot present any PEPI3 from the vaccines.

Example 16 Colorectal Cancer Vaccine Design and Composition

We show another example for colorectal vaccine composition using the same design method demonstrated above. We used the PEPI3+ Test described above to design peptides for use in colorectal cancer vaccines that are effective in a large percentage of patients, taking into account the heterogeneities of both tumour antigens and patient HLAs.

Colorectal cancer CTAs were identified and ranked based on the overall expression frequencies of antigens found in breast cancer tumor samples as reported in peer reviewed publications (FIG. 15) (Choi J, Chang H. The expression of MAGE and SSX, and correlation of COX2, VEGF, and survivin in colorectal cancer. Anticancer Res 2012. 32(2):559-564; Goossens-Beumer I J, Zeestraten E C, Benard A, Christen T, Reimers M S, Keijzer R, Sier C F, Liefers G J, Morreau H, Putter H, Vahrmeijer A L, van de Velde C J, Kuppen P J. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. Br J Cancer 2014. 110(12):2935-2944; Li M, Yuan Y H, Han Y, Liu Y X, Yan L, Wang Y, Gu J. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clinical Cancer Res 2005. 11(5): 1809-1814).

Based on the ranked expression rate we have selected the most frequently expressed CTA as target antigens for the colorectal cancer vaccine. The expression rates of the selected breast cancer specific CTAs are illustrated in FIG. 15.

To select immunogenic peptides from the most frequently expressed colorectal cancer CTAs we used the PEPI3+ Test and the Model Population described in Example 8 to identify the “bestEPIs”.

We multiplied the reported expression frequency for each CTA (N %) by the frequency of the PEPI3+ hotspots in the Model Population (B %) to identify the T cell epitopes (9 mers) that will induce an immune response against colorectal cancer antigens in the highest proportion of individuals (Table 20). We then selected 15 mers encompassing each of the selected 9 mers (Table 20). The 15 mers were selected to bind to most HLA class II alleles of most subjects, using the process described in Example 19 below. These 15 mers can induce both CTL and T helper responses in the highest proportion of subjects.

TABLE 20 BestEPI list (9-mers underlined) for selecting colorectal cancer peptides for vaccine composition. N%: Antigen expression frequency in colorectal cancers; B%: bestEPI frequency, ie. the percentage of individuals with epitopes binding to at least 3 HLA class I of subjects in the model population (433 subjects); HLAII**: Percentage of individuals having CD4+ cell specific PEPI4+ within normal donors (n = 400); N% * B%: N% multiplied by B%. SEQ SEQ ID ID BestEPIs and Optimized 15 mer NO. NO. Antigen Opt. HLAII** 9 mer 15 mer Antigen N% Opt. 15 mer Position B% (CD4) B% * N% 234 251 TSP50 89% VCSMEGTWYLVGLVS 315 58%  72% 52% 21 252 TSP50 89% GFSYEQDPTLRDPEA 105 51%   0% 45% 21 61 TSP50 89% RSCGFSYEQDPTLRD 102 51%   0% 45% 21 253 TSP50 89% YRSCGFSYEQDPTLR 101 51%   0% 45% 22 62 EpCAM 88% VRTYWIIIELKHKAR 139 51% 100% 45% 235 254 EpCAM 88% LLAAATATFAAAQEE 12 39%  28% 34% 24 255 SPAG9 74% KLGFSFVRITALMVS 1140 44% 100% 33% 23 63 TSP50 89% PSTTMETQFPVSEGK 83 36%   0% 32% 24 64 SPAG9 74% GTGKLGFSFVRITAL 1137 44%  94% 32% 23 256 TSP50 89% LPSTTMETQFPVSEG 82 36%   0% 32% 25 65 SPAG9 74% AQKMSSLLPTMWLGA 962 43%  69% 32% 26 66 CAGE1 74% LASKMHSLLALMVGL 613 42%  99% 31% 27 67 FBXO39 39% KFMNPYNAVLTKKFQ 95 78%  43% 30% 28 68 CAGE1 74% PKSMTMMPALFKENR 759 37%  87% 27% 238 257 SPAG9 74% LDSFTVCNSHVLCIA 782 36%   6% 27% 236 258 SPAG9 74% GNILDSFTVCNSHVL 779 36%   4% 26% 29 69 EpCAM 88% YVDEKAPEFSMQGLK 251 28%   0% 25% 29 259 EpCAM 88% QTLIYYVDEKAPEFS 246 28%  34% 25% 30 70 FBXO39 39% FKKTMSTFHNLVSLN 216 58%  92% 23% 31 71 Survivin 86% TAKKVRRAIEQLAAM 127 26%  26% 22% 237 260 TSP50 89% SRTLLLALPLPLSLL 368 24% 100% 21% 32 72 SPAG9 74% SGAVMSERVSGLAGS 16 28%   9% 21% 238 260 TSP50 89% SRTLLLALPLPLSLL 368 23% 100% 20% 34 74 FBXO39 39% KVNFFFERIMKYERL 284 46% 100% 18% 33 73 TSP50 89% SRYRAQRFWSWVGQA 190 20%  88% 18% 239 261 LEMD1 56% FIIVVFVYLTVENKS 164 30%  97% 17% 240 66 CAGE1 74% LASKMHSLLALMVGL 613 22%  99% 16% 241 262 FBXO39 39% RNSIRSSFISSLSFF 142 40% 100% 16% 242 263 CAGE1 74% NIENYSTNALIQPVD 97 21%  14% 16% 243 264 Survivin 86% MGAPTLPPAWQPFLK 1 17%   0% 15% 244 265 CAGE1 74% RQFETVCKFHWVEAF 119 18%  45% 13% 35 75 Survivin 86% KDHRISTFKNWPFLE 15 15%  83% 13% 36 266 MAGE-A8 44% PEEAIWEALSVMGLY 220 20%  78%  9% 36 76 MAGE-A8 44% SRAPEEAIWEALSVM 217 20%   6%  9% 37 77 MAGE-A8 44% DEKVAELVRFLLRKY 113 18%  95%  8% 37 267 MAGE-A8 44% EKVAELVRFLLRKYQ 114 18%  99%  8% 38 268 MAGE-A6 28% KLLTQYFVQENYLEY 244 27%  98%  8% 38 78 MAGE-A6 28% QYFVQENYLEYRQVP 248 27%  93%  8% 40 80 MAGE-A6 28% IGHVYIFATCLGLSY 172 25%  82%  7% 39 79 MAGE-A8 44% EFLWGPRALAETSYV 273 16%  44%  7% 245 269 MAGE-A3 23% IGHLYIFATCLGLSY 172 28%  85%  6% 246 270 MAGE-A3 23% KLLTQHFVQENYLEY 244 27%  77%  6% 247 271 MAGE-A8 44% ASSSSTLIMGTLEEV 39 14%  19%  6% 248 269 MAGE-A3 23% IGHLYIFATCLGLSY 172 25%  85%  6% 249 264 Survivin 86% MGAPTLPPAWQPFLK 1  5%   0%  4% 250 75 Survivin 86% KDHRISTFKNWPFLE 15  4%  83%  3%

Then we designed thirty-one 30 mer peptides (Table 21a). The 30 mers each consist of two optimized 15 mer fragments, generally from different frequent CTAs, each 30 mer generally containing at least one high frequency HLA class-II binding PEPI. The 15 mer fragments are arranged end to end, and each comprises one of the 9 mers (BestEPIs) from Table 20 as described above. Nine of these 30 mer peptides were selected for a panel of peptide vaccines, referred to as PolyPEPI1015 (Table 21b). Expression frequencies for the 8 CTAs targeted by PolyPEPI1015, singly and in combination, are shown in FIG. 15.

TABLE 21a 30 mer colorectal cancer vaccine peptides SEQ HLAI* HLAII** ID TREOSID Source Antigen Peptide (30 mer) (CD8) (CD4) 112 CCV1000-1-1 TSP50 VCSMEGTWYLVGLVSYRSCGFSYEQDPTLR 71%  72% 113 CCV1000-1-2 EpCAM/TSP50 VRTYWIIIELKHKARLPSTTMETQFPVSEG 62% 100% 114 CCV1000-1-4 Survivin TAKKVRRAIEQLAAMMGAPTLPPAWQPFLK 39%  26% 115 CCV1000-1-5 CAGE1 LASKMHSLLALMVGLPKSMTMMPALFKENR 68%  99% 116 CCV1000-1-6 Spag9 KLGFSFVRITALMVSLDSFTVCNSHVLCIA 58% 100% 117 CCV1000-1-7 FBXO39 KFMNPYNAVLTKKFQFKKTMSTFHNLVSLN 91%  92% 118 CCV1000-1-8 Spag9/FBXO39 AQKMSSLLPTMWLGAKVNFFFERIMKYERL 75% 100% 119 CCV1000-1-9 Survivin/Mage-A8 KDHRISTFKNWPFLEPEEAIWEALSVMGLY 39%  93% 120 CCV1000-2-1 TSP50 YRSCGFSYEQDPTLRVCSMEGTWYLVGLVS 71%  72% 121 CCV1000-2-2 EpCAM/Survivin VRTYWIIIELKHKARTAKKVRRAIEQLAAM 57% 100% 122 CCV1000-2-4 TSP50/Spag9 LPSTTMETQFPVSEGKLGFSFVRITALMVS 61% 100% 123 CCV1000-2-5 Survivin/Mage-A8 MGAPTLPPAWQPFLKPEEAIWEALSVMGLY 40%  78% 124 CCV1000-2-6 CAGE1/Survivin LASKMHSLLALMVGLKDHRISTFKNWPFLE 58%  99% 125 CCV1000-2-7 CAGE1/Spag9 PKSMTMMPALFKENRLDSFTVCNSHVLCIA 61%  87% 126 CCV1000-2-8 FBXO39 KFMNPYNAVLTKKFQKVNFFFERIMKYERL 90% 100% 127 CCV1000-2-9 Spag9/FBXO39 AQKMSSLLPTMWLGAFKKTMSTFHNLVSLN 67%  92% 128 CCV1000-3-1 TSP50 GFSYEQDPTLRDPEAVCSMEGTWYLVGLVS 71%  72% 129 CCV1000-3-7 CAGE1/Spag9 PKSMTMMPALFKENRGNILDSFTVCNSHVL 61%  87% 130 CCV1000-5-1 TSP50 PSTTMETQFPVSEGKSRYRAQRFWSWVGQA 53%  88% 131 CCV1000-5-3 EpCAM/Mage-A8 YVDEKAPEFSMQGLKDEKVAELVRFLLRKY 43%  95% 132 CCV1000-5-4 TSP50/Spag9 RSCGFSYEQDPTLRDGTGKLGFSFVRITAL 67%  94% 133 CCV1000-5-5 Mage-A8/Mage-A6 SRAPEEAIWEALSVMQYFVQENYLEYRQVP 45%  94% 134 CCV1000-5-7 CAGE1/Spag9 PKSMTMMPALFKENRSGAVMSERVSGLAGS 57%  87% 135 CCV1000-S-1 SPAG9/FBXO39 SGAVMSERVSGLAGSRNSIRSSFISSLSFF 64% 100% 136 CCV1000-S-2 CAGE1/MAGE-A8 NIENYSTNALIQPVDEKVAELVRFLLRKYQ 28%  99% 137 CCV1000-S-3 CAGE1/MAGE-A6 RQFETVCKFHWVEAFKLLTQYFVQENYLEY 46%  98% 138 CCV1000-S-5 MAGE-A8/MAGE-A3 EFLWGPRALAETSYVKLLTQHFVQENYLEY 39%  91% 139 CCV1000-S-6 MAGE-A8/EpCAM ASSSSTLIMGTLEEVQTLIYYVDEKAPEFS 41%  41% 140 CCV1000-S-7 TSP50/MAGE-A3 SRTLLLALPLPLSLLIGHLYIFATCLGLSY 60% 100% 141 CCV1000-S-9 LEMD1/MAGE-A6 FIIVVFVYLTVENKSIGHVYIFATCLGLSY 51%  99% 142 CCV1000-S-17 EPCAM LLAAATATFAAAQEEQTLIYYVDEKAPEFS 52%  54% *Percentage of individuals having CD8+ T cell specific PEPI3+ within the Model Population (n = 433). **Percentage of individuals having CD4+ T cell specific PEPI4+ within normal donors (n = 400).

TABLE 21b Selected Colorectal Cancer Vaccine peptides for PolyPEPI1015 composition HLAI* HLAII** SEQID TREOSID Source Antigen Peptide (30 mer) (CD8) (CD4) 130 CCV1000-5-1 TSP50 PSTTMETQFPVSEGKSRYRAQRFWSWVGQA  53% 53% 121 CCV1000-2-2 EpCAM/Survivin VRTYWIIIELKHKARTAKKVRRAIEQLAAM  57% 98% 131 CCV1000-5-3 EpCAM/Mage-A8 YVDEKAPEFSMQGLKDEKVAELVRFLLRKY  43% 72% 132 CCV1000-5-4 TSP50/Spag9 RSCGFSYEQDPTLRDGTGKLGFSFVRITAL  67% 82% 133 CCV1000-5-5 Mage-A8/Mage-A6 SRAPEEAIWEALSVMQYFVQENYLEYRQVP  45% 76% 124 CCV1000-2-6 CAGE1/Survivin LASKMHSLLALMVGLKDHRISTFKNWPFLE  58% 95% 134 CCV1000-5-7 CAGE1/Spag9 PKSMTMMPALFKENRSGAVMSERVSGLAGS  57% 57% 126 CCV1000-2-8 FBXO39 KFMNPYNAVLTKKFQKVNFFFERIMKYERL  90% 98% 127 CCV1000-2-9 Spag9/FBXO39 AQKMSSLLPTMWLGAFKKTMSTFHNLVSLN  67% 66% PolyPEPI1015 (9 peptide together) 100% 99% *Percentage of individuals having CD8+ T cell specific PEPI3+ within the Model Population (n = 433). **Percentage of individuals having CD4+ T cell specific PEPI4+ within normal donors (n = 400).

Characterization of PolyPEPI1015 Colorectal Cancer Vaccine

Tumor heterogeneity: The PolyPEPI1015 composition targets 8 different CTAs (FIG. 15). Based on the antigen expression rates for these 8 CTAs, AG50=5.22 and AG95=3 FIGS. 16A-B.

Patient heterogeneity: the AP50=4.73 and AP95=2 (AP95=2) (FIGS. 17A-B). Both tumor and

patient heterogeneity: AGP50=3.16 and AGP95=1 (Model Population) (FIGS. 18A-B).

Example 17—Comparison of Colorectal Cancer Vaccine Peptides with Competing Colorectal Cancer Vaccines

We used the in silico clinical trial model described above to determine T cell responder rate of state of art and currently developed CRC peptide vaccines and compared to and compared to that of polyPEPI1015 (Table 22). Our PEPI3+ test demonstrate that competing vaccines can induce immune responses against one tumor antigen in a fraction of subjects (2%-77%). However, the multi-antigen (multi-PEPI) response determination for the 2 competitor multi-antigen vaccines resulted in no or 2% responders. *% of responders are the ratio of subjects from the Model population with 1≥PEPI3+ for HLAI (CD8+ T cell responses) in case of 1, or for 2, 3, 4 or 5 antigens of the vaccine compositions. Since multi-PEPI responses correlate with clinical responses induced by tumor vaccines, it is unlikely that any of the competing vaccines will demonstrate clinical benefit in 98% of patients. In contrast, we predicted multi-PEPI responses in 95% of subjects suggesting the likelihood for clinical benefit in the majority of patients.

TABLE 22 Predicted immune response rates of polyPEPI1015 and competing colorectal cancer vaccines % of CD8+ T cell responders in 433 subjects* Vaccine Colorectal Cancer antigens % responders against multiple Ags Vaccines Sponsor (Ags) 1 Ag 2 Ags 3Ags 4Ags 5 Ags Stimuvax ®(L-BLP25) Johannes Gutenberg 1  6% — — — — Peptide Vaccine University Mainz WT1 Multipeptide Vaccine Shinshu University, Japan 1 79% — — — — Multiepitope Peptide Kinki University 7  5% 2% 0% 0% 0% Cocktail Vaccine p53 Synthetic Long Leiden University Medical 1 77% — — — — Peptide Vaccine Center HER-2 B Cell Ohio State University 1 18% — — — — Peptide Vaccine Comprehensive Cancer Center NY-ESO-1 peptide pulsed Jonsson Comprehensive 1  0% — — — — dendritic cell vaccine Cancer Center OCV-C02 Otsuka Pharmaceutical Co., 2  2% 0% — — — Ltd. PolyPEPI1015 Treos Bio 8 100%  95%  87%  70%  54% 

Example 18 Ovarian Cancer Vaccine Design and Composition

We used the PEPI3+ Test to design peptides for use in ovarian cancer vaccines using essentially the same design method described in Examples 13 and 16 above.

We multiplied the reported expression frequency for CTAs associated with ovarian cancer (N %) by the frequency of the PEPI3+ hotspots in the Model Population (B %) to identify the T cell epitopes (9 mers) that will induce an immune response against ovarian cancer antigens in the highest proportion of individuals (Table 23). We then selected 15 mers encompassing each of the selected 9 mers (Table 23). The 15 mers were selected to bind to most ELLA class II alleles of most subjects, using the process described in Example 20 below.

TABLE 23 BestEPI list (9-mers underlined) for selecting ovarian cancer peptides for vaccine composition. N%: Antigen expression frequency in colorectal cancers; B%: bestEPI frequency, ie. the percentage of individuals with epitopes binding to at least 3 HLA class I of subjects in the model population (433 subjects); HLAII**: Percentage of individuals having CD4+ T cell specific PEPI4+ within normal donors (n = 400); N% * B%: N% multiplied by B%. SEQ SEQ ID ID BestEPIs and Optimized 15 mer NO. NO. Antigen Opt. HLAII** 9 mer 15 mer Antigen N% Opt. 15 mer Position B% (CD4) B% * N% 272 302 PIWIL-4 90% QGMMMSIATKIAMQM 585 79%  72% 71% 273 303 PIWIL-4 90% KAKAFDGAILFLSQK 153 62%  80% 56% 274 304 WT1 63% SSGQARMFPNAPYLP 121 78%   0% 49% 275 305 EpCam 92% RTYWIIIELKHKARE 140 51% 100% 47% 276 306 BORIS 82% MFTSSRMSSFNRHMK 263 57%  66% 46% 277 307 AKAP4 88% QVNIDYLMNRPQNLR 162 52%  46% 46% 278 308 OY-TES-1 65% STPMIMENIQELIRS 277 67%  82% 43% 279 309 AKAP4 88% MMAYSDTTMMSDDID 1 49%   0% 43% 280 310 SP17 65% AFAAAYFESLLEKRE 37 65% 100% 42% 281 311 PIWIL-4 90% RAIQQYVDPDVQLVM 534 46%   5% 42% 282 312 PIWIL-2 61% GFVASINLTLTKWYS 759 67%  93% 41% 283 313 AKAP4 88% DLQKYALGFQHALSP 117 46%  82% 40% 284 314 PIWIL-3 88% GYVTSVLQYENSITL 266 44%  54% 39% 285 315 SPAG9 90% VREEAQKMSSLLPTM 958 43%   1% 39% 286 316 PIWIL-3 88% MSLKGHLQSVTAPMG 523 42%  17% 37% 287 317 PIWIL-3 88% QKSIAGFVASTNAEL 663 42%  37% 37% 288 318 PIWIL-2 61% RNFYDPTSAMVLQQH 341 60%  49% 37% 289 319 BORIS 82% NMAFVTSGELVRHRR 319 44%  75% 36% 290 320 AKAP4 88% LSFYVNRLSSLVIQM 217 36% 100% 31% 291 321 PRAME 59% LERLAYLHARLRELL 457 52% 100% 30% 292 322 BORIS 82% RFTQSGTMKIHILQK 406 35%  69% 29% 293 323 HIWI 68% HAFDGTILFLPKRLQ 161 39%  83% 27% 294 324 EpCam 92% YVDEKAPEFSMQGLK 251 28%   0% 26% 295 325 SPAG9 90% SGAVMSERVSGLAGS 16 28%   9% 25% 296 326 HIWI 68% GFTTSILQYENSIML 251 37%  86% 25% 297 327 PIWIL-2 61% YSRVVFQMPHQEIVD 772 40%  77% 24% 298 328 PRAME 59% RHSQTLKAMVQAWPF 64 37%  38% 22% 299 329 Survivin 84% AKKVRRAIEQLAAMD 128 26%  25% 22% 300 330 BORIS 82% ERSDEIVLTVSNSNV 210 25%   2% 21% 301 331 WT1 63% RTPYSSDNLYQMTSQ 218 32%   0% 20%

Then we designed 15 30 mer peptides (Table 24).

TABLE 24 30 mer ovarian cancer vaccine peptides HLAI* HLAII** SEQID TREOSID Source Antigen Peptide (30 mer) (CD8) (CD4) 332 OC1212-01 OY-TES-1/PIWIL-4 STPMIMENIQELIRSQGMMMSIATKIAMQM 94%  98% 333 OC1212-02 PIWIL-2/PIWIL-4 RNFYDPTSAMVLQQHKAKAFDGAILFLSQK 89%  90% 334 OC1212-03 BORIS/AKAP4 NMAFVTSGELVRHRRMMAYSDTTMMSDDID 68%  75% 335 OC1212-04 WT1/WT1 SSGQARMFPNAPYLPRTPYSSDNLYQMTSQ 84%   0% 336 OC1212-05 BORIS/HIWI MFTSSRMSSFNRHMKHAFDGTILFLPKRLQ 67%  94% 337 OC1212-06 PIWIL-2/EpCam YSRVVFQMPHQEIVDRTYWIIIELKHKARE 67% 100% 338 OC1212-07 AKAP4/PIWIL-4 LSFYVNRLSSLVIQMRAIQQYVDPDVQLVM 71% 100% 339 OC1212-08 AKAP4/SP17 QVNIDYLMNRPQNLRAFAAAYFESLLEKRE 78% 100% 340 OC1212-09 PIWIL-3/PIWIL-3 GYVTSVLQYENSITLQKSIAGFVASTNAEL 64%  65% 341 OC1212-10 SPAG9/BORIS VREEAQKMSSLLPTMRFTQSGTMKIHILQK 62%  69% 342 OC1212-11 PIWIL-2/EpCam GFVASINLTLTKWYSYVDEKAPEFSMQGLK 74%  93% 343 OC1212-12 PIWIL-3/SPAG9 MSLKGHLQSVTAPMGSGAVMSERVSGLAGS 52%  19% 344 OC1212-13 AKAP4/PRAME DLQKYALGFQHALSPLERLAYLHARLRELL 67% 100% 345 OC1212-14 HIWI/BORIS GFTTSILQYENSIMLERSDEIVLTVSNSNV 49%  86% 346 OC1212-15 PRAME/Survivin RHSQTLKAMVQAWPFAKKVRRAIEQLAAMD 48%  42% *Percentage of individuals having CD8+ T cell specific PEPI3+ within the Model Population (n = 433). **Percentage of individuals having CD4+ T cell specific PEPI4+ within normal donors (n = 400).

Example 19, Efficacy by Design Procedure Exemplified for PolyPEPI1018 Colorectal Cancer Vaccine

The PolyPEPI1018 Colorectal Cancer (CRC) Vaccine (PolyPEPI1018) composition is a peptide vaccine intended to be used as an add-on immunotherapy to standard-of-care CRC treatment options in patients identified as likely responders using a companion in vitro diagnostic test (CDx). Clinical trials are ongoing in the US and Italy to evaluate PolyPEPI1018 in metastatic colorectal cancer patients. The product contains 6 peptides (6 of the 30 mer peptides PolyPEPI1015 described in examples 16 and 17) mixed with the adjuvant Montanide. The 6 peptides were selected to induce T cell responses against 12 epitopes from 7 cancer testis antigens (CTAs) that are most frequently expressed in CRC. The 6 peptides were optimized to induce long lasting CRC specific T cell responses. Likely responder patients with T cell responses against multiple CTAs expressed in the tumor can be selected with a companion diagnostic (CDx). This example sets out the precision process used to design PolyPEPI1018. This process can be applied to design vaccines against other cancers and diseases.

A. Selection of Multiple Antigen Targets

The selection of tumor antigens is essential for the safety and efficacy of cancer vaccines. The feature of a good antigen is to have restricted expression in normal tissues so that autoimmunity is prevented. Several categories of antigen meet this requirement, including uniquely mutated antigens (e.g. p53), viral antigens (e.g. human papillomavirus antigens in cervical cancer), and differentiation antigens (e.g. CD20 in B-cell lymphoma).

The inventors selected multiple cancer testis antigens (CTAs) as target antigens since they are expressed in various types of tumor cells and testis cells, but not expressed in any other normal somatic tissues or cells. CTAs are desirable targets for vaccines for at least the following reasons:

-   -   tumors of higher histological grade and later clinical stage         often show higher frequency of CTA expression     -   only a subpopulation of tumor cells express a certain CTA     -   different cancer types are significantly different in their         frequency of CTA expression     -   tumors that are positive for a CTA often show simultaneous         expression of more than one CTA     -   None of the CTAs appear to be cell surface antigens, therefore         these are unique targets for cancer vaccines (they are not         suitable targets for antibody based immunotherapies)

To identify the target CTAs for PolyPEPI1018, the inventors built a CTA expression knowledgebase. This knowledgebase contains CTAs that are expressed in CRC ranked in order by expression rate. Correlation studies conducted by the inventors (see Example 11) suggest that vaccines which induce CTL responses against multiple antigens that are expressed in tumor cells can benefit patients. Therefore, seven CTAs with high expression rates in CRC were selected for inclusion in PolyPEPI1018 development. Details are set out in Table 25.

TABLE 25 Target CTAs in PolyPEPI1018 CRC vaccine CTA Expression Name Rate Characterization TSP50 89.47% Testis-Specific Protease-Like Protein 50 is an oncogene which induces cell proliferation, cell invasion, and tumor growth. It is frequently expressed in gastric-, breast-, cervical- and colorectal cancer samples; and rarely expressed in normal human tissues, except in spermatocytes of testes. EpCAM 88.35% Epithelial Cell Adhesion Molecule is a tumor associated antigen, which is expressed in colon cancers and over-expressed in various human carcinomas. The high expression of EpCAM in cancer-initiating stem cells makes it a valuable target for cancer vaccines. EpCAM is also expressed in at low or negligible levels in normal epithelial cells, with the exception of squamous epithelium, hepatocytes and keratinocytes. Survivin 87.28% Survivin (Baculoviral IAP repeat-containing protein 5) is a multi- tasking protein that promotes cell proliferation and inhibits apoptosis. Though it is strongly expressed in fetal tissues and necessary for normal development, it is not expressed in most adult tissues. Survivin is expressed in various cancers including carcinomas. Normal tissues that express low level survivin include thymus, CD34⁺ bone-marrow- derived stem cells, and basal colonic epithelium. Dramatic over- expression of survivin compared with normal tissues is observed in tumors in the lung, breast, colon, stomach, esophagus, pancreas, bladder, uterus, ovaries, large-cell non-Hodgkin's lymphoma, leukemias, neuroblastoma, melanoma and non-melanoma skin cancers. CAGE1 74.47% Cancer-associated gene 1 protein is a typical CTA, which might play a role in cell proliferation and tumorigenesis. CAGE1 is highly expressed in colorectal cancer tissues and weakly expressed in adjacent normal colorectal mucosa. In addition, CAGE1 is expressed in melanoma, hepatoma, and breast tumors. No CAGE1 protein expression is detected in healthy human tissues, other than testes. SPAG9 74.36% Sperm-associated antigen 9 is involved in c-Jun N-terminal kinase- signaling and functions as a scaffold protein, thus playing an important role in cell survival, proliferation, apoptosis and tumor development. SPAG9 expression was detected in epithelial ovarian cancer (90%), breast cancer (88%), cervical cancer (82%), renal cell cancer (88%) and colorectal cancer (74%) patients. None of the adjacent noncancerous tissues showed antigen expression. SPAG9 expression is restricted to testis. FBXO39 38.60% FBXO39 (BCP-20) is a testis specific protein and is an important part of the E3 ubiquitin ligase complex. It participates in ubiquitination and has a role in regulating the cell cycle, immune responses, signaling, and proteasomal degradation of proteins. FBXO39 is expressed in colon and breast cancers. FBXO39 expression has also been detected in ovary, placenta, and lung. FBXO39 expression is 100-fold higher in testis and 1,000-fold higher in colorectal cancers compared with normal tissue. MAGEA8 43.75% Melanoma-associated antigen 8 function is not known, though it may play a role in embryonal development and tumor transformation or aspects of tumor progression. MAGE-A8 gene is expressed in CRC and hepatocellular carcinoma. MAGE-A8 expression in normal tissues is restricted to the testis and the placenta. B. Precise Targeting is Achieved by PEPI3+ Biomarker Based Vaccine Design

As described above the PEPI3+ biomarker predicts a subject's vaccine induced T cell responses. The inventors developed and validated a test to accurately identify the PEPIs from antigen sequences and HLA genotypes (Examples 1, 2, 3). The PEPI Test algorithm was used to identify the dominant PEPIs (besEPIs) from the 7 target CTAs to be included in PolyPEPI1018 CRC vaccine.

The dominant PEPIs identified with the process described here can induce CTL responses in the highest proportion of subjects:

-   -   i. Identification of all HLA class I binding PEPIs from the 7         CTA targets in each of the 433 subjects in the Model Population     -   ii. Identification of the dominant PEPIs (BestEPIs) that are         PEPIs present in the largest subpopulation.

The 12 dominant PEPIs that are derived from the 7 CTAs in PolyPEPI1018 are presented in the Table 26. The PEPI % in Model Population indicates the proportion of 433 subjects with the indicated PEPI, i.e. the proportion of subjects where the indicated PEPI can induce CTL responses. There is very high variability (18%-78%) in the dominant PEPIs to induce CTL responses despite the optimization steps used in the identification process.

TABLE 26 CRC specific HLA class I binding dominant PEPIs in PolyPEPI1018 Dominant PEPI3+ for each of the 7 CTAs in PolyPEPI1018 in CRC patients PEPI3+% Peptides in CRC Dominant in Model PolyPEPI1018 Antigens PEPI3+ Population CRC-P1 TSP50 TTMETQFPV 36% YRAQRFWSW 20% CRC-P2 EpCAM RTYWIIIEL 51% Survivin RAIEQLAAM 26% CRC-P3 EpCAM YVDEKAPEF 28% MAGE-A8 KVAELVRFL 18% CRC-P6 CAGE1 KMHSLLALM 42% Survivin STFKNWPFL 15% CRC-P7 CAGE1 KSMTMMPAL 37% SPAG9 VMSERVSGL 28% CRC-P8 FBXO39 FMNPYNAVL 78% FFFERIMKY 46%

The inventors optimized each dominant PEPI to bind to most HLA class II alleles of most subjects. This should enhance efficacy, because it will induce CD4⁺ T helper cells that can augment CD8⁺ CTL responses and contribute to long lasting T cell responses. The example presented in FIG. 4 demonstrates that PEPIs that bind to ≥3 HLA class II alleles most likely activate T helper cells.

The 15-mer peptides selected with the process described here contain both HLA class I and class II binding dominant PEPIs. Therefore, these peptides can induce both CTL and T helper responses in the highest proportion of subjects.

Process:

-   -   1. Identification the HLA class II genotype of 400 normal         donors*     -   2. Extension of each 9-mer dominant PEPI (Table 20) on both         sides with amino acids that match the source antigen     -   3. Prediction of HLA class II PEPIs of 400 normal donors using         an IEDB algorithm     -   4. Selection the 15-mer peptide with the highest proportion of         subject have HLA Class II binding PEPIs     -   5. Ensure the presence of one dominant HLA class II PEPI in each         vaccine peptide when joining two 15-mer peptides

The 12 optimized 15-mer peptides derived from the 7 CTAs in PolyPEPI1018 are presented in the Table 27. These peptides have different HLA class II binding characteristics. There is a high variability (0%-100%) in PEPI generation capacity (≥3 HLA binding) among these peptides despite such an optimized personalized vaccine design.

TABLE 27 Antigen specific HLA class II binding PEPIs in PolyPEPI1018. Average % subjects % subjects % subjects % subjects HLA class with >1 with >2 with >3 with >4 HLA II binding HLA class HLA class HLA class class II Nr. CRC antigens alleles II binding II binding II binding binding CRC-P1 TSP50 (83-97) 0  0%  0%  0%  0% TSP50 (190-204) 4 100% 99% 88% 53% CRC-P2 EPCAM(139-153) 5 100% 100%  100%  98% SURVIVIN(127-141) 2  84% 58% 26% 11% CRC-P3 EPCAM(251-265) 0  0%  0%  0%  0% MAGE-A8(113-127) 4 100% 100%  95% 72% CRC-P6 CAGE1(613-627) 5 100% 100%  99% 95% SURVIVIN(15-29) 3 100% 97% 83% 45% CRC-P7 CAGE1(759-773) 3 100% 98% 87% 56% SPAG9(16-30) 1  66% 35%  9%  2% CRC-P8 FBXO39(95-109) 3 100% 94% 43% 13% FBXO39(284-298) 5 100% 100%  100%  98%

The 30-mer vaccine peptides have the following advantages compared to shorter peptides:

-   -   (i) Multiple precisely selected tumor specific immunogens: each         30 mer contains two precisely selected cancer specific         immunogenic peptides that are capable to induce CTL and T helper         responses in the majority of the relevant population (similar to         the model population).     -   (ii) Ensure natural antigen presentation. 30-mer long         polypeptides can be viewed as pro-drugs: They are not         biologically active by themselves, but are processed to smaller         peptides (9 to 15 amino acid long) to be loaded into the HLA         molecules of professional antigen presenting cells. The antigen         presentation resulting from long peptide vaccination reflects         physiological pathways for presentation in both HLA class I and         class II molecules. In addition, long peptide processing in the         cells is much more efficient than that of large intact proteins.     -   (iii) Exclude induction of tolerizing T cell responses. 9-mer         peptides do not require processing by professional         antigen-presenting cells and therefore bind exogenously to the         HLA class I molecules. Thus, injected short peptides will bind         in large numbers to HLA class I molecules of all nucleated cells         that have surface HLA class I. In contrast, >20-mers long         peptides are processed by antigen presenting cells before         binding to HLA class I. Therefore, vaccination with long         peptides is less likely to lead to tolerance and will promote         the desired antitumor activity.     -   (iv) Induce long lasting T cell responses because it can         stimulate T helper responses by binding to multiple HLA class II         molecules     -   (v) Utility. GMP manufacturing, formulation, quality control and         administration of a smaller number of peptides (each with all of         the above characteristics) is more feasible than a larger number         of peptides supplying different characteristics.

Each 30-mer peptide in PolyPEPI1018 consists of 2 HLA class I binding dominant PEPIs and at least one strong HLA class II binding PEPI. Strong binding PEPIs bind to 4 HLA class II alleles in >50% of individuals. Therefore, the vaccine peptides are tailored to both HLA class I and class II alleles of individual subjects in a general population (which is a relevant population for CRC vaccine design).

As demonstrated above the high HLA genotype variability in subjects results in high variability of T cell responses induced by PolyPEPI1018. This justifies the co-development of a CDx that determines likely responders. The PEPI3+ and >2PEPI3+ biomarkers could predict the immune response and clinical responses, respectively, of subjects vaccinated with PolyPEPI1018 as detailed in Examples 11 and 12. These biomarkers will be used to co-develop a CDx which predicts likely responders to PolyPEPI1018 CRC vaccine.

Example 20—Analysis of the Composition and Immunogenicity of PolyPEPI1018 CRC Vaccine

Selected peptides for the PolyPEPI1018 composition are as shown in Table 28.

TABLE 28 Selected Colorectal Cancer Vaccine peptides for PolyPEPI1018 composition HLAI* HLAII** SEQID TREOSID Source Antigen Peptide (30 mer) (CD8) (CD4) 130 CCV1000-5-1 TSP50 PSTTMETQFPVSEGKSRYRAQRFWSWVGQA 53% 88% 121 CCV1000-2-2 EpCAM/Survivin VRTYWIIIELKHKARTAKKVRRAIEQLAAM 57% 100% 131 CCV1000-5-3 EpCAM/Mage-A8 YVDEKAPEFSMQGLKDEKVAELVRFLLRKY 43% 95% 124 CCV1000-2-6 Cage/Survivin LASKMHSLLALMVGLKDHRISTFKNWPFLE 58% 99% 134 CCV1000-5-7 Cage/Spag9 PKSMTMMPALFKENRSGAVMSERVSGLAGS 57% 87% 126 CCV1000-2-8 FBXO39 KFMNPYNAVLTKKFQKVNFFFERIMKYERL 90% 100% Po1yPEPI1018 (6 peptide together) 98% 100% *Percentage of individuals having HLA class I binding PEPI3+ within the Model Population (n = 433). **Percentage of individuals having HLA class II binding PEPI3+ within the Model Population (n = 433).

The peptides of PolyPEPI1018 are formulated in two mixtures, MIX1 containing the peptides of SEQ ID: 130, 131 and MIX2 containing the peptides of SEQ ID: 121, 124, 134, 126. MIX 1 and MIX 2 may be administered sequentially.

Characterization of Immunogenicity

The inventors used the PEPI3+ Test to characterized the immunogenicity of PolyPEPI1018 in a cohort of 37 CRC patients with complete HLA genotype data. T cell responses were predicted in each patient against the same 9 mer peptides that will be used in clinical trials. These peptides represent the 12 dominant PEPI3+ within the PolyPEPI1018 peptides. The 9 mers are shown in Table 26.

The specificity and sensitivity of PEPI3+ prediction depends on the actual number of HLAs predicted to bind a particular epitope. Specifically, the inventors have determined that the probability that one HLA-restricted epitope induces a T cell response in a subject is typically 4%, which explains the poor sensitivity of the state-of-art prediction methods based on HLA restricted epitope prediction. Applying the PEPI3+ methodology, the inventors determined the probability that T cell response to each of the dominant PEPI3+-specific would be induced by PolyPEPI1018 in the 37 CRC patients. The results from this analysis are summarized in the Table 29.

TABLE 29 Probability of Dominant PEPI in the 6 Peptides of PolyPEPI1018 in 37 CRC Patients CRC-P1 CRC-P2 CRC-P3 CRC-P6 CRC TSP50 TSP50 EpCAM Survivin EpCAM MAGEA8 CAGE1 Patient (83-97) (190-204) (139-153) (127-141) (251-265) (113-127) (613-627) CRC-01 22%  4% 22%  4% 22% 22%  100%  CRC-02 22%  1% 22% 22% 22% 22%  100%  CRC-03 84% 22% 84% 22% 22% 22%  84% CRC-04 22% 84% 22%  4% 22% 4% 98% CRC-05 22% 22%  4%  4% 22% 4% 98% CRC-06 84% 22%  4% 84% 98% 4% 22% CRC-07 22% 22% 22% 22% 22% 4% 98% CRC-08 22% 22% 22% 98% 84% 22%  84% CRC-09 22% 84% 84% 84% 84% 22%  100%  CRC-10  4% 98% 22% 22%  4% 4%  4% CRC-11 22% 22%  4%  4% 22% 4% 84% CRC-12 84% 22%  4% 22%  4% 4% 84% CRC-13 84% 22%  4% 22% 84% 4% 84% CRC-14 22% 84%  4%  4% 22% 4% 84% CRC-15 84% 22% 22% 22% 22% 4% 84% CRC-16  4% 84%  4%  4% 22% 4% 84% CRC-17 84% 84%  4% 84% 84% 4%  4% CRC-18 84% 22% 22% 84% 84% 4% 22% CRC-19 22% 22% 22% 22% 22% 4% 98% CRC-20 84% 22%  4% 22% 84% 4% 84% CRC-21 22% 22% 22% 22% 84% 22%  98% CRC-22 22% 98% 84%  4% 22% 22%  84% CRC-23 84% 84% 84% 84% 84% 22%  84% CRC-24 22% 22% 4%  4% 22% 4% 84% CRC-25 22% 84% 22%  4% 22% 4% 84% CRC-26 84% 22%  4% 22% 84% 4% 84% CRC-27 22% 22%  4%  4% 22% 4% 98% CRC-28 84% 22%  4% 22% 84% 4% 84% CRC-29 84% 84%  4% 22% 22% 4% 84% CRC-30 84% 22%  4% 22% 84% 4% 84% CRC-31 22% 84% 22%  4%  4% 4% 22% CRC-32 84% 84%  4% 84% 22% 4%  4% CRC-33 84% 22%  4% 22% 84% 4% 84% CRC-34 22% 22% 22% 22% 22% 4% 84% CRC-35 22%  4%  4%  1% 22% 4%  4% CRC-36 22%  4%  4%  1% 22% 4%  4% CRC-37 22%  4%  4%  1% 22% 4%  4% CRC-P6 CRC-P7 CRC-P8 Expected CRC Survivin CAGE1 SPAG9 FBXO39 FBXO39 Number Patient (15-29) (759-773) (16-30) (95-109) (284-298) of PEPIs CRC-01 1% 98% 84%  100% 22% 5.01 CRC-02 1% 98% 22%  100% 98% 5.29 CRC-03 22%  22% 22%  100% 22% 5.29 CRC-04 4%  4% 22%  100% 84% 4.70 CRC-05 1%  4% 4% 100% 84% 3.68 CRC-06 4%  4% 4% 100% 98% 5.27 CRC-07 1% 22% 22%  100% 84% 4.41 CRC-08 22%  22% 22%  100% 84% 6.04 CRC-09 4% 22% 22%   98% 84% 7.10 CRC-10 22%  22% 22%   98% 84% 4.06 CRC-11 1%  4% 4%  98% 84% 3.53 CRC-12 4% 84% 4% 100% 22% 4.38 CRC-13 1%  1% 4% 100% 98% 5.07 CRC-14 1%  4% 4% 100% 84% 4.16 CRC-15 4% 22% 4% 100% 84% 4.74 CRC-16 1%  4% 22%  100% 84% 4.16 CRC-17 4%  4% 4% 100% 22% 4.82 CRC-18 22%   4% 4% 100% 84% 5.36 CRC-19 4% 22% 22%  100% 84% 4.45 CRC-20 1%  4% 4% 100% 98% 5.10 CRC-21 4%  4% 22%  100% 84% 5.06 CRC-22 22%  84% 22%   98% 22% 5.84 CRC-23 84%  84% 4% 100% 84% 8.82 CRC-24 1%  4% 4% 100% 84% 3.55 CRC-25 4% 22% 4% 100% 84% 4.56 CRC-26 1%  4% 4% 100% 84% 4.97 CRC-27 1%  4% 4% 100% 84% 3.68 CRC-28 1%  4% 4% 100% 98% 5.10 CRC-29 1% 22% 22%  100% 84% 5.33 CRC-30 1%  4% 4% 100% 98% 5.10 CRC-31 1%  4% 4%  98% 84% 3.53 CRC-32 4%  4% 4%  98% 84% 4.80 CRC-33 1%  4% 4% 100% 98% 5.10 CRC-34 1% 22% 4% 100% 84% 4.09 CRC-35 1%  4% 4%  84% 84% 2.37 CRC-36 1%  4% 4%  84% 84% 2.37 CRC-37 1%  4% 4%  84% 84% 2.37 Abbreviations: CRC = colorectal cancer; PEPI = personal epitope Note: Percentages represent the likelihood of CD8+ T cell Responses Induced by PolyPEPI1018.

Overall, these results show that the most immunogenic peptide in PolyPEPI1018 is CRC-P8, which it is predicted to bind to >3 HLAs in most patients. The least immunogenic peptide, CRC-P3, binds to >1 HLA in many patients and has a 22% chance of inducing T cell responses. Since bioassays used to detect T cell responses are less accurate than PEPI3+, this calculation may be the most accurate characterization of the T cell responses in CRC patients. Though MAGE-A8 and SPAG9 were immunogenic in the Model Population used for vaccine design, MAGE-A8-specific PEPI3+ were absent in the 37 CRC patients, and only one patient (3%) had SPAG9 specific PEPI3+.

Further characterization of the predicted PolyPEPI1018 response rate in the model population described in Example 8 and in 295 CRC patients with known HLA class I genotypes are shown in Tables 30 and 31.

TABLE 30 PolyPEPI1018 Response Rates in the Model Population (433 Normal donors) PolyPEPI1018 Response Rates >=1 >=2 >=3 >=4 >=5 >=6 >=7 >=8 >=9 Multi PEPI 98% 94% 83% 70% 52% 38% 27% 18% 11% Multi Peptide 98% 91% 73% 52% 30% 12% N/D N/D N/D Multi Antigen 98% 92% 72% 49% 31% 14%  6% N/D N/D

TABLE 31 PolyPEPI1018 Response Rates for 295 CRC patients PolyPEPI1018 Response Rates >=1 >=2 >=3 >=4 >=5 >=6 >=7 >=8 >=9 Multi PEPI 99% 96% 92% 85% 69% 53% 40% 32% 25% Multi Peptide 99% 93% 86% 71% 49% 29% N/D N/D N/D Multi Antigen 99% 93% 86% 72% 49% 32% 13% N/D N/D Characterization of Toxicity—immunoBLAST

A method was developed that can be performed on any antigen to determine its potential to induce toxic immune reaction, like autoimmunity. The method is referred to herein as immunoBLAST. PolyPEPI1018 contains six 30-mer polypeptides. Each polypeptide consists of two 15-mer peptide fragments derived from antigens expressed in CRC. Neoepitopes might be generated in the joint region of the two 15-mer peptides and could induce undesired T cell responses against healthy cells (autoimmunity). This was assesses using the immunoBLAST methodology.

A 16-mer peptide for each of the 30-mer components of PolyPEP1018 was designed. Each 16-mer contains 8 amino acids from the end of the first 15 residues of the 30-mer and 8 amino acids from the beginning of the second 15 residues of the 30-mer—thus precisely spanning the joint region of the two 15-mers. These 16-mers are then analysed to identify cross-reactive regions of local similarity with human sequences using BLAST (blast.ncbi.nlm.nih.gov/Blast.cgi), which compares protein sequences to sequence databases and calculates the statistical significance of matches. 8-mers within the 16-mers were selected as the examination length since that length represents the minimum length needed for a peptide to form an epitope, and is the distance between the anchor points during HLA binding.

As shown in FIG. 19, the positions of amino acids in a polypeptide are numbered. The start positions of potential 9-mer peptides that can bind to HLAs and form neoepitopes are the 8 amino acids in positions 8-15. The start positions of tumor antigen derived peptides harbored by the 15-mers that can form the pharmaceutically active epitopes are 7+7=14 amino acids at position 1-7 and 16-22. The ratio of possible neoepitope generating peptides is 36.4% (8/22).

The PEPI3+ Test was to identify neoepitopes and neoPEPI among the 9-mer epitopes in the joint region. The risk of PolyPEPI1018 inducing unwanted T cell responses was assessed in the 433 subjects in the Model Population by determining the proportion of subjects with PEPI3+ among the 9-mers in the joint region. The result of neoepitope/neoPEPI analysis is summarized in Table 32. In the 433 subjects of the Model Population, the average predicted epitope number that could be generated by intracellular processing was 40.12. Neoepitopes were frequently generated; 11.61 out of 40.12 (28.9%) epitopes are neoepitopes. Most of the peptides were able to be identified as a neoepitope, but the number of subjects that present neoepitopes varied.

Epitopes harbored by PolyPEPI1018 create an average of 5.21 PEPI3+. These PEPIs can activate T cells in a subject. The amount of potential neoPEPIs was much lower than neoepitopes (3.7%). There is a marginal possibility that these neoPEPIs compete on T cell activation with PEPIs in some subjects. Importantly, the activated neoPEPI specific T cells had no targets on healthy tissue.

TABLE 32 Identification of Potential Neoepitopes of PolyPEPI1018 Epitope & PEPI3+ binding in 433 Subjects of the Model Population Epitope Binding PEPI3+ binding (1 × HLA) (3 × HLA) PolyPEPI1018 Potential NeoEPI NeoPEPI Peptide ID: Neoepitope Sub# Sub % NeoEPI count Sub# Sub % NeoPEPI count CRC-P1 QFPVSEGKS 0 0.0% 7 0 0.0% 3 FPVSEGKSR 160 37.0% X 1 0.2% X PVSEGKSRY 150 34.6% X 0 0.0% VSEGKSRYR 194 44.8% X 1 0.2% X SEGKSRYRA 113 26.1% X 0 0.0% EGKSRYRAQ 77 17.8% X 0 0.0% GKSRYRAQR 37 8.5% X 0 0.0% KSRYRAQRF 337 77.8% X 33 7.6% X CRC-P2 IELKHKART 32 7.4% X 7 0 0.0% 1 ELKHKARTA 63 14.5% X 0 0.0% LKHKARTAK 59 13.6% X 0 0.0% KHKARTAKK 166 38.3% X 1 0.2% X HKARTAKKV 0 0.0% 0 0.0% KARTAKKVR 70 16.2% X 0 0.0% ARTAKKVRR 134 30.9% X 0 0.0% RTAKKVRRA 41 9.5% X 0 0.0% CRC-P3 EFSMQGLKD 0 0.0% 5 0 0.0% 1 FSMQGLKDE 188 43.4% X 0 0.0% SMQGLKDEK 138 31.9% X 0 0.0% MQGLKDEKV 16 3.7% X 0 0.0% QGLKDEKVA 0 0.0% 0 0.0% GLKDEKVAE 0 0.0% 0 0.0% LKDEKVAEL 186 43.0% X 3 0.7% X KDEKVAELV 51 11.8% X 0 0.0% CRC-P6 LLALMVGLK 252 58.2% X 7 0 0.0% 1 LALMVGLKD 86 19.9% X 0 0.0% ALMVGLKDH 65 15.0% X 0 0.0% LMVGLKDHR 97 22.4% X 0 0.0% MVGLKDHRI 67 15.5% X 0 0.0% VGLKDHRIS 0 0.0% 0 0.0% GLKDHRIST 4 0.9% X 0 0.0% LKDHRISTF 195 45.0% X 5 1.2% X CRC-P7 PALFKENRS 0 0.0% 5 0 0.0% 1 ALFKENRSG 0 0.0% 0 0.0% LFKENRSGA 41 9.5% X 0 0.0% FKENRSGAV 114 26.3% X 0 0.0% KENRSGAVM 261 60.3% X 0 0.0% ENRSGAVMS 0 0.0% 0 0.0% NRSGAVMSE 227 52.4% X 0 0.0% RSGAVMSER 197 45.5% X 2 0.5% X CRC-P8 AVLTKKFQK 181 41.8% X 7 0 0.0% 3 VLTKKFQKV 208 48.0% X 2 0.5% X LTKKFQKVN 0 0.0% 0 0.0% TKKFQKVNF 25 5.8% X 0 0.0% KKFQKVNFF 250 57.7% X 12 2.8% X KFQKVNFFF 273 63.0% X 23 5.3% X FQKVNFFFE 163 37.6% X 0 0.0% QKVNFFFER 110 25.4% X 0 0.0% Abbreviations: CRC = colorectal cancer; HLA = human leukocytic antigen; PEPI = personal epitope

Each of the 30-mer peptides in PolyPEPI1018 were released for clinical development since none of the 8-mers in the joint regions matched any human protein, except the target CTAs.

Characterisation of Activity/Efficacy

The inventors have developed pharmacodynamic biomarkers to predict the activity/effect of vaccines in individual human subjects as well as in populations of human subjects. These biomarkers expedite more effective vaccine development and also decrease the development cost. The inventors have the following tools:

Antigen expression knowledgebase: The inventors have collected data from experiments published in peer reviewed scientific journals regarding the tumor antigens expressed by tumor cells and organized by tumor type to create a database of CTA expression levels—CTA database (CTADB). As of April 2017, the CTADB contained data from 145 CTAs from 41,132 tumor specimens, and was organized by the CTA expression frequencies in different types of cancer. In silico trial populations: The inventors have also collected data on the HLA genotypes of several different model populations. Each individual in the populations has complete 4-digit HLA genotype and ethnicity data. The populations are summarized in Table 33.

TABLE 33 In silico trial populations Number of Population Subjects Inclusion criteria Model Population 433 Complete HLA class I genotype Diverse ethnicity CRC patients 37 Complete HLA class I genotype CRC diagnosis, unknown ethnicity “Big” Population 7,189 Complete HLA class I genotype Diverse ethnicity Chinese Population 234 Complete HLA class I genotype Chinese ethnicity Irish Population 999 Complete HLA class I genotype Irish ethnicity Abbreviations: CRC = colorectal cancer; HLA = human leukocyte antigen

Using these tools (or potentially equivalent databases or model populations), the following markers can be assessed:

-   -   AG95—potency of a vaccine: The number of antigens in a cancer         vaccine that a specific tumor type expresses with 95%         probability. AG95 is an indicator of the vaccine's potency, and         is independent of the immunogenicity of the vaccine antigens.         AG95 is calculated from the tumor antigen expression rate data,         which is collected in the CTADB. Technically, AG95 is determined         from the binomial distribution of CTAs, and takes into account         all possible variations and expression rates. In this study,         AG95 was calculated by cumulating the probabilities of a certain         number of expressed antigens, by the widest range of antigens         where the sum of probabilities was less than or equal to 95%.         The correct value is between 0 (no expression expected with 95%         probability) and maximum number of antigens (all antigens         expressed with 95% probability).     -   PEPI3+ count—immunogenicity of a vaccine in a subject:         Vaccine-derived PEPI3+ are personal epitopes that induce T cell         responses in a subject. PEPI3+ can be determined using the         PEPI3+ Test in subjects who's complete 4-digit HLA genotype is         known.     -   AP count—antigenicity of a vaccine in a subject: Number of         vaccine antigens with PEPI3+. Vaccines like PolyPEPI1018 contain         sequences from antigens expressed in tumor cells. AP count is         the number of antigens in the vaccine that contain PEPI3+, and         the AP count represents the number of antigens in the vaccine         that can induce T cell responses in a subject. AP count         characterizes the vaccine-antigen specific T cell responses of         the subject since it depends only on the HLA genotype of the         subject and is independent of the subject's disease, age, and         medication. The correct value is between 0 (no PEPI presented by         the antigen) and maximum number of antigens (all antigens         present PEPIs).     -   AP50—antigenicity of a vaccine in a population: The mean number         of vaccine antigens with a PEPI in a population. The AP50 is         suitable for the characterization of vaccine-antigen specific T         cell responses in a given population since it depends on the HLA         genotype of subjects in a population. Technically, the AP count         was calculated in the Model Population and the binomial         distribution of the result was used to calculate the AP50.     -   AGP count—effectiveness of a vaccine in a subject: Number of         vaccine antigens expressed in the tumor with PEPI. The AGP count         indicates the number of tumor antigens that vaccine recognizes         and induces a T cell response against (hit the target). The AGP         count depends on the vaccine-antigen expression rate in the         subject's tumor and the HLA genotype of the subject. The correct         value is between 0 (no PEPI presented by expressed antigen) and         maximum number of antigens (all antigens are expressed and         present a PEPI).     -   AGP50—effectiveness of a cancer vaccine in a population: The         mean number of vaccine antigens expressed in the indicated tumor         with PEPI (i.e., AGP) in a population. The AGP50 indicates the         mean number of tumor antigens that the T cell responses induced         by the vaccine can recognize. AGP50 is dependent on the         expression rate of the antigens in the indicated tumor type and         the immunogenicity of the antigens in the target population.         AGP50 can estimate a vaccine's effectiveness in different         populations and can be used to compare different vaccines in the         same population. The computation of AGP50 is similar to that         used for AG50, except the expression is weighted by the         occurrence of the PEPI3+ in the subject on the expressed vaccine         antigens. In a theoretical population, where each subject has a         PEPI from each vaccine antigen, the AGP50 will be equal to AG50.         In another theoretical population, where no subject has a PEPI         from any vaccine antigen, the AGP50 will be 0. In general, the         following statement is valid: 0≤AGP50≤AG50.     -   mAGP—a candidate biomarker for the selection of likely         responders: Likelihood that a cancer vaccine induces T cell         responses against multiple antigens expressed in the indicated         tumor. mAGP is calculated from the expression rates of         vaccine-antigens in CRC and the presence of vaccine derived         PEPIs in the subject. Technically, based on the AGP         distribution, the mAGP is the sum of probabilities of the         multiple AGP (≥2 AGPs).         Application of these Markers to Assess Antigenicity and         Effectiveness PolyPEPI1018 in Individual Patients with CRC

Table 34 shows the antigenicity and effectiveness of PolyPEPI1018 in 37 CRC patients using AP and AGP50, respectively. As expected from the high variability of PolyPEPI1018 specific T cell responses (see Table 29), the AP and AGP50 have high variability. The most immunogenic antigen in PolyPEPI1018 was FOX039; each patient had a PEPI3+. However, FOX039 is expressed only 39% of CRC tumors, suggesting that 61% of patients will have FOX039 specific T cell responses that do not recognize the tumor. The least immunogenic antigen was MAGE-A8; none of the 37 CRC patients had a PEPI3+ despite the antigen being expressed in 44% of CRC tumors. These results illustrate that both expression and immunogenicity of antigens can be taken into account when determining a cancer vaccine's effectiveness.

AGP50 indicates the mean number of expressed antigens in CRC tumor with PEPIs. Patients with higher AGP50 values are more likely to respond to PolyPEPI1018 since higher AGP50 values indicate that the vaccine can induce T cell responses against more antigens expressed in CRC cells.

The last column in the table 32 shows the probability of mAGP (multiple AGP; i.e., at least 2 AGPs) in each of the 37 CRC patients. The average mAGP in patients with CRC is 66%, suggesting that there is a 66% likelihood that a CRC patient will induce T cell responses against multiple antigens expressed in the tumor.

TABLE 34 Antigenicity (AP count), Effectiveness (AGP50 count), and mAGP of PolyPEPI1018 in 37 CRC Patients Antigens (CTAs) in PolyPEPI1018 MAGE- Number Number of TSP50 EpCAM Survivin CAGE1 SPAG9 FBXO39 A8 of AP AGP50 CRC Expression rate (AP (AGP50 Patients 89% 88% 87% 74% 74% 39% 44% count) count) mAGP CRC-01 0 0 0 1 1 1 0 3 1.87 90% CRC-02 0 0 0 1 0 1 0 2 1.13 85% CRC-03 1 1 0 1 0 1 0 4 2.91 97% CRC-04 1 0 0 1 0 1 0 3 2.03 91% CRC-05 0 0 0 1 0 1 0 2 1.13 78% CRC-06 1 1 1 1 0 1 0 5 3.78 99% CRC-07 0 0 0 1 0 1 0 2 1.13 84% CRC-08 0 1 1 1 0 1 0 4 2.89 98% CRC-09 1 1 1 1 0 1 0 5 3.78 99% CRC-10 1 0 0 0 0 1 0 2 1.28 86% CRC-11 0 0 0 1 0 1 0 2 1.13 79% CRC-12 1 0 0 1 0 1 0 3 2.03 88% CRC-13 1 1 1 1 0 1 0 5 3.78 98% CRC-14 1 0 0 1 0 1 0 3 2.03 87% CRC-15 1 0 0 1 0 1 0 3 2.03 90% CRC-16 1 0 0 1 0 1 0 3 2.03 85% CRC-17 1 1 1 0 0 1 0 4 3.04 96% CRC-18 1 1 1 1 0 1 0 5 3.78 98% CRC-19 0 0 0 1 0 1 0 2 1.13 85% CRC-20 1 1 1 1 0 1 0 5 3.78 98% CRC-21 0 1 0 1 0 1 0 3 2.01 93% CRC-22 1 1 0 1 0 1 0 4 2.91 97% CRC-23 1 1 1 1 0 1 0 5 3.78 99% CRC-24 0 0 0 1 0 1 0 2 1.13 82% CRC-25 1 0 0 1 0 1 0 3 2.03 89% CRC-26 1 1 0 1 0 1 0 4 2.91 95% CRC-27 0 0 0 1 0 1 0 2 1.13 78% CRC-28 1 1 1 1 0 1 0 5 3.78 98% CRC-29 1 0 0 1 0 1 0 3 2.03 92% CRC-30 1 1 1 1 0 1 0 5 3.78 98% CRC-31 1 0 0 0 0 1 0 2 1.28 80% CRC-32 1 0 1 0 0 1 0 3 2.15 91% CRC-33 1 1 1 1 0 1 0 5 3.78 98% CRC-34 0 0 0 1 0 1 0 2 1.13 82% CRC-35 0 0 0 0 0 1 0 1 0.39 55% CRC-36 0 0 0 0 0 1 0 1 0.39 55% CRC-37 0 0 0 0 0 1 0 1 0.39 55% Abbreviations: CRC = colorectal cancer; PEPI = personal epitope; CTA = cancer testis antigen; AP = expressed antigens with ≥1 PEPI

These biomarkers have immediate utility in vaccine development and in the routine clinical practice because they do not require invasive biopsies. Antigen expression data can be obtained from achieved tumor specimen and organized in databases. 4-digit HLA genotyping can be done from a saliva specimen. It is a validated test performed by certified laboratories worldwide for transplantation and paternity testing. These assessments will allow drug developers and physicians to gain deeper insights into the immunogenicity and activity of tumor response and the possible emergence of resistance.

Application of these Markers to Asses Antigenicity and Effectiveness PolyPEPI1018 in Populations

Antigenicity of PolyPEPI1018 CRC Vaccine in a General Population

The antigenicity of PolyPEPI1018 in a subject is determined by the AP count, which indicates the number of vaccine antigens that induce T cell responses in a subject. The AP count of PolyPEPI1018 was determined in each of the 433 subjects in the Model Population using the PEPI Test, and the AP50 count was then calculated for the Model Population.

As shown in FIG. 20 the AP50 of PolyPEPI1018 in the Model Population is 3.62. Therefore, the mean number of immunogenic antigens (i.e., antigens with ≥1 PEPI) in PolyPEPI1018 in a general population is 3.62.

Effectiveness of PolyPEPI1018 CRC Vaccine in a General Population

Vaccine induced T cells can recognize and kill tumor cells if a PEPI in the vaccine is presented by the tumor cell. The number of AGPs (expressed antigens with PEPI) is an indicator of vaccine effectiveness in an individual, and is dependent on both the potency and antigenicity of PolyPEPI1018. As shown in FIG. 21, the mean number of immunogenic CTAs (i.e., AP [expressed antigens with ≥1 PEPI]) in PolyPEPI1018 is 2.54 in the Model Population.

The likelihood that PolyPEPI1018 induces T cell responses against multiple antigens in a subject (i.e., mAGP) in the Model Population is 77%.

Comparison of the PolyPEPI1018 CRC Vaccine Activities in Different Populations

Tables 35 to 37 show comparison of the immunogenicity, antigenicity, and effectiveness of PolyPEPI1018 in different populations.

TABLE 35 Comparison of Immunogenicity, Antigenicity, and Effectiveness of PolyPEPI1018 in Different Sub-populations Number Number of PEPI3+ Number of AP Number of AGP50 Populations of subject Average SD Average SD Average SD CRC 37 5.16 1.98 3.19 1.31 2.21 1.13 Model 433 5.02 2.62 3.62 1.67 2.54 1.25 Big 7,189 5.20 2.82 3.75 1.74 2.66 1.30 Chinese 324 5.97 3.16 4.28 1.78 3.11 1.30 Irish 999 3.72 1.92 2.86 1.46 1.94 1.10 Abbreviations: CRC = colorectal cancer; PEPI = personal epitope; SD = standard deviation; AP = expressed antigens with ≥1 PEPI

The average number of PEPI3+ and AP results demonstrate that PolyPEPI1018 is highly immunogenic and antigenic in all populations; PolyPEPI1018 can induce an average of 3.7-6.0 CRC specific T cell clones against 2.9-3.7 CRC antigens. PolyPEPI1018 immunogenicity was similar in patients with CRC and the average population (p>0.05), this similarity may have been due to the small sample size of the CRC population. Additional analyses suggest that PolyPEPI1018 is significantly more immunogenic in a Chinese population compared to an Irish or a general population (p<0.0001). The differences in immunogenicity are also reflected in the effectiveness of the vaccine as characterized by AGP50; PolyPEPI1018 is most effective in a Chinese population and less effective in an Irish population. Since a CDx will be used to select likely responders to PolyPEPI1018, ethnic differences will only be reflected in the higher percentage of Chinese individuals that might be eligible for treatment compared with Irish individuals.

TABLE 36 PolyPEPI1018 CRC Vaccine, Predicted Immune Response Rates Against Multiple CRC Antigens PolyPEPI1018 MultiAG CTL Responses Population No. subjects >3 >4 >5 >6 7 CRC Vietnamese 211 91% 81% 56% 38% 17% Patients US 44 57% 34% 20%  5%  0% Caucasian 83 75% 51% 30% 17%  4% Normal US 400 61% 39% 25% 12%  3% Donors Europe 1,386 55% 30% 18%  7%  1% Chinese 324 84% 68% 45% 26% 15% Okinawan (JP) 104 81% 57% 36% 16% 13% Japanese 45 77% 55% 34% 16% 13%

TABLE 37 PolyPEPI1018 CRC Vaccine, Predicted Immune Response Rates Against Multiple CRC Antigens No. Number of PEPI Number of AP Number of AGP50 Population subjects Average SD Average SD Average SD CRC Vietnamese 211 6.96 3.01 4.81 1.58 3.47 1.16 Patients US 44 4.05 2.05 3.00 1.46 2.05 1.12 Caucasian 83 4.75 2.39 3.57 1.76 2.50 1.27 Normal US 400 4.30 2.50 3.19 1.74 2.17 1.30 Donors Europe 1,386 3.84 2.01 2.94 1.51 2.00 1.14 Chinese 324 5.97 3.16 4.28 1.78 3.11 1.30 Okinawan (JP) 104 5.29 2.58 4.01 1.63 2.91 1.19 Japanese 45 5.31 3.27 3.67 1.77 2.66 1.29

Example 21—Personalised Immunotherapy Composition for Treatment of Ovarian Cancer

This example describes the treatment of an ovarian cancer patient with a personalised immunotherapy composition, wherein the composition was specifically designed for the patient based on her HLA genotype based on the disclosure described herein. This Example and Example 22 below provide clinical data to support the principals regarding binding of epitopes by multiple HLA of a subject to induce a cytotoxic T cell response on which the present disclosure is based. The HLA class I and class II genotype of metastatic ovarian adenocarcinoma cancer patient XYZ was determined from a saliva sample.

To make a personalized pharmaceutical composition for patient XYZ thirteen peptides were selected, each of which met the following two criteria: (i) derived from an antigen that is expressed in ovarian cancers, as reported in peer reviewed scientific publications; and (ii) comprises a fragment that is a T cell epitope capable of binding to at least three HLA class I of patient XYZ (Table 38). In addition, each peptide is optimized to bind the maximum number of HLA class II of the patient.

TABLE 38 XYZ ovarian cancer patient's personalized vaccine MAX MAX Target Antigen HLA HLA XYZ's vaccine Antigen Expression 20mer peptides classI classII POC01_P1 AKAP4 89% NSLQKQLQAVLQWIAASQFN 3 5 POC01_P2 BORIS 82% SGDERSDEIVLTVSNSNVEE 4 2 POC01_P3 SPAG9 76% VQKEDGRVQAFGWSLPQKYK 3 3 POC01_P4 OY-TES-1 75% EVESTPMIMENIQELIRSAQ 3 4 POC01_P5 SP17 69% AYFESLLEKREKTNFDPAEW 3 1 POC01_P6 WT1 63% PSQASSGQARMFPNAPYLPS 4 1 POC01_P7 HIWI 63% RRSIAGFVASINEGMTRWFS 3 4 POC01_P8 PRAME 60% MQDIKMILKMVQLDSIEDLE 3 4 POC01_P9 AKAP-3 58% ANSVVSDMMVSIMKTLKIQV 3 4 POC01_P10 MAGE-A4 37% REALSNKVDELAHFLLRKYR 3 2 POC01_P11 MAGE-A9 37% ETSYEKVINYLVMLNAREPI 3 4 POC01_P12a MAGE-A10 52% DVKEVDPTGHSFVLVTSLGL 3 4 POC01_P12b BAGE 30% SAQLLQARLMKEESPVVSWR 3 2

Eleven PEPI3 peptides in this immunotherapy composition can induce T cell responses in XYZ with 84% probability and the two PEPI4 peptides (POC01-P2 and POC01-P5) with 98% probability, according to the validation of the PEPI Test shown in Table 3. T cell responses target 13 antigens expressed in ovarian cancers. Expression of these cancer antigens in patient XYZ was not tested. Instead the probability of successful killing of cancer cells was determined based on the probability of antigen expression in the patient's cancer cells and the positive predictive value of the ≥1 PEPI3+ Test (AGP count). AGP count predicts the effectiveness of a vaccine in a subject: Number of vaccine antigens expressed in the patient's tumor (ovarian adenocarcinoma) with PEPI. The AGP count indicates the number of tumor antigens that vaccine recognizes and induces a T cell response against the patient's tumor (hit the target). The AGP count depends on the vaccine-antigen expression rate in the subject's tumor and the HLA genotype of the subject. The correct value is between 0 (no PEPI presented by expressed antigen) and maximum number of antigens (all antigens are expressed and present a PEPI).

The probability that patient XYZ will express one or more of the 12 antigens is shown in FIGS. 22A-B. AGP95=5, AGP50=7.9, mAGP=100%, AP=13.

A pharmaceutical composition for patient XYZ may be comprised of at least 2 from the 13 peptides (Table 38), because the presence in a vaccine or immunotherapy composition of at least two polypeptide fragments (epitopes) that can bind to at least three HLA of an individual (≥2 PEPI3+) was determined to be predictive for a clinical response. The peptides are synthetized, solved in a pharmaceutically acceptable solvent and mixed with an adjuvant prior to injection. It is desirable for the patient to receive personalized immunotherapy with at least two peptide vaccines, but preferable more to increase the probability of killing cancer cells and decrease the chance of relapse.

For treatment of patient XYZ the 12 peptides were formulated as 4×3/4 peptide (POC01/1, POC01/2, POC01/3, POC01/4). One treatment cycle is defined as administration of all 13 peptides within 30 days.

Patient History:

Diagnosis: Metastatic ovarian adenocarcinoma

Age: 51

Family anamnesis: colon and ovary cancer (mother) breast cancer (grandmother)

Tumor Pathology:

BRCA1-185delAG, BRAF-D594Y, MAP2K1-P293S, NOTCH1-S2450N

-   -   2011: first diagnosis of ovarian adenocarcinoma; Wertheim         operation and chemotherapy; lymph node removal     -   2015: metastasis in pericardial adipose tissue, excised     -   2016: hepatic metastases     -   2017: retroperitoneal and mesenteric lymph nodes have         progressed; incipient peritoneal carcinosis with small         accompanying ascites         Prior Therapy:     -   2012: Paclitaxel-carboplatin (6×)     -   2014: Caelyx-carboplatin (1×)     -   2016-2017 (9 months): Lymparza (Olaparib) 2×400 mg/day, oral     -   2017: Hycamtin inf. 5×2.5 mg (3× one seria/month)         -   PIT vaccine treatment began on 21 Apr. 2017.

TABLE 39 Patient XYZ peptide treatment schedule Vaccinations Lot # 1^(st) cycle 2^(nd) cycle 3^(rd) cycle 4^(th) cycle POC01/1 N1727 21.04.2017 16.06.2017 30.08.2017 19.10.2017 POC01/2 N1728 28.04.2017 31.05.2017 POC01/3 N1732 16.06.2017 02.08.2017 20.09.2017 POC01/4 N1736 15.05.2017 06.07.2017 Patient' Tumor MRI Findings (Baseline Apr. 15, 2016)

-   -   Disease was confined primarily to liver and lymph nodes. The use         of MRI limits detection of lung (pulmonary) metastasis     -   May 2016-January 2017: Olaparib treatment     -   Dec. 25, 2016 (before PIT vaccine treatment) There was dramatic         reduction in tumor burden with confirmation of response obtained         at FU2     -   January-March 2017—TOPO protocol (topoisomerase)     -   Apr. 6, 2017 FU3 demonstrated regrowth of existing lesions and         appearance of new lesions leading to disease progression     -   Apr. 21, 2017 START PIT     -   Jul. 21, 2017 (after the 2^(nd) Cycle of PIT) FU4 demonstrated         continued growth in lesions and general enlargement of pancreas         and abnormal para pancreatic signal along with increased ascites     -   Jul. 26, 2017—CBP+Gem+Avastin     -   Sep. 20, 2017 (after 3 Cycles of PIT) FU5 demonstrated reversal         of lesion growth and improved pancreatic/parapancreatic signal.         The findings suggest pseudo progression     -   Nov. 28, 2017 (after 4 Cycles of PIT) FU6 demonstrated best         response with resolution of non-target lesions         MRI data for patient XYZ is shown in Table 40 and FIG. 23.

TABLE 40 Summary Table of Lesions Responses FU1 FU2 FU3 FU4 FU5 FU6 Lesion/ Baseline %Δ %Δ %Δ %Δ %Δ %Δ Best PD Time (%Δ from from from from from from Response Time Point from BL) BL) BL) BL) BL) BL) BL) Cycle Point TL1 NA −56.1 −44.4 −44.8 +109.3 −47.8 −67.3 FU6 FU4 TL2 NA −100.0 −100.0 −47.1 −13.1 −100.0 −100.0 FU1 FU3 TL3 NA −59.4 −62.3 −62.0 −30.9 −66.7 −75.9 FU6 FU4 TL4 NA −65.8 −100.0 −100.0 −100.0 −100.0 −100.0 FU2 NA SUM NA −66.3 −76.0 −68.9 −23.5 −78.2 −85.2 FU6 FU4

Example 22 Design of Personalised Immunotherapy Composition for Treatment of Breast Cancer

The HLA class I and class II genotype of metastatic breast cancer patient ABC was determined from a saliva sample. To make a personalized pharmaceutical composition for patient ABC twelve peptides were selected, each of which met the following two criteria: (i) derived from an antigen that is expressed in breast cancers, as reported in peer reviewed scientific publications; and (ii) comprises a fragment that is a T cell epitope capable of binding to at least three HLA class I of patient ABC (Table 41). In addition, each peptide is optimized to bind the maximum number of HLA class II of the patient. The twelve peptides target twelve breast cancer antigens. The probability that patient ABC will express one or more of the 12 antigens is shown in FIG. 24.

TABLE 41 12 peptides for ABC breast cancer patient BRC09 vaccine Target Antigen MAXHLA MAXHLA peptides Antigen Expression 20mer peptide Class I Class II PBRC01_cP1 FSIP1 49% ISDTKDYFMSKTLGIGRLKR 3 6 PBRC01_cP2 SPAG9 88% FDRNTESLFEELSSAGSGLI 3 2 PBRC01_cP3 AKAP4 85% SQKMDMSNIVLMLIQKLLNE 3 6 PBRC01_cP4 BORIS 71% SAVFHERYALIQHQKTHKNE 3 6 PBRC01_cP5 MAGE-A11 59% DVKEVDPTSHSYVLVTSLNL 3 4 PBRC01_cP6 NY-SAR-35 49% ENAHGQSLEEDSALEALLNF 3 2 PBRC01_cP7 HOM-TES-85 47% MASFRKLTLSEKVPPNHPSR 3 5 PBRC01_cP8 NY-BR-1 47% KRASQYSGQLKVLIAENTML 3 6 PBRC01_cP9 MAGE-A9 44% VDPAQLEFMFQEALKLKVAE 3 8 PBRC01_cP10 SCP-1 38% EYEREETRQVYMDLNNNIEK 3 3 PBRC01_cP11 MAGE-A1 37% PEIFGKASESLQLVFGIDVK 3 3 PBRC01_cP12 MAGE-C2 21% DSESSFTYTLDEKVAELVEF 4 2

Predicted efficacy: AGP95=4; 95% likelihood that the PIT Vaccine induces CTL responses against 4 CTAs expressed in the breast cancer cells of BRC09. Additional efficacy parameters: AGP50=6.3, mAGP=100%, AP=12.

Detected efficacy after the 1^(st) vaccination with all 12 peptides: 83% reduction of tumor metabolic activity (PET CT data).

For treatment of patient ABC the 12 peptides were formulated as 4×3 peptide (PBR01/1, PBR01/2, PBR01/3, PBR01/4). One treatment cycle is defined as administration of all 12 different peptide vaccines within 30 days.

Patient History

Diagnosis: bilateral metastatic breast carcinoma: Right breast is ER positive, PR negative, Her2 negative, Left Breast is ER, PR and Her2 negative.

First diagnosis: 2013 (4 years before PIT vaccine treatment)

2016: extensive metastatic disease with nodal involvement both above and below the diaphragm. Multiple liver and pulmonar metastases.

2016-2017 treatment: Etrozole, Ibrance (Palbociclib) and Zoladex

Results

Mar. 7, 2017: Prior PIT Vaccine treatment

Hepatic multi-metastatic disease with truly extrinsic compression of the origin of the choledochal duct and massive dilatation of the entire intrahepatic biliary tract. Celiac, hepatic hilar and retroperitoneal adenopathy

May 26, 2017: After 1 cycle of PIT

Detected efficacy: 83% reduction of tumor metabolic activity (PET CT) liver, lung lymph nodes and other metastases.

Detected safety: Skin reactions

Local inflammation at the site of the injections within 48 hours following vaccine administrations

Follow Up:

BRC-09 was treated with 5 cycles of PIT vaccine. She was feeling very well and she refused a PET CT examination in September 2017. In November she had symptoms, PET CT scan showed progressive disease, but she refused all treatments. In addition, her oncologist found out that she did not take Palbocyclib since spring/summer. Patient ABC passed away in January 2018.

The combination of pablocyclib and the personalised vaccine was likely to have been responsible for the remarkable early response observed following administration of the vaccine. Palbocyclib has been shown to improve the activity of immunotherapies by increases CTA presentation by HLAs and decreasing the proliferation of Tregs: (Goel et al. Nature. 2017:471-475). The PIT vaccine may be used as add-on to the state-of-art therapy to obtain maximal efficacy.

Example 23—Personalised Immunotherapy Composition for Treatment of Patient with Late Stage Metastatic Breast Cancer

Patient BRC05 was diagnosed with inflammatory breast cancer on the right with extensive lymphangiosis carcinomatose. Inflammatory breast cancer (IBC) is a rare, but aggressive form of locally advanced breast cancer. It's called inflammatory breast cancer because its main symptoms are swelling and redness (the breast often looks inflamed). Most inflammatory breast cancers are invasive ductal carcinomas (begin in the milk ducts). This type of breast cancer is associated with the expression of oncoproteins of high risk Human Papilloma Virus. Indeed, HPV16 DNA was diagnosed in the tumor of this patient.

Patient's stage in 2011 (6 years prior to PIT vaccine treatment):

T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules)

pN3a: Metastases in ≥10 axillary lymph nodes (at least 1 tumor deposit ≥2.0 mm); or metastases to the infraclavicular (level III axillary lymph) nodes.

14 vaccine peptides were designed and prepared for patient BRC05 (Table 42). Peptides PBRC05-P01-P10 were made for this patient based on population expression data. The last 3 peptides in the Table 42 (SSX-2, MORC, MAGE-B1) were designed from antigens that expression was measured directly in the tumor of the patient.

TABLE 42 Vaccine peptides for patient BRC05 BRC05 vaccine Target Antigen MAXHLA MAXHLA peptides Antigen Expression 20mer peptide Class I Class II PBRC05_P1 SPAG9 88% XXXXXXXXXXXXXXXXXXXX 3 4 PBRC05_P2 AKAP4 85% XXXXXXXXXXXXXXXXXXXX 3 4 PBRC05_P3 MAGE-A11 59% XXXXXXXXXXXXXXXXXXXX 3 3 PBRC05_P4 NY-SAR-35 49% XXXXXXXXXXXXXXXXXXXX 3 3 PBRC05_P5 FSIP1 49% XXXXXXXXXXXXXXXXXXXX 3 3 PBRC05_P6 NY-BR-1 47% XXXXXXXXXXXXXXXXXXXX 3 4 PBRC05_P7 MAGE-A9 44% XXXXXXXXXXXXXXXXXXXX 3 3 PBRC05_P8 SCP-1 38% XXXXXXXXXXXXXXXXXXXX 3 6 PBRC05_P9 MAGE-A1 37% XXXXXXXXXXXXXXXXXXXX 3 3 PBRC05_P10 MAGE-C2 21% XXXXXXXXXXXXXXXXXXXX 3 3 PBRC05_P11 MAGE-A12 13% XXXXXXXXXXXXXXXXXXXX 3 4 PBRC05_P12 SSX-2  6% XXXXXXXXXXXXXXXXXXXX 3 1 PBRC05_P13 MORC ND XXXXXXXXXXXXXXXXXXXX 3 4 PBRC05_P14 MAGE-B1 ND XXXXXXXXXXXXXXXXXXXX 3 3

T cell responses were measured cells in peripheral mononuclear cells 2 weeks after the 1^(st) vaccination with the mix of peptides PBRC05_P1, PBRC05_P2, PBRC05_P3, PBRC05_P4, PBRC05_P5, PBRC05_P6, PBRC05_P7.

TABLE 43 Antigen specific T cell responses: Number of spots/300,000 PBMC Antigen Stimulant Exp1 Exp2 Average SPAG9 PBRC05_P1 2 1 1.5 AKAP4 PBRC05_P2 11 4 7.5 MAGE-A11 PBRC05_P3 26 32 29 NY-SAR-35 PBRC05_P4 472 497 484.5 FSIP1 PBRC05_P5 317 321 319 NY-BR-1 PBRC05_P6 8 12 10 MAGE-A9 PBRC05_P7 23 27 25 None Negative Control (DMSO) 0 3 1.5

The results show that a single immunization with 7 peptides induced potent T cell responses against 3 out of the 7 peptides demonstrating potent MAGE-A11, NY-SAR-35, FSIP1 and MAGE-A9 specific T cell responses. There were weak responses against AKAP4 and NY-BR-1 and no response against SPAG9.

REFERENCES

-   ¹ Bagarazzi et al. Immunotherapy against HPV16/18 generates potent     TH1 and cytotoxic cellular immune responses. Science Translational     Medicine. 2012; 4(155): 155ra138. -   ² Gudmundsdotter et al. Amplified antigen-specific immune responses     in HIV-1 infected individuals in a double blind DNA immunization and     therapy interruption trial. Vaccine. 2011; 29(33):5558-66. -   ³ Bioley et al. HLA class I—associated immunodominance affects CTL     responsiveness to an ESO recombinant protein tumor antigen vaccine.     Clin Cancer Res. 2009; 15(1):299-306. -   ⁴ Valmori et al. Vaccination with NY-ESO-1 protein and CpG in     Montanide induces integrated antibody/Th1 responses and CD8 T cells     through cross-priming. Proceedings of the National Academy of     Sciences of the United States of America. 2007; 104(21):8947-52. -   ⁵ Yuan et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses     correlate with clinical benefit in advanced melanoma patients     treated with ipilimumab. Proc Natl Acad Sci USA. 2011; 108(40):     16723-16728. -   ⁶ Kakimi et al. A phase I study of vaccination with NY-ESO-lf     peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients     with cancers expressing the NY-ESO-1 antigen. Int J Cancer. 2011;     129(12):2836-46. -   ⁷ Wada et al. Vaccination with NY-ESO-1 overlapping peptides mixed     with Picibanil OK-432 and montanide ISA-51 in patients with cancers     expressing the NY-ESO-1 antigen. J Immunother. 2014; 37(2):84-92. -   ⁸ Welters et al. Induction of tumor-specific CD4+ and CD8+ T-cell     immunity in cervical cancer patients by a human papillomavirus type     16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 2008; 14(1):     178-87. -   ⁹ Renter et al. Vaccination against HPV-16 oncoproteins for vulvar     intraepithelial neoplasia. N Engl J Med. 2009; 361(19): 1838-47. -   ¹⁰ Welters et al. Success or failure of vaccination for     HPV16-positive vulvar lesions correlates with kinetics and phenotype     of induced T-cell responses. PNAS. 2010; 107(26): 11895-9. -   ¹¹ www.ncbi.nlm.nih.gov/projects/gv/mhc/main.fcgi?cmd=initThe MHC     database, NCBI (Accessed Mar. 7, 2016). -   ¹² Karkada et al. Therapeutic vaccines and cancer: focus on     DPX-0907. Biologics. 2014; 8:27-38. -   ¹³ Butts et al. Randomized phase IIB trial of BLP25 liposome vaccine     in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005;     23(27):6674-81. -   ¹⁴ Yuan et al. Safety and immunogenicity of a human and mouse gp100     DNA vaccine in a phase I trial of patients with melanoma. Cancer     Immun. 2009; 9:5. -   ¹⁵ Kovjazin et al. ImMucin: a novel therapeutic vaccine with     promiscuous MHC binding for the treatment of MUC1-expressing tumors.     Vaccine. 2011; 29(29-30):4676-86. -   ¹⁶ Cathcart et al. A multivalent bcr-abl fusion peptide vaccination     trial in patients with chronic myeloid leukemia. Blood. 2004;     103:1037-1042. -   ¹⁷ Chapuis et al. Transferred WT1-reactive CD8+ T cells can mediate     antileukemic activity and persist in post-transplant patients. Sci     Transl Med. 2013; 5(174):174ra27. -   ¹⁸ Keilholz et al. A clinical and immunologic phase 2 trial of Wilms     tumor gene product 1 (WT1) peptide vaccination in patients with AML     and MDS. Blood; 2009; 113(26):6541-8. -   ¹⁹ Walter et al. Multipeptide immune response to cancer vaccine     IMA901 after single-dose cyclophosphamide associates with longer     patient survival. Nat Med. 2012; 18(8): 1254-61. -   ²⁰ Phuphanich et al. Phase I trial of a multi-epitope-pulsed     dendritic cell vaccine for patients with newly diagnosed     glioblastoma. Cancer Immunol Immunother. 2013; 62(1): 125-35. -   ²¹ Kantoff et al. Overall survival analysis of a phase II randomized     controlled trial of a Poxviral-based PSA-targeted immunotherapy in     metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;     28(7): 1099-105. -   ²² Tagawa et al. Phase I study of intranodal delivery of a plasmid     DNA vaccine for patients with Stage IV melanoma. Cancer. 2003;     98(1): 144-54. -   ²³ Slingluff et al. Randomized multicenter trial of the effects of     melanoma-associated helper peptides and cyclophosphamide on the     immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol.     2011; 29(21):2924-32. -   ²⁴ Kaida et al. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine     and gemcitabine combination therapy in patients with advanced     pancreatic or biliary tract cancer. J Immunother. 2011; 34(1):92-9. -   ²⁵ Fenoglio et al. A multi-peptide, dual-adjuvant telomerase vaccine     (GX301) is highly immunogenic in patients with prostate and renal     cancer. Cancer Immunol Immunother; 2013; 62:1041-1052. -   ²⁶ Krug et al. WT1 peptide vaccinations induce CD4 and CD8 T cell     immune responses in patients with mesothelioma and non-small cell     lung cancer. Cancer Immunol Immunother; 2010; 59(10): 1467-79. -   ²⁷ Slingluff et al. Clinical and immunologic results of a randomized     phase II trial of vaccination using four melanoma peptides either     administered in granulocyte-macrophage colony-stimulating factor in     adjuvant or pulsed on dendritic cells. J Clin Oncol; 2003;     21(21):4016-26. -   ²⁸ Hodi et al. Improved survival with ipilimumab in patients with     metastatic melanoma. N Engl J Med; 2010; 363(8):711-23. -   ²⁹ Carmon et al. Phase I/II study exploring ImMucin, a pan-major     histocompatibility complex, anti-MUC1 signal peptide vaccine, in     multiple myeloma patients. Br J Hematol. 2014; 169(1):44-56. -   ³⁰     www.merckgroup.com/en/media/extNewsDetail.html?newsId=EB4A46A2AC4A52E7C1257AD9     001F3186&newsType=1 (Accessed Mar. 28, 2016) -   ³¹ Trimble et al. Safety, efficacy, and immunogenicity of VGX-3100,     a therapeutic synthetic DNA vaccine targeting human papillomavirus     16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia     2/3: a randomised, double-blind, placebo-controlled phase 2b trial.     Lancet. 2015; 386(10008):2078-88. -   ³² Cusi et al. Phase I trial of thymidylate synthase poly epitope     peptide (TSPP) vaccine in advanced cancer patients. Cancer Immunol     Immunother; 2015; 64:1159-1173. -   ³³ Asahara et al. Phase I/II clinical trial using HLA-A24-restricted     peptide vaccine derived from KIF20A for patients with advanced     pancreatic cancer. J Transl Med; 2013; 11:291. -   ³⁴ Yoshitake et al. Phase II clinical trial of multiple peptide     vaccination for advanced head and neck cancer patients revealed     induction of immune responses and improved OS. Clin Cancer Res;     2014; 21(2):312-21. -   ³⁵ Okuno et al. Clinical Trial of a 7-Peptide Cocktail Vaccine with     Oral Chemotherapy for Patients with Metastatic Colorectal Cancer.     Anticancer Res; 2014; 34: 3045-305. -   ³⁶ Rapoport et al. Combination Immunotherapy after ASCT for Multiple     Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive     Transfer of Vaccine-Primed and Costimulated Autologous T Cells. Clin     Cancer Res; 2014; 20(5): 1355-1365. -   ³⁷ Greenfield et al. A phase I dose-escalation clinical trial of a     peptide based human papillomavirus therapeutic vaccine with Candida     skin test reagent as a novel vaccine adjuvant for treating women     with biopsy-proven cervical intraepithelial neoplasia 2/3.     Oncoimmunol; 2015; 4:10, e1031439. -   ³⁸ Snyder et al. Genetic basis for clinical response to CTLA-4     blockade in melanoma. N Engl J Med. 2014; 371 (23):2189-99. -   ³⁹ Van Allen et al. Genomic correlates of response to CTLA-4     blockade in metastatic melanoma. Science; 2015; 350:6257. -   ⁴⁰ Li et al. Thrombocytopenia caused by the development of     antibodies to thrombopoietin. Blood; 2001; 98:3241-3248 -   ⁴¹ Takedatsu et al. Determination of Thrombopoietin-Derived Peptides     Recognized by Both Cellular and Humoral Immunities in Healthy Donors     and Patients with Thrombocytopenia. 2005; 23(7): 975-982 -   ⁴² Eisenhauer et al. New response evaluation criteria in solid     tumors: revised RECIST guideline (version 1.1). Eur J Cancer; 2009;     45(2):228-47. -   ⁴³ Therasse et al. New guidelines to evaluate the response to     treatment in solid tumors: European Organization for Research and     Treatment of Cancer, National Cancer Institute of the United States,     National Cancer Institute of Canada. J Natl Cancer Inst; 2000;     92:205-216. -   ⁴⁴ Tsuchida & Therasse. Response evaluation criteria in solid tumors     (RECIST): New guidelines. Med Pediatr Oncol. 2001; 37:1-3. -   ⁴⁵ Durie et al. International uniform response criteria for multiple     myeloma. Leukemia; 2006; 20:1467-1473. 

What is claimed is:
 1. A method of treating ovarian cancer using immunotherapy in an individual in need thereof, the method comprising: administering to the individual a pharmaceutical composition comprising a peptide having the amino acid sequence of any of SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 342, SEQ ID NO: 343, SEQ ID NO: 344, SEQ ID NO: 345, or SEQ ID NO:
 346. 2. The method of claim 1, wherein the composition comprises two or more peptides, each peptide comprising a different amino acid sequence, and each sequence having the amino acid sequence of any of SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 342, SEQ ID NO: 343, SEQ ID NO: 344, SEQ ID NO: 345, or SEQ ID NO:
 346. 3. The method of claim 1, wherein the composition further comprises at least one additional peptide comprising a fragment of an antigen selected from OY-TES-1, PIWIL-2, PIWIL-3, PIWIL-4, BORIS, AKAP4, WT1, HIWI, EpCam, SP17, SPAG9, PRAME and SURVIVIN.
 4. The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable adjuvant, diluent, carrier, preservative, excipient, buffer, stabilizer, or combination thereof.
 5. The method of claim 4, wherein the composition further comprises a pharmaceutically acceptable adjuvant.
 6. The method of claim 5, wherein the pharmaceutically acceptable adjuvant is selected from the group consisting of water-in-oil emulsions, QS-21, GM-CSF, cyclophosamide, bacillus Calmette-Guerin (BCG), Corynbacterium parvum, levamisole, azimezone, isoprinisone, dinitrochlorobenezene (DNCB), keyhole limpet hemocyanins (KLH), complete Freunds adjuvant, incomplete Freunds adjuvant, mineral gels, aluminum hydroxide (Alum), lysolecithin, pluronic polyols, polyanions, oil emulsions, dinitrophenol, diphtheria toxin (DT), and combinations thereof.
 7. The method of claim 1, further comprising administering a chemotherapeutic agent, a checkpoint inhibitor, a targeted therapy, radiation therapy, another immunotherapy, or combination thereof to the identified individual. 